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Introduction: Non-inferiority trials (NI) test the efficacy of an experimental treatment in 
comparison to an active-controlled treatment and indirectly with the historical placebo to 
demonstrate that the new treatment is no worse than the active comparator. Setting the NI 
margin depends on the assumptions of constancy, assay sensitivity and the absence of 
placebo creep and bio-creep. 
Research Question: This PhD research will investigate the changes in the efficacy of the 
placebo and active control over time.  It will show how this could affect the setting of the 
NI margin and the conclusion of non-inferiority. The context is where there is a wish to 
make a retrospective indirect comparison of the experimental treatment with historical 
placebo. 
Methods:  An overview of Cochrane reviews of placebo-controlled trials was conducted 
to measure the correlations between the placebo, active treatment and the treatment 
difference with the year of publication. From the constructed dataset from the Cochrane 
reviews, a weighted regression model was built to investigate factors affecting the estimate 
of the future trial from a meta-analysis of historical trials, followed by proposing a method 
for the use of meta-regression to adjust for time while setting the NI margin. 
Results: The correlations between the placebo, active treatment and treatment difference 
and the year of publication varied from strong negative to strong positive correlations. The 
median correlation for the treatment difference = - 0.1. The estimate of any future trial 
could be predicted from a meta-analysis of historical trials with coefficient of 0.92 and 
range from 0.75 to 1.047 of the historical trials. Moreover, increasing the year of prediction 
and increasing the year difference in the meta-analysis will reduce the predicted estimate 
by 0.015 and 0.005 respectively. Pairwise meta-regression and network meta-regression 
can be used to assess the constancy, to set the adjusted non-inferiority margin and to analyse 
the non-inferiority trial when the constancy assumption does not hold. 
Conclusion: In NI trials, the constancy assumption needs to be assessed not assumed. 
Adjusting for the time will reduce the chance of the conclusion of non-inferiority of an 
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Chapter 1 Introduction  
1.1  Background 
The gold standard in evidence-based medicine is a randomised clinical trial (RCT) 
(D’Agostino, Massaro, & Sullivan, 2003). For RCTs, two types of control could be used, a 
placebo, which for this thesis would include a placebo, no treatment, or usual care (if usual 
treatment is no treatment), or an active treatment which could be a comparator treatment or 
current treatment. RCTs are not only drug trials. They could compare different treatments, 
procedures or protocols.  
Placebo-controlled trials are the main RCTs that are conducted to evaluate the efficacy and 
safety of the new treatment. Placebo-controlled trials are considered ethical if no standard 
treatment exists or if there will be no harm to the patients from delaying treatment. Placebo-
controlled trials are considered unethical if they prevent or delay patients from getting 
access to an effective treatment, which may lead to harm (D’Agostino et al., 2003). In such 
a situation, active-controlled trials are undertaken. In active-controlled trials, the new 
treatment is compared with an established treatment rather than a placebo.  
RCTs can be broadly divided into superiority trials that aim to conclude that the test 
treatment is better than the comparator and non-inferiority (NI) trials that aim to show that 
the test treatment is not worse than the comparator (FDA, 2016). Placebo-controlled trials 
are the most closely associated with the superiority trials, while non-inferiority trials are 
the most closely associated with the active-controlled trials. Usually, non-inferiority trials 
are efficacy trials that aim to prove that the efficacy of the new experimental treatment is 
not inferior to the current treatment and could promise maybe better safety or adherence or 
be less expensive. However, in recent years, NI trials have been used to evaluate the safety 
of the test treatment with placebo controlled trials (Mauri & D’Agostino, 2017). 
The terminology of active-controlled trials and non-inferiority trials has become more 
popular since the 1990s (Rothmann et al., 2003). The concept of a better substitute to 
superiority placebo-controlled trials was the rationale for the introduction of non-inferiority 
trials (Mauri & D’Agostino, 2017). The number of non-inferiority trials that have been 
published has increased by a factor of six in a decade (Mauri & D’Agostino, 2017).  
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According to the GAO (Governmental Accountability Office, USA) report in 2010, 
between 2002 and 2009 a total of 175 new drugs were submitted for FDA approval, 43 of 
them based on at least one non-inferiority trials (GAO, 2010). A review of 583 non-
inferiority trials published between 1989 and 2009 showed an increasing trend of 
publication of NI trials, with a third of these trials being infectious diseases or cardiology 
trials (Suda, Hurley, McKibbin, & Moroney, 2011). For this thesis, a search in PubMed for 
the term “active control or non-inferiority trials” revealed only one manuscript in 1990 
compared with 510 papers in 2018; this reflects the growing interest in the active control 
and NI trials.  Figure 1.1 demonstrates the growing interest in the active control and NI 
trials from 1990 to 2018. This search was conducted in 2016 and updated in January 2019. 
 
 
Figure 1-1 Number of Published papers of NI trials or Active control trials per year 
(Note: the search done PubMed on April/ 2016 and updated in January/ 2019 with search terms: Search non-inferior* OR                                                                         





The International Conference on Harmonization (ICH-E9) produced the first published 
regulatory guidelines on conducting clinical trials across regulatory jurisdictions (ICH, 
1998). Due to the growing interest in active-controlled and non-inferiority trials, regulatory 
guidelines have been established to advise on the conducting and reporting of active control 
and NI trials. There is guidance on the choice of control in a study from ICH E-10 (ICH, 
2001), the Committee for Medicinal Products for Human Use (CHMP, 2005). There are 
also the US Food and Drug Administration (FDA) guidelines regarding setting, conducting 
and analysis of NI trials (FDA, 2016). However, none of these guidelines establishes any 
enforceable responsibilities (FDA, 2016). Instead, they give only advice and guidance. To 
note also, for reporting, the Consolidated Standards of Reporting Trials (CONSORT) 
statement on the appropriate reporting of NI trials in medical journals has been released 
(Piaggio et al., 2012). 
Compared to traditional superiority trials, NI trials present methodological and regulatory 
challenges that can influence the analysis and inference of their results (D’Agostino et al., 
2003). These include choosing an appropriate active comparator (it could be the best 
available treatment or could be the standard of care), the subjectivity in the setting of the 
non-inferiority margin both statistically and clinically, and the use of an indirect 
comparison to compare the efficacy of the test treatment with the historical placebo. 
The non-inferiority margin is a pre-specified amount (M), which is used to demonstrate 
that the test treatment is no worse than the active control (D’Agostino et al., 2003; FDA, 
2016). It is the amount the active control can exceed the test treatment and for a conclusion 
of the test treatment being non-inferior to the active control to be made (D’Agostino et al., 
2003). If in the past the active control had been compared to placebo then this could be 
used to determine the non-inferiority margin so that through the active control an indirect 
comparison could be made for the test treatment to show superiority over placebo (indirect 
comparison).  
An indirect comparison is a comparison that is made between two treatments that have 
never been tested in the same trial but are used treat the same disease in the same patient 
population, sharing a common control treatment (Julious & Wang, 2008). 
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To demonstrate the meaning of indirect comparison, suppose two trials are conducted: 
Trial 1: - Compared treatment (A) with treatment (B) 
Trial 2: - Compared treatment (C) with the active control (B) 
treatment A could be indirectly compared with treatment C since both of them had a 
common comparator B 
(𝐴 − 𝐵) − (𝐶 − 𝐵) = 𝐴 − 𝐶,      (1.1)  
Where A is the effect size of treatment A, 
B is the effect size of treatment B, 
C is the effect size of treatment C. 
The situation in non-inferiority trials is: 
Trial 1: (historical placebo-controlled trial): compares the active control (C) with the 
placebo (P), 
Trial 2: (non-inferiority trial in present time): - compares Test treatment (T) with the active 
control (C), 
(𝑇 − 𝐶) − (𝑃 − 𝐶) = 𝑇 − 𝑃,     (1.2)  
where T is the effect size of test treatment, 
C is the effect size of the active control, and 
P is the effect size of the placebo, 
The aim of trial 2 is to show that the test treatment is not inferior to the active control and 
indirectly superior to the historical placebo. This comparison is not straightforward, and 
several regulatory and methodological challenges accompany this comparison. 
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For an NI trial, the first step will be choosing the appropriate active control. Once this has 
been sorted, then a non-inferiority margin should be determined.  According to ICH-E10 
(ICH, 2001), designing and conducting non-inferiority trials can be summarised in four 
steps: 
1- Determining that historical evidence of sensitivity to drug effects exists 
(HESDE): This means that the historical trials that were used in the past can 
distinguish the effective treatment from an ineffective one. It should be specified 
that the treatment that will be used as an active control was found reliably superior 
to the placebo in the historical placebo-controlled trials. HESDE should be 
determined before the beginning of the NI trial (ICH, 2001).  
2- Designing a trial with a detailed protocol: The NI trial should be designed with a 
detailed protocol about inclusion and exclusion criteria, population, primary 
endpoints, and type of statistical analysis that will be used. 
3- Defining a non-inferiority margin (M):  as mentioned earlier, M is a  pre-specified 
amount which is used to demonstrate that the test product is no worse than the 
comparator by more than this amount (FDA, 2016). The NI margin should be 
defined, taking into account the historical data that were used to estimate the effect 
of the active control, clinical judgement, and statistical considerations like 
regression to the mean bias and presence of the effect modifiers (Rothmann, Wiens, 
Chan, Crc, & Group, 2012). FDA defined two margins that should be specified: M1, 
the statistical NI margin, and M2, the clinically determined margin (FDA, 2016).  
4- Conduct of the trial: The NI trial should be conducted according to regulatory and 
statistical guidelines. An NI trial should be similar  to the historical trials that were 
used in determining the NI margin (ICH, 2001). 
 
1.2  The research rationale, aims and objectives 
As highlighted in Section 1.1, conducting and interpreting NI trials is accompanied by 
several methodological and regulatory challenges. The research rationale behind this thesis 
is to investigate how the changes in the placebo and active treatment effect over time could 
affect the estimation of the NI margin and NI trials conducting in general. In addition, what 




The objectives of this thesis are to investigate:  
 The methodological and regulatory challenges associated with the planning, 
conducting and reporting of non-inferiority trials, 
 The changes in the placebo and active treatment effects over time and their impact 
on the design and analysis of NI trials,  
 To quantify and model placebo and active treatment responses over time with 
recommendations for retrospective comparison back to placebo. 
 Propose a method for adjusment for time from indirect comparison while setting 
the NI margin (in the design phase of NI trial). 
 
1.3 Outlines of the thesis  
Aiming to answer the objectives for this research, this thesis will be divided into three parts. 
Part one (Chapters 2, 3, and 4) will include the review chapters that will review the 
conducting, regulation and reporting of non-inferiority trials. The second part will 
investigate the changes in the placebo and active control over time (Chapter 5 and 6), and 
the final part will introduce new methods for setting the adjusted non-inferiority margin 
(Chapters 7 and 8), This research will be concluded in Chapter 9 with the summary, 
discussion, and main conclusion. Recommendations will be provided on how to adjust for 
a time in NI trials. Figure 1.2 illustrates the thesis road map. 
Review Chapters: 
 Chapter 2 will review the literature on the designing of NI trials, focusing on the 
choice of appropriate active control and the main assumptions, considerations and 
limitations of the NI trials. Moreover, it will present the methods used for setting 
the NI margin and the methods used for the analysis on NI trials; both Frequentist 
and Bayesian methods will be presented. 
 Chapter 3 will review the regulatory guidelines that deal with NI trials and the 
differences and the similarities between these guidelines.  
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 Chapter 4 will conduct a systematic review of the published NI trials in 2015 in the 
top four medical journals to investigate the quality of the published NI trials in the 
clinical practice. 
Chapters investigate the changes in the placebo and active treatment effect over time: 
 Chapter 5 will provide an overview of Cochrane reviews published in 2015-2016 
on placebo-controlled trials. Correlations and partial correlations between the year 
of publication and the sample size, placebo, active treatment and treatment 
difference will be reported to measure the changes in the treatment effect over time. 
 In Chapter 6, data collected in Chapter 5 will be used to build a weighted regression 
model to investigate the predictors of a treatment effect on the trial based on the 
available historical trials. The relations between the year of publication, time 
difference, and type of model (fixed or random) will be studied. 
Chapters 7 and 8 will review and propose a new method for adjusting for time in NI trials: 
 Chapter 7 will review the available possible methods for adjusting for time while 
setting the NI margin.  
 In Chapter 8, based on the review from chapter 7, a new method will be proposed 
to adjust for time while setting the NI margin from indirect comparison. Two 
possible scenarios of setting the NI margin will be presented: the first example 
willinvolve setting the margin when the constancy assumption cannot hold, and the 
second example will involve checking the validity of the proposed method for both 
cases when constancy is assumed. 














Chapter 2 Literature Review: What is a Non-
inferiority Trial? 
2.1  Introduction 
As mentioned in Chapter 1, designing and conducting non-inferiority trials can be 
summarised in four steps (ICH, 2001): determining that historical evidence of sensitivity 
to treatment effects exists (HESDE); designing a trial with the detailed protocol; defining 
a non-inferiority margin; and finally, conducting the trial.  
This chapter will review the general considerations and assumptions for designing NI trials, 
setting the NI margin, and methods for analysing the non-inferiority trials. Section 2.3 will 
present the main considerations and assumptions regarding choice of the appropriate active 
control, determining its sensitivity and constancy assumption, the placebo creep and bio-
creep as main challenges in the non-inferiority trial and other challenges in conducting the 
non-inferiority trial. This will be followed in Section 2.4 by presentation of the setting of 
the non-inferiority margin and the role of meta-analysis in the setting of the non-inferiority 
margin. The available methods for the analysis of non-inferiority trials will then be 
reviewed in Section 2.5. An example of the analysis of the non-inferiority trials using the 
different presented methods will be illustrated in Section 2.6. The chapter will close with a 
summary of the findings in Section 2.7.  
2.2 Aims and Objectives: 
 Review the literature regarding designing of NI trials 
 Review the assumptions, considerations associated with NI trials 
 Address the definitions and the differences between the two types of non-inferiority 
margins. 





2.3 Challenges, considerations and assumptions of non-inferiority trials 
For an NI trial, the first step will be to choose the appropriate active control. Once that has 
been sorted, then a non-inferiority margin should be determined. In general, when possible, 
the most effective available standard treatment should be used as the active control in the 
NI trial (Rothmann et al., 2012). That means appropriately designed and conducted trials 
in the past that used a specific active treatment and regularly showed this active control to 
be superior to placebo. These findings allow for a reliable estimate of the effect size of the 
active control compared to the placebo in the historical trials, and this will form a base to 
estimate the effectiveness of active control in the current NI trial (FDA, 2016).  
Fleming defined the appropriate “suitable” active control as a widely used treatment whose 
efficacy was proven by well-designed randomised controlled trials that documented its 
superiority and which is expected to have the same efficacy in the current active-controlled 
trial (Fleming, 2008).  
The effectiveness of active control could be concluded from two determinations: 
1. HESDE: the historical trials that were used in the indirect comparison should be 
similar to the non-inferiority trial in efficacy endpoint and population and should 
be evaluated before the beginning of the NI trial (FDA, 2016). The conclusion from 
these trials should be that the active control is reliably superior to the placebo in 
these historical trials (CHMP, 2005).  
2. Proper NI trial conducting: the NI trial should be conducted under the regulatory 
guidelines to ensure its ability to distinguish effective treatment from less effective 
ones (FDA, 2016). 
There are some considerations regarding the estimate of the effect size of active control 
from previous studies and applying it in the current NI trial. These include assay sensitivity, 
constancy assumption, bias minimising (regression to mean bias, publication bias, and the 
bio-creep and placebo creep) (D’Agostino et al., 2003; FDA, 2016; Rothmann et al., 2003). 
In this section, these considerations and assumptions will be discussed in more detail, as 
well as how the violation of these assumptions could affect the setting of the NI margin. 
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2.3.1 Assay sensitivity of the active control 
ICH- E10 defined assay sensitivity as:  
“A property of a clinical trial to distinguish an effective treatment from a less effective or 
ineffective treatment”; the trial should provide assurance that if a placebo is included in 
that trial, the active-control will show superiority to the placebo (ICH, 2001).  
Assay sensitivity is essential in any trial (superior or non-inferior). In a superiority trial, 
assay sensitivity is established once the superiority of the test treatment is concluded 
(conclusion of efficacy achieved). However, assay sensitivity cannot be established directly 
from NI trials (FDA, 2016; Snapinn, 2000). The efficacy in NI trials is demonstrated by 
showing that a test treatment is no worse (non-inferior) than the active control. As a result 
of this, even if the trial’s assumption of assay sensitivity does not hold, the trial may find 
an ineffective treatment to be non-inferior to active control (which is ineffective against 
placebo), and thus a biased conclusion of efficacy could be made (FDA, 2016; ICH, 2001).  
2.3.2 Constancy Assumption 
The difference between the active control and the placebo in the historical trial is assumed 
to hold in the designing of the NI trial; this is referred to as the “constancy assumption” 
(D’Agostino et al., 2003; FDA, 2016). Fleming considered the assumption of constancy as 
the most critical challenge in designing and conducting NI trials (Fleming, 2008).      
Proving that the effect size of the difference between the active control and the placebo is 
constant over time (same in historical and NI trial) is difficult, especially with the rapid 
changes in medical practice and standard of care in many therapeutic areas (Fleming, 2008). 
Changes in medical practice over the years could reduce the efficacy of the active control 
and improve standard care (LeLorier, Grégoire, Benhaddad, Lapierre, & Derderian, 1997).  
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An example of how medical practice can change can be taken from the therapeutic area of 
antibiotics resistance. Vancomycin was considered an effective treatment for urinary tract 
infection compared to no treatment (placebo). However, the development of vancomycin 
resistant enterococci in recent years reduced the efficacy of vancomycin in treating urinary 
tract infections. In this situation, using vancomycin as an active control in an NI trial to 
establish the non-inferiority of any new treatment compared to vancomycin will be sub-
optimal, since the assumption of the constant effect of vancomycin cannot be held. Even 
though the superiority of vancomycin to placebo was established in previous historical 
trials, the constancy assumption cannot be held due to change in the infective agent itself, 
not the active control (Fleming, 2008).  
Supporting the constancy assumption is difficult to achieve, not only in anti-infective NI 
trials but in NI trials in general (FDA, 2016). The presence of effect modifiers like 
differences between the historical trials and the NI trial in the population, in the definition 
of the endpoint, changes in procedures, and changes in causes of the disease could affect 
the constancy assumption and lead to false favourable rates of the effect of active control 
compared to placebo. This will lead to approval of non-effective new treatments (K. Odem-
Davis & Fleming, 2015).  
Including a placebo arm in an NI trial design will establish both assay sensitivity and 
constancy of active control without the need for indirect comparison between two different 
trials that were conducted at a different time point. However, this is not feasible most of 
the time for clinical and ethical reasons (FDA, 2016). Another possible way to secure the 
constancy assumption in the NI trial is to ensure the similarity between both the past trials 
and the new NI trial. Both trials should be as close as possible in all essential respects, 
including the primary outcome, study population, and structure of the study. However, the 
similarity of these trials may not be possible to assess fully until the NI study is completed 




2.3.3 Variability of historical trials 
Another problem facing the determination of the effectiveness of the active control is the 
presence of different historical trials with different sample sizes, different methods of 
analysis and different conclusions. This variability between historical trials could affect the 
measurement of the efficacy of the active control based on these trials (FDA, 2016). Even 
though the use of meta-analysis to estimate the effect size of active control from historical 
trials could resolve part of the problem regarding the sample size and conclusion, meta-
analysis cannot address the effect of the time difference between the trials in its estimate 
since it does not take into consideration the time changes (Julious & Wang, 2008).  
Determining the effectiveness of the active control based on a single randomised placebo-
controlled trial is also an issue that could affect the precision of effectiveness of the active 
control (FDA, 2016). The heterogeneity of the effect of the active control cannot be 
assessed if there was only one historical study (Rothmann et al., 2003). Lelorier et al. stated 
that using a single large randomised controlled trial is more accurate and less biased than 
the use of traditional meta-analysis methods (LeLorier et al., 1997). However, according to 
FDA regulations, the use of only one randomised controlled trial as historical evidence is 
possible in only one situation, namely where both the active control and the experimental 
treatment belong to the same pharmacological family (FDA, 2016). 
The sample size of historical trials that are used to estimate the effect of the active control 
will affect the width of the confidence interval that is used to estimate the effect of the 
active control. Studies with a small sample size will produce a wide CI; hence, a large 
sample size will be required for an NI trial to achieve the non-inferiority (Rothmann et al., 
2003). 
The variability in the effect of the active control across the studies could lead to an 
inconsistent estimate of the actual active control effect. In this case, using the random effect 
model in the pairwise meta-analysis could account for the between trials variability 
(Rothmann et al., 2003). However, a random effect model will give more weight for smaller 
trials, which are usually older, and with extreme results. Another problem with assessing 
the efficacy of active control using historical trials is the publication bias; historical trials 
with positive results are published more frequently than trials with negative results, which 
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could lead to overestimating of the effect size of active control compared to placebo 
(Rothstein, Sutton, & Borenstein, 2005). 
2.3.4 Regression to the mean  
Everitt ( 2002) defined regression to the mean as:  
“The phenomenon that a variable that is extreme on its first measurement will tend to be 
closer to the centre of the distribution for a later measurement”. 
As mentioned earlier, the most effective available treatment is chosen to be the active 
control in an NI trial. Estimation of the effect of active control could have the potential for 
regression toward the mean bias since the effect of active control is based on the maximum 
performance of the active control in the historical trials, not on its random effect, which 
would lead to overestimation of the effect of active control in the NI trial (Rothmann et al., 
2012).  
As an example of regression to the mean, suppose in the therapeutic area of cardiovascular 
there were three placebo-controlled trials with three different drugs for reducing the total 
blood cholesterol level (drug A, drug B, and drug C). In these trials, drug B showed a higher 
reduction in the total cholesterol level compared to drug A and C. Drug B is now used as 
the active control in any new NI trial. However, due to the regression toward the mean 
phenomenon, the efficacy of the drug B in any future trials (including NI trial) will be less 
than its efficacy in the first trial. Moreover, setting the NI margin depending on its efficacy 
in the first trial will lead to overestimation of its effectiveness and possibly to concluding 
non-inferiority of an ineffective drug. Making the appropriate adjustments for the 
population age or structural changes to the effect of the active control will mitigate the 
effect of the regression to the mean (FDA, 2016; Rothmann et al., 2003). 
2.3.5 Changes in the treatment effect over time (placebo and active treatment) 
The use of the word “placebo” in medicine goes back to the end of the 18th century, when 
it was used to describe a kind of treatment to make a patient comfortable (Kerr, Milne, & 
Kaptchuk, 2008). The word placebo has been used since 1811 to mean a medicine given 
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more to please than to benefit the patient (Thomas, 2001). Shapiro & Morris (Shapiro, 1978)  
defined placebo as  
“a placebo is any therapy or component of therapy used for its nonspecific, 
psychological, or psychophysiological effect, or that is used for its presumed specific 
effect but is without specific activity for the condition being treated.” 
Although the use of the word placebo to refer to a control treatment in clinical trials started 
in the 20th century, its use to describe a control group with no treatment can be traced as far 
back as the first trial conducted by James Lind in 1740 (Bown, 2003).  The placebo-
controlled trial has usually been considered as the gold standard for testing the efficacy of 
new treatments. The placebo in these trials is usually used as a control to test the effect of 
the active treatment due to its inert contents.   
The placebo effect has accompanied the practice of medicine from its very beginning, but 
interest in placebo effects only began with the widespread adoption of the randomised 
controlled trial (RCT) after world war II (Koshi, E., & Short, 2007).  In 1955, Beecher 
published his paper “The powerful placebo” (Beecher, 1955). Beecher used the words 
“placebo effect” to describe the positive effect of placebo in a clinical trial (Beecher, 1955). 
He claimed that in the 15 clinical trials he studied, placebo groups showed clinical 
improvement and the placebo had a therapeutic effect on the patients (Beecher, 1955). 
Beecher’s article was reanalysed by Kienle in 1997 with the surprising result that no 
evidence was found of any change in the placebo effect in any of the studies cited by 
Beecher (Kienle & Kiene, 1997).  Kienle claimed that the reported improvements in 
patients in these trials were due to other factors like a spontaneous improvement, 
fluctuation of symptoms, regression to the mean, additional treatments, irrelevant response 
variables, but not due to the therapeutic effect of the placebo itself (Kienle & Kiene, 1997). 
In 2000, Talbot wrote a cover article for The New York Times Magazine, concluding that 
placebos are very powerful, and medicine should regularly make use of “the powerful 
placebo” (Talbot, 2000). This article revived the dilemma about the placebo effect and 
triggered a wave of similar articles on the same theme. A year later, an article by 
Hróbjartsson and Gøtzsche, published in the New England Journal of Medicine, concluded 
that placebos have no effect on the objective outcomes of treatment and there is no 
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justification for the use of placebos outside the setting of clinical trials (Hróbjartsson & 
Gøtzsche, 2001). This article prompted a wave of articles that now question the very 
existence of the placebo effect (Koshi, E., & Short, 2007). In conclusion, there may be an 
improvement in the placebo group, which is less than the active treatment (if the active 
treatment has a therapeutic effect). However, these improvements are usually due to the 
nature of the disease and the characteristics of the participants and not due to the therapeutic 
effect of the placebo. 
Improvement of placebo response over time (placebo creep)  was documented by several 
systematic and narrative reviews which revealed a continuous improvement in the placebo 
response over the past decades and decrease in the difference between the placebo and 
active treatment, mainly in antidepressant, antipsychotic and pain trials (Dold & Kasper, 
2015).  
Increase in the placebo response in antidepressant trials is well documented and usually 
considered as the main reason for the rising number of failed antidepressant trials in recent 
years (Furukawa et al., 2018). Walsh et al. found a positive correlation of 0.43 between the 
publication year and placebo response in 53 antidepressant trials published from 1980-2000 
(Walsh et al., 2002). Additionally, Julious et al. found a weighted correlation of - 0.39 
between the placebo response in antidepressants and the year of publication from 1966 to 
2001 (Julious & Wang, 2008).  
Khan et al. investigated the placebo response in antidepressant clinical trials by reviewing 
FDA data from 1987 to 2013 and concluded that the placebo response had increased since 
2000 by 6.4%. However, the difference in treatment response between the placebo and the 
active treatment has remained steady over time (Khan, Fahl Mar, Faucett, Khan Schilling, 
& Brown, 2017). Additionally, Furukawa et al. used meta-regression to study the changes 
in placebo response in antidepressants in both published and unpublished trials (Furukawa 
et al., 2016). The review concluded that the placebo response remained constant between 
1987 and 2015, ranging between 35% and 40%, and the improvement in the placebo 
response was not due to the placebo effect itself but instead to other trial characteristics like 
length of the trial and  number of study centres (Furukawa et al., 2016). The differences 
between the Furukawa review (Furukawa et al., 2016) and  the Khan review (Khan et al., 
2017) are that Furukawa et al. (Furukawa et al., 2016) used meta-regression weighted for 
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the sample size from both published and unpublished trials. Khan et al. (Khan et al., 2017), 
on the other hand, used a linear regression without weighing for sample size and used data 
reported from FDA reviews which usually involve trials with positive results (Furukawa et 
al., 2018). Moreover, Khan et al. (Khan et al., 2017) examined only three covariates, while 
Furukawa et al. (Furukawa et al., 2016)examined 14 different covariates  (Furukawa et al., 
2018). 
The improvement of placebo response was also investigated in relation to antipsychotic 
medication. Leucht et al. conducted a meta-regression for 38 antipsychotics placebo-
controlled trials, with year of publication as moderator, and found that the drug-placebo 
difference became smaller over time. However, this difference was not statistically 
significant (Leucht, Arbter, Engel, Kissling, & Davis, 2009).  
Aiming to investigate the potential causes of increasing placebo response over time in 
antipsychotics, Agid and colleagues (Agid et al., 2013) analysed all placebo-controlled 
antipsychotic drug trials since 1970 with meta-regression. They found that placebo 
response had increased over time, and this increase was associated with multi-centre trials, 
in trials conducted by pharmaceutical companies, shorter trial duration, younger patients, 
short duration of illness, higher illness severity at baseline, and a lower percentage of 
patients assigned to the placebo group. The number of treatment arms, country, and 
duration of drug washout periods were not associated with increased placebo response over 
time (Agid et al., 2013).  
To investigate the predictors of placebo response in negative symptoms in schizophrenia, 
Fraguas et al. (Fraguas, Díaz-Caneja, Pina-Camacho, Umbricht, & Arango, 2018) 
conducted a meta-regression of all double-blinded randomised placebo-controlled trials 
that reported the treatment and placebo effect on negative symptoms of schizophrenia. They 
concluded that even though the active treatment was more effective than placebo in 
reducing the negative symptoms, the placebo response was statistically significant and 
clinically relevant. The moderators of the placebo response were a more significant number 
of trial arms, larger number of study sites and being funded by apharmaceutical company 
(Fraguas et al., 2018). 
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Both antidepressants and antipsychotics trials are considered as trials with subjective 
measures and this could be the reason for the changes in the placebo response. However, 
the improvement of placebo response over time has been documented in therapeutic areas 
where an objective measure was used. For example, a meta-analysis of a large set of 
antiepileptic clinical trials (1987-2009) conducted by Rheims et al. (Rheims, Perucca, 
Cucherat, & Ryvlin, 2011) found an improvement in both the treatment and placebo effect 
by increasing the year of publication. However, the treatment effect (differences between 
the placebo and the active treatment) was not improved and remain stable over time 
(Rheims et al., 2011).  
Khan et al. (Khan, Fahl Mar, Schilling, & Brown, 2018b) assessed the magnitude and the 
pattern of the placebo effect in antiepileptic medication by reviewing data from the FDA 
between 1996 to 2016. The review concluded that the placebo response was increased over 
the 20 years; the reduction in seizure frequency increased from 5% to 20% (Khan et al., 
2018b). 
Khan et al. documented the improvement of placebo response (placebo creep) in anti-
hyperglycaemic agents (Khan, Fahl Mar, Schilling, & Brown, 2018c). They found 
improvement of placebo response by 0.5%  HBA1c reduction in the placebo group with no 
change in the effect size in general (Khan et al., 2018c). The improvement of placebo 
response was statistically significant in an antihypertensive trial (Khan, Fahl Mar, Schilling, 
& Brown, 2018a). Improvement of placebo response has also been documented in other 
medical fields, such as in Crohn’s disease (Gallahan, Case, & Bloomfeld, 2010) and in 
acupuncture trials (We, Koog, Park, & Min, 2012).  
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Despite the considerable amount of data concluding the improvement of the placebo effect 
in different therapeutic areas, some argue that these changes are not due to the placebo itself 
but instead to the changing quality of the trials conducted and improvement of the standard 
care (Furukawa et al., 2018; Kirsch, 2013). Kirsch argued that the observed placebo 
response is not actually a placebo effect; rather the changes are due to the regression to 
mean phenomenon (Kirsch, 2013) (Section 2.7). However, whether due to the effect of the 
placebo itself or due to changes of the medical setting and the improvement of the quality 
of the clinical trials it is nonetheless difficult to ignore the noticed changes in the placebo 
response. With all this evidence, the use of historical data for indirect comparison in NI 
trials will be accompanied by higher chances of concluding the effectiveness of inferior 
treatments.  
 
2.3.6 Placebo creep and bio-creep 
Placebo creep is a cyclic phenomenon that occurs when the effect of a placebo improves 
over time because of improvement in the standard of care and, at the same time, the 
effectiveness of the active control is slightly reduced over time due to drug resistance or 
shifting in the human population (Julious & Wang, 2008) or other unknown reasons. Few 
studies have investigated the presence of placebo creep. Julious and Wang presented 
evidence of improvement of placebo response over time in anti-depressant drug trials 
between 1966 and 2011 with a weighted correlation of - 0.39 (Julious & Wang, 2008). 
Explanations as to the causes of placebo creep include improvement of standard 
(concomitant) care, population drifts and geographical differences (Julious & Wang, 2008). 
In the literature, the information about placebo creep is minimal, and most of the time, there 
is confusion between bio-creep and placebo creep.  
D’Agostino et al. (2003) defined bio-creep as; “The phenomenon that can occur when a 
slightly inferior treatment becomes the active control for the next generation of non-
inferiority trials and so on until the active controls become no better than a placebo.” The 
main concern regarding the presence of bio-creep in NI trials was highlighted in the GAO 
report in 2010 (GAO, 2010) as “A concern that successive generations of drugs approved 
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based on non-inferiority trial, with the active control changing in each new generation, 
could lead to the adoption of decreasingly effective drugs.” 
Figure 2-1 illustrates the presence of placebo creep and the effect of bio-creep on the 
efficacy of active control:  
 The placebo was used as the comparator with treatment one (T1) in the period (A). 
The efficacy of (T1) compared to the placebo (P) was established, in the period (A).  
 T1 became the active comparator (as it was unethical to use the placebo any more) 
and was compared to treatment two (T2) in the period (B). The non-inferiority of 
T2, compared to T1, was established. 
 With time T2 became the active comparator and was compared with treatment three 
(T3) in the present time (period C).  
 By the end of the different trials, the conclusion was that T3 is non-inferior to T2, 
but it is inferior to T1, and its efficacy is almost the same as the efficacy of placebo, 
which is known as bio-creep. Using T2 as active comparator instead of T1 or 
placebo will lead to overestimation of the efficacy of the new treatment T3, which 
could lead to approval of an ineffective drug.  
It is also clear from the figure that the effect of placebo improved over time, which is due 
to placebo creep.
 
























Choosing the active control and estimating its effect size from both the historical trials and 
NI trials are the most important factors in affecting the occurrence of bio-creep (Everson-
Stewart & Emerson, 2010; Fleming, 2008).  
Fleming explained the hazard of bio-creep in anti-infective trials where generations of non-
inferiority trials were conducted, leading to approval of antibiotics that may not be 
providing as large a clinical effect compared to the placebo as perceived and could induce 
safety risks and development of resistance (Fleming, 2008).  
Addressing the possibility of bio-creep by choosing the best active control available is very 
important in any NI trial (D’Agostino et al., 2003).  The efficacy of the active control should 
be protected and maintained in any NI trial. 
Odem-Davis & Fleming (2015) reported several factors that could influence the risk of bio-
creep in NI trials. Besides choosing the appropriate active control, these factors include the 
method for choosing the non-inferiority margin to account for publication bias and random 
high bias and regression to the mean. 
Several methods were proposed to minimise the occurrence of bio-creep in NI trials 
(Fleming, 2008; Odem-Davis & Fleming, 2015; Odem-Davis & Fleming, 2013; Rothmann 
et al., 2003). The FDA guideline published in 2016 recommends the use of the 95% - 95% 
fixed margin method for this purpose (FDA, 2016). 
2.4 Setting of the non-inferiority margin 
As highlighted earlier in this chapter, once the effectiveness of treatment becomes such that 
placebo-controlled trials are no longer possible, this active treatment could then be the 
active control for further new treatments through NI trials. In this context, there will be a 
need to determine an acceptable non-inferiority margin that takes into account the historical 
evidence, the relevant statistical considerations, and medical judgement. The non-
inferiority margin is usually established from the main estimate from the meta-analysis of 
the placebo-controlled trials that compare the active treatment to the placebo. In this section, 
the role of pairwise meta-analysis in the setting of the NI margin will be discussed, followed 
by the methods for setting the NI margin.   
23 
 
2.4.1  The role of pairwise meta-analysis in setting the Non-inferiority Margin 
GLASS (1976) defines meta-analysis as 
“The statistical analysis of a large collection of analysis results from individual studies 
for the purpose of integrating the findings.” 
Meta-analyses are considered to be the top evidence-based medical studies and an 
important tool for treatment approval (Paul & Leibovici, 2014). In NI trials, a meta-analysis 
can be used to estimate the historical effect of the active control compared to the placebo 
to set the NI margin.  
Pairwise meta-analysis depends on a direct comparison between two treatments. In NI trials, 
a pairwise meta-analysis is conducted to measure the effect size of the active comparator 
from historical placebo-controlled trials. Two comparator treatments are included (the 
placebo and the active control). The point estimate and the 95% CI extracted from this 
meta-analysis is used for setting the NI margin to indirectly compare the efficacy of the 
experimental treatment compared to the placebo either by the fixed margin approach or the 
synthesis approach.  
There are several issues that accompany the planning, conducting and analysis of a meta-
analysis. These include the source of data used, study selection (publication bias), 
differences between the studies (heterogeneity), and choosing the appropriate model for 
analysis (fixed versus random models). In the case of NI trials, violation of these 
assumptions will lead to either over or underestimation of the effect size of the active 
control compared to the placebo, which eventually leads to a biased NI margin. 
2.4.1.1 Heterogeneity 
Heterogeneity is defined as any variability among studies that are included in the meta-
analysis. Heterogeneity could be in the form of clinical diversity, methodological diversity 
or statistical heterogeneity (Higgins & Green, 2008). Heterogeneity should be investigated 
initially by inspection of the 95% CI in the studies. Non-overlapping CI is an initial 
indicator of heterogeneity (Pinto, 2013). Cochran’s Q is a chi-square distributed method 
that is used to measure the heterogeneity. It is calculated as the weighted sum of squared 
differences between individual study effects and the pooled effect across studies, with the 
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weights being those used in the pooling method. The interpretation of the results from 
Cochran’s 𝑄  test should be treated with caution since it has low power to detect 
heterogeneity in a meta-analysis that contains studies with small sample size or when small 
numbers of studies are included in the meta-analysis (Higgins & Green, 2008). In contrast, 
if a large number of studies are included in the meta-analysis, Cochran’s 𝑄 test will have a 
high power to detect a small amount of heterogeneity, which could have no clinical 
importance (Higgins & Green, 2008). 
The I² statistic is an alternative method to measure heterogeneity. It describes the 
percentage of variation across studies that is due to heterogeneity rather than chance, and 
is a derivative from the Q statistics. I² is an intuitive and simple expression of the 
inconsistency of studies’ results. Unlike Q it does not inherently depend upon the number 
of studies considered (Higgins & Green, 2008).  
I² > 50% is indicative of considerable heterogeneity, I² ≥ 30 % and ≤ 50 % is indicative of 
moderate heterogeneity, and  I² < 30 per cent is indicative of mild heterogeneity (Whitehead, 
2002).  
In the case of NI trials, the variability (heterogeneity) between historical placebo-controlled 
trials could affect the measurement of the efficacy of the active control based on these trials 
(FDA, 2016). A high percentage of heterogeneity requires additional investigation to 
attempt to explain the heterogeneity. Sensitivity analysis, subgroup analysis, and including 
the possible effect modifiers should be undertaken. 
 
2.4.1.2 Publication bias 
Another issue that could be faced in a meta-analysis is the chance of reporting bias 
(publication bias). Studies with positive results are more likely to be published than studies 
with negative results. They are more likely to be rapidly published in high impact journals 
and more likely to be cited by others (Rothstein, Sutton, & Borenstein, 2006). A meta-
analysis that contains only studies with positive results tends to have positively biased 
results. In the case of NI trials, the presence of publication bias could lead to concluding 
the efficacy of ineffective active control, which eventually will lead to the conclusion of 
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non-inferiority of the inferior experimental treatment. The funnel plot is the most 
commonly used visual method to assess the publication bias (Rothstein et al., 2006).To 
minimise the effect of publication bias, meta-analyses should include both published and 
unpublished studies. However, searching for unpublished studies is usually hard and 
challenging to perform, especially for older trials. 
2.4.1.3 Fixed effect model (FE) versus random effects model (RE) 
The fixed-effect model assumes all trials are to estimate a common treatment effect with 
any differences across trials in observed effects assumed to be due to sampling variation 
(within trial variations only). The random-effects approach allows for between trial and 
within trial variations. Selection of the model affects the overall effect size, mostly where 
the studies in the analysis include both small and large studies. A fixed effect model gives 
more weight to studies with larger sample size, while a random effects model gives more 
weight for smaller studies; this means under a random effect model studies with extreme 
results will have less influence if they are large and more influence if they are small 
(Borenstein, 2009). However, smaller studies tend to have more extreme results than large 
ones. The variance, standard error and the confidence interval are wider in the random 
effect model compared to the fixed model, since the random model accounts for both the 
sampling variance and the between-study variance (Borenstein, 2009).  
The selection between random or fixed models depends on the nature of studies included, 
number of studies, and the assumption of heterogeneity. Usually, a random effect model is 
more appropriate for meta-analyses that include a large number of studies with different 
sample sizes. On the other hand, a fixed effect model is more appropriate if the meta-
analysis includes studies with similar sample sizes and a small number of studies 
(Borenstein, 2009).  
Even though the random effects model accounts more for the heterogeneity, there are 
multiple concerns regarding using it to estimate the effect of the active control in NI trials. 
First, the random effect model will give more weight to trials with smaller sample size 
compared to the fixed effect model; this will violate the assumption of the similarity 
between NI trial and the historical trials since NI trials tend to be conducted with larger 
sample size  (Rothmann et al., 2012). In Chapter 5 of this thesis the changes in sample size 
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over time will be investigated, as well as their effect on the main estimate in the meta-
analysis. In Chapter 6, the difference between fixed and random models will be investigated. 
2.4.2 Non-inferiority Margin (M) 
An NI trial is undertaken based on the quantification of a margin that in turn depends on 
evidence on the effectiveness of the active control in historical well-conducted placebo-
controlled trials. This assessment of the effectiveness needs to account for any possible 
biases, effect modifiers and the clinical judgement.  
There are different methods used to set the NI margin, most of which in general follow one 
of two approaches to set the appropriate NI margin (Rothmann et al., 2012).  The first 
approach depends on making adjustments for any possible biases or uncertainty and then 
using a test procedure that targets a pre-specified type I like error rate (Rothmann et al., 
2012). The second approach involves the use of methods for analysis with the hope that 
they will account for any possible biases that could arise from the use of unadjusted active 
control effect (Rothmann et al., 2012). This thesis will present the most common methods 
used to set the NI margin, namely the fixed margin method and the synthesis method, since 
these are the only methods identified by the regulations (FDA, 2016).   
 
The NI margin is a pre-specified amount (M), which can be used to demonstrate that the 
test product is no worse than the active control (D’Agostino et al., 2003; FDA, 2016). It is 
the amount by which the active control can exceed the test treatment for it to be concluded 
that the test treatment is non-inferior to the active control and indirectly superior to the 
placebo (D’Agostino et al., 2003). 
The null hypothesis means that the active control is superior to the test treatment, and the 
alternative hypothesis means that the test treatment is not inferior to the active control 
(D’Agostino et al., 2003). The determination of the non-inferiority margin is based on both 
statistical consideration and clinical judgement (ICH, 2001; CHMP, 2005; FDA, 2016). 
According to FDA regulations, two NI margins should be identified in any NI trial: M1 and 
M2. M1 “is the whole effect of the active control relative to placebo” (FDA, 2016). M1 is 
estimated indirectly from the historical placebo-controlled trials where active control 
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worked as a test treatment against placebo. The validity of the NI trial depends on the choice 
of M1 (ICH, 2001; CHMP, 2005; FDA, 2016). 
M2 “is the largest clinically acceptable difference (degree of inferiority) of the test 
treatment compared to an active control” (FDA, 2016). M2 represents clinical judgement. 
M2 is a fraction of M1 that is judged the clinically acceptable difference between the active 
control and test treatment and should always be smaller than M1. Both the point estimate 
and the boundaries of the confidence interval (CI) are essential in the statistical analysis of 
non-inferiority. Different methods are used to set the NI margin, and these include the fixed 
margin method and the synthesis method. 
The Hypothesis to be tested is: 
𝐻0: 𝐶 − 𝑇 ≥ 𝑀2  , (active control is superior to test treatment)    (2.1) 
𝐻𝑎: 𝐶 − 𝑇 < 𝑀2 , (test treatment is not inferior to the active control)   (2.2),  
Where C is the effect size of the active control, T is the effect size of the test treatment 
Figure 2.2 gives four different scenarios for the results of the NI trial method: 
a- The point estimate is less than zero, which favours the test treatment. The upper 
bound of 95% CI is less than zero; the superiority of the test treatment over the 
active control is concluded. 
b- The point estimate is equal to zero and the upper bound of 95% CI is less than M2; 
non-inferiority of test treatment is concluded. 
c- The point estimate is equal to zero, but the upper bound of 95% CI is less than M1 
and larger than M2; clinical judgement could lead to the conclusion of effectiveness 
(FDA, 2016). 
d- The point estimate favours active control and the upper bound of 95% CI is greater 




Figure 2-2 The possible outcomes in the NI trial 
 (adapted from FDA guidelines, 2016) 
 
2.4.2.1 Fixed margin method for setting the NI margin  
This is considered as the most common method for setting the NI margin. The fixed margin 
approach is also known as the two confidence intervals approach and or the 95% - 95% 
method. This method is the method recommended by the regulatory guidelines (FDA, 
2016). It depends on choosing a fixed margin in the designing stage of the NI trial based 
on historical data. 
To obtain this margin, the estimate of the active control effect from the historical placebo-
controlled trials needs to be obtained. The lower bound of the CI of the historical placebo-
controlled trials will be defined as M1. Both the variability of the active control effect and 
constancy assumption should be addressed in this stage.  
M2 will be taken as a fraction of M1 depending on the clinical judgement. Using a fraction 
of the lower bound of the confidence interval as the NI margin (M2) is a common practice 
and is recommended by FDA regulations. It is especially important if the primary endpoint 
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is mortality or irreversible morbidity, and this is referred to as “preservation of effect”, and 
it guarantees that some fraction of the effect of the active control is preserved (FDA, 2016; 
Rothmann et al., 2012).  
From historical trials: M1 = lower bound of 95% CI of (C-P)   (2.3) 
M2 = percentage of M1        (2.4) 
From the NI trial: The upper bound of 95% CI (T-C)  > M2    (2.5) 
Where C is the active control, P is the placebo, T is the test treatment, M1 is the statistical 
NI margin, and M2 is the clinical NI margin  
M2 is the fixed margin in this method, not the M1. Using M2 instead of M1 will account 
for any effect modifiers, regression to the mean bias or deviation from the constancy 
assumption (Rothmann et al., 2012). M1 and M2 are used to demonstrate that the test 
treatment is superior to placebo and is not unacceptably worse than the active control 
(Rothmann et al., 2012). The determination of M2 should always be implied after the 
choosing of M1. In cardiovascular diseases, M2 is usually 50% of M1 (FDA, 2016). In 
anti-infective trials, M2 is usually set at 10-15% of an absolute risk difference scale 
between treatments (FDA, 2016). Figure 2.2 illustrates the different outcomes using the 
fixed margin method. 
There is an argument that using a fraction of the lower bound of the confidence interval is 
uniformly conservative (chance of concluding the non-inferiority of an inferior treatment 
is low) (Sankoh, 2008). Sankoh recommends the use of a fraction of the point estimate 
instead of the lower bound of the CI (Sankoh, 2008). However, using a fraction of the lower 
bound of CI is not conservative if the constancy assumption is violated or in cases where 
the regression to the mean and other biases are major problems (Rothmann et al., 2012). 
Moreover, choosing a fraction of M1 can provide an allowance for the deviation from the 
constancy assumption (Rothmann et al., 2012). 
The 95% CI is the most commonly used CI with this approach. It is known as the 95% - 
95% approach because two different 95% CIs, one from the historical placebo-controlled 
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trial and the other from the NI trial, are used to estimate the non-inferiority margin 
(Rothmann et al., 2012).  
The advantages of using this method are: separation of the calculation, justification, and 
determination of the NI margins from the NI analysis stage (since the NI margins will be 
determined in the design phase of NI trial). The separation will keep the variability of  
estimated treatment effect from the past trials and variability of observed treatment effect 
from the NI trial separate (Wangge et al., 2010). The pre-specified margin will be used in 
determining the sample size of the NI trial needed to provide sufficient power for testing 
the NI hypothesis and controlling for type I error. Choosing a fraction of M1 can provide 
an allowance for the deviation from the constancy assumption. 
2.4.2.2The synthesis method 
The synthesis method is usually used in the analysis phase of the trial, where both the main 
estimates from the meta-analysis of placebo-controlled trials are used to set the M1 (instead 
of the 95% CI boundaries). Then a fraction (percentage) from the active control effect will 
be determined to be the M2.   
2.5 Methods for analysis of NI trials 
The most common approaches used are the fixed margin method and the synthesis method 
(the regulatory approaches), and the network meta-analysis (the predictive approach). 
2.5.1 Fixed margin approach  
As mentioned in section (2. 4.2.1), a NI margin M2 will be specified in the designing phase 
of the NI trial. This margin represents a fraction of the effectiveness of active control. In 
the analysis phase of the NI trial, the effectiveness of the test treatment is judged by the 
upper boundary of the confidence interval (CI) from the conducted NI trial. 
2.5.2 Synthesis method 
The synthesis method combines the estimate of treatment effect relative to the control from 
the NI trial with the estimate of the control effect from the historical trials (FDA, 2016). It 
treats both sources of data as if they came from the same source (which is opposite to the 
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separate approach in the fixed margin method) to establish the placebo effect in the NI trial. 
A single confidence interval is then used, combining the results from both the NI trials and 
the historical trials to test the null hypothesis that the treatment is non-inferior to the active 
control, without actually specifying any fixed NI margin based on the control effect (FDA, 
2016). 
This approach assumes that the constancy assumption holds for any NI trial, i.e. that there 
is no between trials variability. As only one 95% CI is used, which in turn is derived from 
the historical placebo-controlled trials, this approach is both less conservative (concluding 
the non-inferiority of an inferior treatment) and less accessible to measure the difference 
between test treatment and placebo (Rothmann et al., 2012). This approach can be used 
with both Frequentist and Bayesian approaches (Rothmann et al., 2012). 
This method compares test statistics based on the estimates from the NI trial and from the 




   (2.7) 
Where C is the effect size of the active control, T is the effect size of the test treatment, 
P is the effect size of the placebo, ∆̂𝑇𝑃 =  (T - C) - (P - C) is the difference between test 
treatment and placebo, TC is the difference between the effect size of test treatment and 
active control, CP is the difference between the effect size of the placebo and active control. 
𝑆𝐸 (𝐶𝑃) is the standard error of the difference between C and P (from the meta-analysis of 
historical trials), and 𝑆𝐸(𝑇𝐶) is the standard error on the NI trial. If the Z is smaller than 
the predetermined Z value (for Type I error), the NI will be concluded. 
The main difference between the synthesis and fixed margin methods is in the standard 
error measure, the fixed margin method assuming the standard error of the indirect 
comparison is the sum of the standard error of the meta-analysis of historical trials and the 
standard error of the NI trial 
𝑍 =  
((∆ ̂𝑇𝑃)
√(𝑆𝐸2 (𝑇𝐶)+ √𝑆𝐸2(𝐶𝑃)
    (2.8) 
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In the synthesis method, M1 is the main estimate of the meta-analysis of the placebo-
controlled trial (instead of the 95% CI boundaries in the fixed method), M2 is the 
percentage of the preserved active treatment effect that will be pre-specified (based on the 
clinical judgement) of the main estimate (FDA, 2016).  
According to the FDA regulations, using synthesis method will lead to smaller sample size 
and greater power for a given sample size compared to the fixed margin approach if the 
constancy assumption holds (FDA, 2016). That is because the synthesis method uses a 
smaller standard error compared to the fixed margin approach method.  
2.5.3 Network meta-analysis (NMA) (Predictive Approach) 
Network meta-analysis (NMA) is a meta-analysis where multiple treatments are compared 
both directly and indirectly based on the common comparator. The idea behind the use of 
NMA is that for many diseases, there are many interventions possible for treatment, and so 
there is a need to compare these treatments (in the case of NI trials comparing placebo, 
active treatment and the experimental treatment). However, in clinical trials, it is difficult 
and costly to compare more than two treatments in the same trial. A network meta-analysis 
was introduced just over 20 years ago as a solution to this problem (Tonin, Rotta, Mendes, 
& Pontarolo, 2017). A network meta-analysis allows synthesis, estimation and comparison 
of the effectiveness of several treatments in one setting (Donegan, Williamson, 
D’Alessandro, & Smith, 2013). It uses all direct and indirect evidence to produce relative 
effects of all compared treatments. 
Lumley first introduced the network meta-analysis (NMA) in 2002 (Lumley, 2002). The 
model introduced by Lumley was extended by Lu and Ades in 2004 who included multiple 
treatment comparisons in the model through Bayesian and were able to rank the included 
treatments from best to worst (Lu & Ades, 2004).   
Figure 2.3 illustrates the simplest form of a network meta-analysis in NI trials that include 
only three treatments. The common comparator in the model is the active control (C), the 
nodes represent the interventions (the included treatments). 
The use of NMAs allows for both head-to-head comparison and indirect comparison in the 
same model, which is considered as an advantage compared to traditional indirect 
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comparisons. Moreover, NMA reduces the cost of conducting additional clinical trials and 
offers an overview of the entire set of the clinical condition (available treatments, possible 
outcomes, side effects of each treatment). 
 
Figure 2-3 Network meta-analysis 
The thickness of the lines represents the sample size, nodes represent treatments, and dashed line 
represents the indirect comparison   
 
NMA allows for the determination of the amount of agreement between results from 
different comparisons for the same treatment (Tonin et al., 2017).  Since 2008, the number 
of published studies that include NMA has increased, mostly in pharmacological 
interventions and mostly in the therapeutic areas of cardiovascular, oncology, mental 
disorders and infectious diseases (Tonin et al., 2017). NMA models are available for all 
types of data in both the Frequentist and Bayesian framework with different software 
available for analysis including R, STATA, SAS and Win bugs (Tonin et al., 2017). 
As mentioned earlier, the conduct and analysis of NI trials depend on the indirect 
comparison between the test treatment and placebo. For this reason, NMA can be used in 
the designing phase to compare all possible active controls with placebo and to set an NI 
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margin. Moreover, it can be used in the analysis phase of NI trials to provide both direct 
and indirect comparison between all possible active controls, placebo and the test treatment 
in the same model. NMA  allows for a comparison of multiple treatments in the same model,  
which increases the reliability of the comparisons and ensures the selection of the best 
available active control to compare with the test treatment (Schmidli & Wandel, 2011). The 
direct comparisons were between the placebo and the active treatment in the historical trials 
and between the active treatment and test treatment in the NI trial. The indirect comparison 
is between the test treatment and the placebo. The strength of the network depends on the 
treatments in the network, how they are presented in the model, and the evidence they carry 
(Tonin et al., 2017). The analysis framework can be implemented using either Frequentist 
or Bayesian approaches. As in pairwise meta-analysis, fixed and random effects models 
can be used in NMA. In addition to the assumptions of homogeneity, the consistency 
assumption is also essential in NMA. 
These assumptions must be based as far as possible on both statistical and clinical 
judgement (Tonin et al., 2017). These assumptions include the homogeneity assumption, 
where trials in the network meta-analysis that are directly compared must be sufficiently 
similar, and the similarity assumption, where the trials included in NMA should be selected 
based on well-defined criteria that ensure the similarity between the trials. The study 
population, study design, efficiency measures and the effect modifiers should be 
comparable to reduce the chance of bias in the pooled estimate (Tonin et al., 2017). 
Finally, for the consistency (transitivity) assumptions, which are specific for network meta-
analysis, there should be an agreement between direct and indirect evidence (White, Barrett, 
Jackson, & Higgins, 2012). When direct and indirect evidence are combined for a particular 
comparison, it is vital that the indirect estimate is not biased, and there is no discrepancy 
between the direct and indirect comparisons (Tonin et al., 2017). The statistical 
manifestation of the consistency is called transitivity (Tonin et al., 2017).  
Hoaglin describes both fixed and random effect models, implemented using both 




2.5.3.1Fixed effect network meta-analysis 
In the following results, A is the primary reference treatment (active control), B is the 
placebo, and C is the test treatment. AB trials are the historical trials, and AC trial is the NI 
trial. The indirect comparison will be between B (placebo) and C (test treatment) (Hoaglin 
et al., 2011). The fixed effect model is given by: 
𝜂𝑗𝑘 = {
𝜇𝑗𝑏                                                                  𝑏 = 𝐴, 𝐵, 𝐶, 𝑖𝑓 𝑘 = 𝑏                       
𝜇𝑗𝑏 + 𝑑𝑏𝑘 = 𝜇𝑗𝑏 + 𝑑𝐴𝐾 − 𝑑𝐴𝑏                𝑘 = 𝐴, 𝐵, 𝐶, 𝐷 𝑖𝑓 𝑡ℎ𝑒 𝑘 𝑖𝑠 𝑎𝑓𝑡𝑒𝑟 𝑏
𝑑𝐴𝐴=0
 (2.9) 
Where 𝜂𝑗𝑘 is the outcome of treatment k in study j, 𝜇𝑗𝑏 is the outcome for treatment b in 
study j, dbk is the fixed effect of treatment k relative to treatment b. The 𝑑𝑏𝑘are identified 
by expressing them in terms of effects relative to treatment A: 𝑑𝑏𝑘 = 𝑑𝐴𝑘−𝑑𝐴𝑏with 𝑑𝐴𝐴=0 
(the order of the subscripts on 𝑑𝑏𝑘 is conventional, but counterintuitive). For the underlying 
effects, this relation is a statement of consistency: the “direct” effect 𝑑𝑏𝑘and the “indirect” 
effect 𝑑𝐴𝑘−𝑑𝐴𝑏are equal. 
2.5.3.2Random effect network meta-analysis 
The random effect model takes into consideration both within trial variation (sample 
variation) and within between-trial variation. The study-specific treatment effects 𝛿𝑗𝑏𝑘 are 
assumed to follow a Normal distribution 𝛿𝑗𝑏𝑘~𝑁(𝑑𝑏𝑘, 𝜎
2), where σ2 is the random effect 
variance and when σ2  = 0 (i.e. there is no between-study heterogeneity) a fixed effect 
model is specified (Hoaglin et al., 2011). 
The random effects model can be written as: 
𝜂𝑗𝑘 = {
𝜇𝑗𝑏                                                                                  𝑏 = 𝐴, 𝐵, 𝐶, 𝑖𝑓 𝑘 = 𝑏                       
𝜇𝑗𝑏 + 𝛿𝑗𝑏𝑘                                                                    𝑘 = 𝐴, 𝐵, 𝐶, 𝐷 𝑖𝑓 𝑡ℎ𝑒 𝑘 𝑖𝑠 𝑎𝑓𝑡𝑒𝑟 𝑏
 
𝛿𝑗𝑏𝑘~𝑁(𝑑𝑏𝑘 + 𝛽𝑏𝑘𝑋𝑗, 𝜎
2) = 𝑁(𝑑𝐴𝑘 − 𝑑𝐴𝑏 + (𝛽𝐴𝑘 − 𝛽𝐴𝑏)𝑋𝑗, 𝜎
2)    (2.10) 




The 𝑑𝑏𝑘are identified by expressing them in terms of effects relative to treatment A: 𝑑𝑏𝑘 =
𝑑𝐴𝑘−𝑑𝐴𝑏with 𝑑𝐴𝐴=0 (the order of the subscripts on 𝑑𝑏𝑘 is conventional, but counterintuitive). 
For the underlying effects, this relation is a statement of consistency: the “direct” effect 
𝑑𝑏𝑘and the “indirect” effect 𝑑𝐴𝑘−𝑑𝐴𝑏are equal. 
The random effect model allows for heterogeneity between and within the trials, but it 
cannot explain it (Hoaglin et al., 2011). Using network meta-regression models that take 
into account the covariates in the model may account for and explain heterogeneity, and 
therefore reduce both inconsistency and biases (Jansen et al., 2011). However, Rothmann 
et al. argue that the use of the random effect model could lead to biased results since it gives 
more weight for smaller trials which usually tend to have more extreme results (Rothmann 
et al., 2012). 
Both Frequentist and Bayesian approaches could be used for NMA. The Frequentist 
approach measures the probability that the observed results occurred under specific 
sampling distribution of the hypothesised values of the parameters (Tonin et al., 2017). 
This approach applies traditional statistical methods to make the comparison. A network 
meta-analysis belongs to a category of generalised linear mixed models that use a 
likelihood-based function to estimate model parameters (point estimate) and estimate the 
confidence interval (CI) (Schmidli & Wandel, 2011). In the case of NI trials, the primary 
interest is the indirect prediction of the efficacy of the test treatment compared to placebo.  
Bayesian Network Meta-analysis combines the likelihood function with prior information 
about these parameters to obtain a posterior distribution for these parameters (Hoaglin et 
al., 2011). The Bayesian approach can lead to a straightforward prediction of the treatment 
effect. However, a common criticism is that the results could be biased if an inappropriate 
prior was chosen (Hoaglin et al., 2011).  
37 
 
Using Bayesian methods in the analysis of NI trials became more popular due to the 
advances and the availability of Bayesian software, also because Bayesian methods provide 
an intuitive framework for accounting more for the heterogeneity between the trials (Lin et 
al., 2016). In the Bayesian model, the likelihood function represents the extent to which 
different values for the parameter of interest are supported by the data (Hoaglin et al., 2011). 
The posterior distribution (the outcome) can be interpreted regarding probabilities of which 
treatment from the compared treatments is the best and also other probabilities can be 
definined (Jansen et al., 2011). 
An example of a Bayesian random effect model with log odds as the outcome measure 
(Hoaglin et al., 2011) is given below: 
Likelihood:         (2.11) 
𝑟𝑗𝑘~𝑏𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑃𝑗𝑘 , 𝑛𝑗𝑘) 
Model: 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑗𝑘) = {
𝜇𝑗𝑏                        𝑏 = 𝐴, 𝐵, 𝐶, 𝑖𝑓 𝑘 = 0
𝜇𝑗𝑏 + 𝛿𝑗𝑏𝑘,      𝑘 = 𝐵, 𝐶, 𝐷, 𝑖𝑓 𝑘 𝑎𝑓𝑡𝑒𝑟 𝑏
                               
𝛿𝑗𝑏𝑘~𝑁(𝑑𝑏𝑘, 𝜎
2)~𝑁(𝑑𝐴𝐾 − 𝑑𝐴𝑏 , 𝜎
2)        
   𝑑𝐴𝐴 = 0     
Priors: 
𝑑𝐴𝑘~𝑛𝑜𝑟𝑚𝑎𝑙 (0, 10
6) 𝑘 = 𝐵, 𝐶, 𝐷  
  𝜎 ~ 𝑢𝑛𝑖𝑓𝑜𝑟𝑚 [0, 2]        
The main challenge in using a Bayesian approach is choosing the appropriate prior 
distribution (Hoaglin et al., 2011; Lin et al., 2016; Schmidli & Wandel, 2011). The choice 
of prior should be based on the nature of the studies that are included in the network, as 
well as the purpose of the analysis.  
38 
 
The choice of the prior depends on the distribution of the data (e.g. continuous or binomial) 
and the structure of the network (the number of treatments included in the network). A 
stronger prior is needed if not enough data is available (Hoaglin et al., 2011).  
In the analysis of the Essence trial, Schmidli and colleagues used a standard reference 
normal prior for the random effect means and a half normal prior for the between-trial 
standard deviation (Schmidli, Wandel, & Neuenschwander, 2012).  This approach was the 
same approach as used by Hoaglin et al. and Lin et al. (Hoaglin et al., 2011; Lin et al., 
2016). There is a need to check the assumptions in the Bayesian approach in the same way 
as in the Frequentist approach (Hoaglin et al., 2011). Several methods were proposed for 
evaluating the consistency assumption (Lu & Ades, 2006; Lumley, 2002). 
Both Frequentist and Bayesian methods have their pros and cons. A Frequentist approach 
will result in point estimated confidence intervals, while a Bayesian approach provides a 
posterior distribution of the parameters from which summaries such as median and 95% 
credible intervals (CrI) can be taken (Hoaglin et al., 2011). Checking the assumptions is 
very important in both approaches.  
Addressing inconsistency is the main challenge in the Frequentist approach. In the Bayesian 
approach, the subjectivity in choosing the prior distribution is the main issue. The Bayesian 
approach covers the uncertainty in the study parameters and makes direct probability 
statements regarding interested parameters, i.e. it has a straightforward way to make 
predictions with more flexible prediction models (Tonin et al., 2017).   
As mentioned in Chapter 1 (1.2.1) the main aim of this thesis is to investigate how the 
adjustment for the time scale could improve the estimate used for setting the NI margin; 
using network meta-analysis in the analysis of NI trials while adjusting for co-variables 
(network meta-regression) could be one possible solution.  
2.6 Illustrated Example 
Until now, this thesis has described three possible methods for analysing the NI trial: two 
that are described as regulatory approaches (fixed effect method and synthesis method) and 
the network meta-analysis (the predictive approach). This example, will illustrate how these 
different methods could be used to analyse an NI trial. 
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The OASIS-5 was a multicentre double-blinded randomised controlled trial that 
investigated the non-inferiority of fondaparinux (test treatment) compared to enoxaparin 
(Active control) (low molecular heparin LMWH). It included 20,078 patients from 576 
centres from forty-one countries. The primary endpoint was the triple endpoint of death, 
myocardial infarction (MI) or refractory ischemia (OASIS investigators, 2006) 
There were no placebo-controlled trials to compare the enoxaparin and placebo. The 
investigators used a meta-analysis of historical placebo-controlled trials that compared 
either heparin (unfractionated heparin UFH) or other LMWH to placebo (Eikelboom et 
al., 2000) to establish the efficacy of enoxaparin compared to placebo. The estimate from 
the historical meta-analysis shows that the odds of death or myocardial infarction in the 
UFH and LMWH groups compared to placebo group were 0.52 [0.37; 0.72]. This means 
the odds of death in the placebo group compared to active control (UFH or LMWH) were 
1.92 [1.38; 2.70]. Figure 4.2 illustrates the forest plot for the difference between the 








2.6.1 .Using the fixed margin method for analysis of OASIS trial 
From Figure (2.4), the M1 will be the lower limit of the 95% CI of placebo versus (LMWH 
and UFH) =1.38. M2 will be the ½ log odds at the lower limit of the 95% CI = 1.18. The 
reason for chosing the 50% of the M1 is based on clinical judgement and the 
recommendation from the FDA (OASIS investigators, 2006; FDA, 2016). In the OASIS 
trial, the odds of death or MI (95 % CI) = 0.9 (0.81; 1.01), the upper limit of the 95% CI 
was less than the M2 (1.18). Based on these results, the non-inferiority of the fondaparinux 
compared to enoxaparin can be concluded. 
 
2.6.2 Using the Synthesis method for the analysis of OASIS trial 
Under the synthesis method, a 50% fraction from the main estimate from the meta-analysis 
of placebo-controlled trial (LMWH and UFH versus placebo) will be used as M2 instead 
of the whole estimate M1. Test statistics (Z) will be used for the analysis (FDA, 2016). The 
predetermined Z< -1.96.  
Log odds (T-C) (fondaparinux versus enoxaparin from the NI trial) = log 0.9 
Log odds (C-P) (LMWH & UFH versus Placebo from the meta-analysis) = log (1/1.8) 
(𝑇 (Fondaparinux) − 𝑃(𝑃𝑙𝑎𝑐𝑒𝑏𝑜)) =  
(log 𝑜𝑑𝑑𝑠 (𝑇−𝐶))+1 2⁄ (log 𝑜𝑑𝑠𝑠 (𝐶−𝑃))
√(𝑆𝐸(𝑇−𝐶))2+(1 2⁄ 𝑆𝐸 (𝐶−𝑃))
2
  (2.12),  




 = - 6.5 
The (- 6.5) is less than (more negative) -1.96. The non-inferiority of the fondaparinux 
compared to enoxaparin is concluded. 
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2.6.3 Using the network meta-analysis for the analysis of OASIS trial 
The NMA will be conducted using the Frequentist package “netmeta” R Package (Guido 
Schwarzer, 2015). The historical placebo-controlled trials used by the OASIS investigator 
to set the non-inferiority margin will be incorporated in a network with the OASIS trial to 
investigate the efficacy of the test treatment fondaparinux compared to enoxaparin 
(LMWH). The network is composed of the placebo, the active control (LMWH and UFH) 
and the test treatment (fondaparinux) (Figure 2.5). 
  
 
Figure 2-5 Evidence of network of the three included treatments 
 




Table 2.1 Comparison of the odds ratio of the three treatments in the network 
 Fondaparinux, odds 
(95% CI) 
Active control, odds 
(95% CI) 
Placebo, odds (95% CI) 
Fondaparinux 1.00 0.90(0.80; 1.01) 0.49(0.34; 0.71) 
Active control 1.10(0.99; 1.25) 1.00 0.55(0.39; 0.77) 
Placebo 2.01(1.41; 2.86) 1.81(1.29; 2.52) 1.00 
Active control; LMWH or UFH 
From Table (2.1) and Figure (2.6), the conclusion is that both the active control and the 
fondaparinux were superior to placebo. Moreover, NMA can provide the rank of the best 
possible treatments based on the probability. The probability fondaparinux will be ranked 
as the best treatment was 98.47%, the remaining 1.53% is the probability of being ranked 
second or third. The probability that the active control will be ranked first is 51%. For 
placebo, the probability of it being ranked the best is 0.0%. 
The results from the three methods are the same. The conclusion is that the fondaparinux 
was superior to placebo and non-inferior to the active control (enoxaparin). It should be 
noticed that the investigators used placebo-controlled trials that did not include the active 
control of enoxaparin specifically. Instead, they used placebo-controlled trials of other 
treatments similar to enoxaparin.  
2.7 Summary 
This chapter has described the concepts, assumptions and challenges associated with the 
design of NI trials, the setting of NI margin, and the methods used for the analysis of NI 
trials. Compared to traditional superiority trials, NI trials have many methodological and 
regulatory challenges that can influence proper analysis and inference of the results. 
A major challenge in designing and conducting any NI trial is the choice of the appropriate 
active control and obtaining its efficacy indirectly from historical studies. Assay sensitivity 
and the constancy of active control effect size over time and controlling for bio-creep and 
placebo creep are the main issues in choosing appropriate active control. Including a 
placebo arm in the NI trial will control for most of these challenges. However, this is not 
feasible most of the time for clinical reasons. Other methods like population homogeneity 
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and similarity between trials could reduce the risk of bio-creep and placebo creep but 
cannot control it.  
This thesis will investigate the changes in the treatment difference between the active 
control and placebo and how adjusting for these changes could adjust the constancy 
assumptions and reduce the chance of placebo creep. The bio-creep and the assay 
sensitivity assumptions will be included in the context of the investigation of the constancy 
assumption and placebo creep. 
This chapter has reviewed the different available methods for analysing NI trials. These 
include the fixed margin and synthesis approach (regulatory approaches), network meta-
analysis (predictive approach). None of these methods adjusts for changes in the time, and 
it is evident that setting the NI margin by any of these methods depends on the availability 
of the historical trials (Table 2.2). 
Table 2.2 Comparison between the different methods for the analysis of NI trials 
Comparison Fixed margin method Synthesis method  NMA 
Active control Only one active control can 
be included  
Only one active control 
can be included 
Can include more 
than one active 
control  
M1 Specified in the designing 
phase  using the boundaries 
of the 95% CI of historical 
placebo-controlled trials 
Specified in the designing 
phase  using the main 
estimate of the 95% CI of 
historical placebo-
controlled trials 
Cannot be specified 
in the designing 
phase 
M2 Specified in the designing 
phase as a fraction of M1 
Specified in the designing 
phase as a fraction of M1 
Cannot be specified 




No No Yes 
 
Includes co-
variables in the 
analysis 




Choosing the appropriate method is dependent on the type of NI trial, the primary endpoints 
and the availability of historical trials and a different comparator. Chapter 7 of this thesis 
will review the available methods for setting an adjusted NI margin. In Chapter 8, the 
chosen methods will be applied to two case studies of setting the non-inferiority margin. 
The next chapter will review the available regulations regarding conducting, analysing, and 





Chapter 3 Guidelines for Non-inferiority Trials 
3.1 Introduction 
The concepts of active-controlled trials and non-inferiority (NI) trials have become more 
popular since the 1990s (Figure 1.1). As mentioned in Chapter 1, NI trials are conducted to 
test and market a new treatment, to find an alternative or second-line treatment or to prove 
the efficacy of an existent treatment when a placebo-controlled trial is not possible. 
Different sponsors are involved in the funding of NI trials, including pharmaceutical 
companies, public health institutes, and educational institutes. Moreover, NI trials have 
several methodological challenges, especially in choosing the appropriate active 
comparator and determining the NI margin.  
These factors raise the need for guidelines on the conducting and reporting of active control 
and NI trials. In 1998, the international conference on harmonisation (ICH-E9) published 
the guidelines for conducting randomised control trials in general (ICH, 1998). Today there 
are several guidelines for the appropriate conduct of active-control and NI trials. These 
guidelines include ICH-E10, issued in 2001, regarding the choice of control group (ICH, 
2001), Committee for Medicinal Products for Human Use (CHMP), issued in 2005, that 
discussed the choice of NI margin (CHMP, 2005), and the Food and Drug Administration 
(FDA) draft guidelines for NI trials, issued in 2010 (FDA, 2010), and its final version, 
issued in 2016 (FDA, 2016), which concentrate on the design and setting and analysis of 
NI trials.  
In 2006 the Consolidated Standards of Reporting Trials (CONSORT) organisation released 
the CONSORT statement on the appropriate reporting of NI trials in medical journals, 
which was updated in 2012 (Piaggio et al., 2012). However, none of these guidelines 
establishes hard definitions; they provide guidance and recommendations only (FDA, 
2016). Moreover, most of these guidelines concentrate on drug trials. 
In this chapter, the most important American and European regulatory guidelines for non-
inferiority trials will be summarised in Section (3.2), the main topics discussed in these 
regulations will be explained in Section (3.3), and finally, the differences between the 
European and American guidelines will be identified. 
46 
 
3.2 Regulatory Guidelines 
3.2.1 ICH-E9: a statistical principle for clinical trials 
ICH-E9 could be considered as the bedrock for the statistical, regulatory guidelines for 
clinical trials. It gives a broad description of the design of all types of clinical trials, 
including non-inferiority trials (ICH, 1998). No methods for determining the NI margin 
were discussed. However, it specified that the margin should be justified clinically. 
Concerning the confidence interval, it recommends that the use of a one-sided interval and 
a type I error should be separate from the use of a one-sided or two-sided test (ICH, 1998). 
Furthermore, it highlighted the use of the full set analysis (all patients randomly assigned 
to a treatment group having at least one efficacy assessment after randomisation) as being 
non-conservative (concluding the non-inferiority of an inferior treatment) in NI trials.  
 A draft for the ICH-E9 addendum on estimands and sensitivity analysis was published in 
August 2017 (ICH, 2017). The addendum defined the estimands for a confirmatory clinical 
trial as 
“The target of estimation to address the scientific question of interest posed by the trial 
objective.” 
The document describes NI trials as non-conservative (concluding the non-inferiority of an 
inferior treatment) trials, and, because of that, the choice of estimand should be aimed to 
minimise the number of protocol violations and non-adherence and withdrawals (ICH, 
2017). 
3.2.2 ICH-E10: choice of the control group in a clinical trial and related issues 
ICH-E10 deals mainly with the choice of an appropriate control group in any clinical trial 
(superiority or NI trials). Different types of control groups are discussed in detail. It 
concentrates on different purposes of clinical trials and distinguishes between active control 
and placebo trials, and the concept of indirect comparison. However, no specific guidance 
was given on the choice of the non-inferiority margin. In these guidelines, the concept of 
assay sensitivity was highlighted and discussed. The constancy assumption was also 




3.2.3 European Medicines Agency (EMA) guidelines on choice of non-inferiority margin  
Adopted in July 2005 by the Committee for Medical Products for Human Use (CHMP), 
the guidelines focused on the actual choice of the non-inferiority margin and described the 
different situations where it is appropriate to conduct the non-inferiority trial. These 
guidelines are concerned with both the absolute efficacy of the test treatment compared to 
the placebo and the relative efficacy of the test treatment to the active control. Besides, they 
discuss the choice of NI margin in more detail compared to ICH-9 and ICH-10. CHMP 
recommends that the decision to perform an NI trial and choice of a specific NI margin 
should be justified in the protocol and should be based on both statistical reasoning and 
clinical judgement. 
According to CHMP guidelines, a three arm non-inferiority trial that includes placebo, 
active treatment and test treatment is the recommended design whenever possible since this 
kind of design will allow within-trial validation of the choice of NI margin. Choosing the 
appropriate margin will assure that the test treatment is clinically superior to the placebo. 
The primary focus of NI trials is on the relative efficacy of the test treatment and active 
control  (CHMP, 2005). CHMP stated that it is not possible to perform NI trials in all 
situations. The decision on choosing NI design should be justified in the protocol, 
considering both the therapeutic area and the active control (CHMP, 2005). Using a wider 
NI margin is possible according to CHMP if the trial is an efficacy trial, and the test 
treatment has advantages in other aspects. Still, the superiority to placebo should be 
confirmed. Finally, in extreme situations, it could be acceptable to run a superior trial with 
a level of two-sided significance greater than 0.05 as an alternative to the NI trial (CHMP, 
2005). 
3.2.4 The extension of the Consolidated Standards of Reporting Trial (CONSORT) 
The CONSORT statement for NI trials was published in 2006, with its extension published 
in 2012. It describes the publication of NI trials and the quality of published NI trials before 
and after 2006 and updates the recommendations to authors on how to report the design, 
conduct, and results of non-inferiority trials. It includes a checklist and flow diagram to 
help authors improve their reporting of NI trials (Piaggio et al., 2012). According to the 
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checklist, the authors should provide a rationale for choosing a non-inferiority design, 
providing the results from trials used to base the active control effect (Piaggio et al., 2012). 
 
3.2.5 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) 
This statement guides the elements that should be included in a clinical trials protocol, 
including the scientific, ethical, administrative elements. It provides a checklist of 33 items 
that applies to protocols for all clinical trials, concentrating on content, not the formatting 
(Chan et al., 2013). Regarding the NI trials, it recommends the use of sensitivity analysis 
to assess the robustness of trial results and to handle missing data. It recommends the use 
of both Per Protocol (PP)  and  Intent to Treat (ITT) analyses (Chan et al., 2013). 
3.2.6 The Food and Drug Administration (FDA) guidelines on non-inferiority clinical 
trials 
In 2016, the FDA finalised the draft guidelines published in 2010 regarding conducting and 
interpretation of non-inferiority trials. The document is the most detailed regulatory 
guidelines document for pharmaceutical and biotechnological companies wanting to use 
the NI design to test new treatment efficacy and for treatment approval. 
The guidelines are in four sections. Section 1 provides a general discussion of the main 
concept, design, and statistical analysis of non-inferiority trials. Section 2 provides details 
on different approaches used to determine the non-inferiority margin. Section 3 answers 
the most commonly asked questions about NI studies. Section 4 presents four examples for 
successful and unsuccessful NI trials to explain the different possible challenges that could 
arise during the process of designing, conducting, analysis, and the interpretation of non-
inferiority trials (FDA, 2016).  
This regulatory document highlighted the main issues with the NI trials and the difference 
between the superiority trial and NI trials in establishing the effectiveness, as well as 
reporting the main reasons for conducting NI trials and the number of NI trials needed for 
drug approval. FDA described the use of the fixed margin methods for determining the NI 
margin as the most conservative (chance of concluding the non-inferiority of an inferior 
treatment is low) method and the recommended method for setting the NI margin (FDA, 
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2016). The FDA regulations identified three alternative designs that can replace NI trials. 
These include an Add-on study, identifying a population not known to benefit from 
available treatment where the placebo-controlled trial is ethically acceptable and finally 
early escape, rescue treatment, randomised withdrawal for patients in placebo-controlled 
trials (FDA, 2016). 
3.3 Main regulatory points regarding NI trials 
3.3.1 Situations where NI trials could be used 
According to FDA and ICH-10 guidelines, the non-inferiority active-controlled design 
should be used instead of superiority design if the use of the placebo arm in the trial is 
unethical or if there is an interest in comparing the effectiveness or assessing the sensitivity 
of a placebo-controlled trial (FDA, 2016; ICH, 2001). CHMP presented different situations 
where NI trials could be conducted. These include the situation where the experimental 
treatment has a considerably better safety profile than the active comparator; areas where 
bioequivalence trials are not possible; cases where no important loss of efficacy compared 
to the active control would be acceptable; disease areas where the use of a placebo arm is 
not possible and an active control trial is used to demonstrate the efficacy of the test product 
(CHMP, 2005). 
3.3.2 Blinding 
All regulatory guidelines state that blinding is a necessary process to minimise bias. An 
open-label design can be adopted if blinding is not possible (FDA, 2016; ICH, 2001). 
3.3.3 Non-inferiority margin 
All regulatory guidelines recommend that an acceptable pre-specified non-inferiority 
margin should be pre-defined, and should not be larger than the presumed entire effect of 
the active control in the NI trial. The determination of the margin in the non-inferiority trial 
is based on both statistical reasoning and clinical judgement. According to the FDA 
regulation, two margins (defined previously in Section (2.4.2)) should be identified: the 
statistical margin (M1) and the clinical margin (clinical judgement) (M2). 
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M1 should be identified based on previous experience in properly designed placebo-
controlled trials sharing similar conditions to those planned for the NI trial and could be 
supported by dose-response or active control studies. 
 M2 should be based on clinical judgement and should be a fraction of M1 (FDA, 2016). 
In the anti-infective therapeutic field, FDA regulations recommend the use of 10% of the 
M1 margin as preferred NI margin (FDA, 2016). For cardiology, FDA regulations 
recommend the use of 50% of the statistically calculated M1 as the NI margin (M2) (FDA, 
2016). However, in other fields, such as oncology, no specific percentage is recommended. 
The fixed margin approach has also been recommended as an approach for analysing NI 
trials (FDA, 2016). The fixed margin approach was described in detail in sections (2.4.2.1 
and 2.5.1). According to the extension of the CONSORT statement, the margin should be 
specified in the publication (Piaggio et al., 2012).  
3.3.4  Sample size estimation 
The calculation of sample size for NI trials was described in detail in the FDA guidelines 
(FDA, 2016). The sample size of a non--inferiority trial should be based on a fixed margin 
approach and based on the need to rule out inferiority greater than M2, and this should be 
clearly stated in the protocol in the planning stage (FDA, 2016).  
Both the clinically estimated margin (M2) and the estimated variance of treatment effect 
will affect the sample size calculation (FDA, 2016). An increase in M2 will lead to a 
decrease in the required sample size to conclude the non-inferiority. NI trials typically have 
larger sample sizes compared with superiority trials. However, Fleming argues that the 
need for a larger sample size for trials that have a rigorous margin is a myth that was 
introduced by some industrial representatives at the meeting of the FDA Anti-infective 
Drugs Advisory Committee in 2002 (Fleming, 2008). The effectiveness of the test 
treatment compared to the active control plays a vital role in determining the sample size. 
If the test treatment is more effective than the control, a smaller sample size could rule out 
any given non-inferiority margin. However, in less effective or inferior test treatment, the 
larger sample size is needed to rule out the non-inferiority (FDA, 2016).  
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The extension of the CONSORT statement required reporting of justification of sample 
size (Piaggio et al., 2012). The appropriate choice of NI margin will lead to appropriate 
sample size calculation in the case of the NI trial. 
3.3.5 Analysis population 
NI trials in terms of analysis populations are different to superiority trials. In intent to treat 
(ITT) analysis, participants are compared in terms of their results within the groups to 
which they were originally randomised, regardless of receiving the treatment, having 
dropped out or violated the protocol. ITT is the preferred analysis in superiority trials since 
it protects the trial from serious errors associated with selection bias, protocol violations, 
and loss for follow up. The situation is different in NI trials. ITT analysis alone is not 
preferred since it could lead to a false conclusion of non-inferiority for a less effective test 
treatment (FDA, 2016).  
The alternative option is per protocol (PP) where only subjects meeting the inclusion 
criteria, receiving the treatment, and continuing until the end of the trial are considered in 
the final analysis. PP analysis is considered a conservative approach (chance of concluding 
the non-inferiority of an inferior treatment is low) in NI trials as it maximises estimates of 
the treatment difference. Hence PP analysis is the preferred primary analysis for NI trials, 
although the use of the PP analysis will lead to excluding patients from the analysis and 
could lead to an imbalance of the number of patients in each treatment arm, which will lead 
to bias in both directions (Rehal, Morris, Fielding, Carpenter, & Phillips, 2016). 
All of the regulatory guidelines recommend the use of both ITT and PP analyses, with both 
of these analyses having equal importance and being reported in NI trials (CHMP, 2005; 
CPMP, 2000; FDA, 2016; ICH, 2001). However, the definitions of PP and ITT populations 
were not the same and obscure between the guidelines. The CONSORT statement described 
the PP analysis as excluding patients who did not take the treatment or were not protocol 
adherent. While ICH-E9 described the analysis population as asubset of patients who 
complied with the protocol, adding to that the use of “as treated analysis” or modified ITT 
analysis. 
If differences emerge in the results of the two analyses (ITT and PP), further examination 




3.3.6 Switching between non-inferiority and superiority 
According to FDA guidelines, a planned NI trial can be tested for superiority without the 
need for adjusting for type I error. However, the conclusion of non-inferiority after a failed 
superiority trial gives uncertain results, and such a trial should be considered as a failed 
superiority trial (since the NI margin needs to be pre-specified before, not after, conducting 
the trial) (FDA, 2016). 
Switching between superiority and non-inferiority could be possible in some situations. In 
2000, The Committee for Proprietary Medicinal Products (CPMP) published a document 
setting out points to consider when switching between superiority and non-inferiority 
(CPMP, 2000). According to this document, switching could be feasible if: 
 The non-inferiority margin was predefined and well justified 
 Both the ITT and PP analysis were similar 
 The trial was adequately designed and conducted according to the regulatory 
guidelines 
 The trial has high sensitivity that is capable of detecting relevant existingdifferences 
 The efficacy of the control treatment is shown by either direct or indirect evidence. 
 
3.4 Differences between EMA and FDA guidelines 
The growing interest in NI trials has led to the development of several regulatory guidelines 
from both EMA and FDA. All of these guidelines aimed to specify and regulate the 
conducting of NI trials. The guidelines from both EMA and FDA are conceptually similar. 
However, the terminology used was different: margin M1 in FDA guidelines corresponds 
to demonstrating efficacy in EMA guidelines. Moreover, M2 in FDA guidelines 
corresponds to establishing acceptable relative efficacy to active control in EMA (CHMP, 
2005; FDA, 2016; ICH, 2001) 
FDA guidelines stated clearly that the fixed margin method is the recommended method 
for analysing NI trials (FDA, 2016). By comparison, EMA recommended the use of both 
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statistical and clinical judgement and did not specify a specific method for selecting the 
margin (CHMP, 2005; ICH, 2001). 
3.5 Summary 
In this chapter, different regulatory guidelines were summarised and presented. All of the 
guidelines set recommendations on the appropriate designing and conducting of non-
inferiority trials. However, none of them gives firm rules, and there is an apparent 
inconsistency between the guidelines that could negatively affect the quality and reporting 
of NI trials. 
Despite the availability of these regulatory documents, the conducting of NI trials is still a 
challenge. Given that NI trials are conducted by both public and pharmaceutical industry 
bodies and can be used for the drug approval process (FDA, 2016), it was important to 
review these regulations in this chapter since they are considered as an important aspect of 
the designing, conducting and reporting of NI trials. 
In the next chapter, a review of the NI trials that have been published in high impact journals 
will be presented; the review will aim to investigate whether these trials were conducted in 
accordance to the regulatory guidelines presented in this chapter. By the end of Chapter 4, 
a complete picture of the designing, conducting and reporting of NI trials will be formulated 






Chapter 4 Review of NI Trials Published in JAMA, 
Lancet, BMJ and NEJM in 2015 
4.1 Introduction  
The main challenges, assumption, and methods used for setting the NI margin were 
reviewed in Chapter 2 of this thesis and the main published regulatory guidelines regarding 
NI trials were reviewed in Chapter 3.  
This chapter aims to investigate the design, analysis, interpretation and reporting of NI 
trials in four top medical journals. Moreover, it will investigate the use of historical 
information to set the NI margin. The main concentration will be on the setting and 
reporting of NI margin and how it follows the regulatory guidelines; how the sample size 
of the NI trial was reported. The secondary objective is to compare the trials according to 
the source of funding. 
This chapter will start with the methodological section (4.2), where the methods of 
extraction and analysis will be presented. This will be followed by the results section (4.3), 
which will include the general characteristics of the trials, the NI margin setting and 
reporting and differences between the publicly and pharmaceutical company funded trials. 
A detailed discussion will be presented in Section 4.4, followed by a summary of the 
findings of this review in Section 4.5. 
4.2 Methods 
The Lancet, British Medical Journal (BMJ), Journal of American Medical Association 
(JAMA) and the New England Journal of Medicine (NEJM) were the medical journals 
chosen for inclusion in this review because they are considered as thehighest quality 
medical journals with robust publication standards and more likelihood of having a major 
influence on clinical practice. NI trials published in these journals will represent high 
standards of publication. 
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A search for NI trials published in these four journals between 1/1/2015 and 31/12/2015 in 
the PubMed database was performed by one reviewer (E.Duro). The original aim was to 
review trials conducted from 2010/2017. However, the advice from the confirmation 
review committee in August/ 2016 was that one year was sufficient to address the aims of 
this chapter and the thesis as a whole and for this reason only the year 2015 was used in the 
review.  
The inclusion criteria were NI trials that were randomised clinical trials, done on adult 
humans, published in English and with the full text available. A standardised data extraction 
form was created (Appendix A). Data extracted using the form included general 
information on the journal’s name, registration number on registry database, type of 
treatment (cardiovascular, anti-infective, surgical, gynaecology, and others), the phase of 
the trial (II, III, or IV), single centre or multicentre, and source of funding (public, private 
or both).  
Information about blinding was obtained in accordance to the manuscript (open-label: no 
blinding, single: only the participants are blinded, double-blinding: both the researcher and 
the participants are blinded, or ambiguously stated: not clearly stated in the manuscript); 
type of statistical analysis used: ITT or PP or both (the definitions of ITT and PP were 
presented in section 3.3.6), primary endpoints (efficacy, safety, or both), sample size and 
power (calculation and justification), presence of placebo arm, study design (double arm, 
triple or four arm and parallel or crossover design) and conclusion (non-inferiority 
concluded or not, or if superiority was also concluded beside the non-inferiority), and the 
presence of ethical committee were retrieved.  
Specific information on the setting of the NI margin was also extracted, including how it 
was calculated; if based on statistical consideration or clinical judgement or both; and how 
it was interpreted, if the primary analysis was similar to the one stated in the protocol or 
not. Clinical trials registries were used to fill out any missing information regarding the 
protocol, type of population used in the analysis and NI margin. Data were summarised, 






In total, 387 articles were retrieved. Only 45 articles were published in the Lancet, BMJ, 
JAMA and NEJM, of which 37 were analysed, six articles were excluded because they 




Figure 4-1 Flow chart for the trials extraction process 
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4.3.1 General Characteristics 
Table 4.1 provides the general characteristics of the included trials. All of the 37 trials 
included in this review were randomised, multicentre trials. The study protocol was 
available online for most of the included trials. Out of these 37 articles, 15 were published 
in the Lancet, 12 in NEJM, five in BMJ and five in JAMA. Regarding the type of treatment, 
12 (32.4%) of the studies were cardiovascular, and homoeostasis studies, six (16.2%) were 
anti-infective, four (10.8%) were oncology studies, four (10.8%) were trials on 
gynaecology and obstetrics. Additionally, three (8.1%) related to surgical procedures, three 
(8.1%) to each of autoimmune disease and rheumatology, and four (10.8%) to each of 
dermatology, diabetes mellitus, ophthalmology, vaccines and respiratory disease. A full list 
of included trials is presented in Appendix B. According to the source of funding, 19 
(51.4%) of the trials were funded publicly, 15 (40.5%) were funded by pharmaceutical 
companies, and in three (8.1%) trials, the funding was provided by a combination of public 
and private sector organisations. All of the trials were multicentre trials with a median 
sample size of 571, minimum of 106 and maximum of 14215 patients.  
Regarding the blinding, 25 (67.6%) of the studies were open-label studies (no blinding); 
among these open-label trials, in 15 (60%) blinding was not possible, with no specific 
reason given for the non-blinding in the other ten (40%) trials. Blinding is considered an 
essential part of any randomised controlled trial, either superior or NI trials. Although all 
the regulatory guidelines (FDA, 2016; ICH, 2001) recommended the use of double blinding 
to reduce the chances of bias in randomised clinical trials, only eight trials in this review 
were double-blinded, and 25 trials were open-label. Most of the open-label trials (60%) 
justified their use of open-label design by stating that blinding was not possible, while the 
remaining 40% did not justify the use of open-label design. 
The phase of the trial was not reported in 27 (73%) trials, eight trials (21.6%) were 
described as phase III trials, and the other two (5.4%) were described as phase II trials. The 
primary endpoint was efficacy endpoint in 30 (81.1%) trials, five (13.5%) trials had two 
primary endpoints for efficacy, as an NI trial and safety as a superiority trial. One trial 
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tested both the efficacy and safety as an NI design and the other one tested safety as NI and 
efficacy as superiority. 
Table 4.1 The characteristics of included NI trials 
Category Number of trials (%) 
Type of Treatment  
Anti-infective 6 (16.2%) 
Cardiology 12 (32.4%) 
Oncology 4 (10.8%) 
Others 15 (40.6 %) 
Funding  
Public 19 (51.4%) 
Private 15 (40.5%) 
Both 3 (8.1%) 
Blinding  
Open Label 25 (67.6%) 
Single Blinded 4 (10.8%) 
Double Blinded 8 (21.6%) 
Conclusion  
NI concluded 25 (67.6%) 
NI not concluded 8 (21.6%) 
Both NI and Superiority concluded  4 (10.8%) 
Analysis  
Intent to Treat (ITT) 9 (24.3%) 
Per Protocol (PP) 5 (13.5%) 
Primary ITT and PP as sensitivity 18 (48.6%) 
Primary PP and ITT as sensitivity 5 (13.5%) 
ITT; Intent to treat, PP; per protocol 
Regarding the study design, 30 (81.1%) trials had two arms parallel design. Four trials had 
three arms, one trial had four arms, one had a 2X2 design, and one had crossed over design. 
Ten (27%) of the trials conducted an interim analysis. Sensitivity analysis was conducted in 28 
(75.7%) of the trials. Finally, 23 (62.16%) of the studies used both ITT and PP analyses. 
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Most of the manuscripts reported that the reason for choosing the NI trial instead of the 
superiority trials was the presence of standard active treatment instead of placebo. The choice 
of the active comparator (the active control) was justified in all of the trials as being the most 
used or recommended treatment by the regulations.  
Given that the classical NI trial is considered to be the trial where two active treatments are 
compared to conclude the non-inferiority of the test treatment to the active control and 
indirectly superiority of test treatment to placebo, the design of the reviewed trials was not the 
classical active-controlled NI form. Only 21 (56.8%) of the trials compared two treatments 
(active versus test treatment) and six (16.2%) trials compared two surgical procedures. The NI 
design was used to compare the duration for the same treatment (Barone et al., 2015; Bernard 
et al., 2015), route of administration (Cox et al., 2015; Le Page et al., 2015), surgical versus 
medical treatment (Kehoe et al., 2015; Salminen et al., 2015).  
Usually, NI trials do not include a placebo arm since the presence of a placebo arm is 
considered unethical or not good practice. However, in this review, four trials included a 
placebo arm. In one trial (Bachelez et al., 2015) the placebo was used to test the superiority of 
the test treatment (tofacitinib) versus placebo and to test the non-inferiority of tofacitinib 
compared to the active treatment etanercept.  This trial was the only trial that used a placebo in 
this way and concluded the superiority of the test treatment to the placebo in addition to the 
non-inferiority of the test treatment to the active control directly. In the ELIXA trial (Pfeffer et 
al., 2015) the aim was to conclude that the test treatment (lixisenatide) was not inferior to the 
placebo in regard to cardiovascular outcome in diabetic patients (since the efficacy of this 
treatment to improve the glycaemic control and weight reduction in the diabetic patient was 
already known). However, it was not understood why the author used the NI design instead of 
safety superiority design (the study was funded by the company who manufactured this 
medicine). This study concluded that the lixisenatide was not inferior to placebo in the 
reduction of cardiac events in patients with type II diabetes.  
Two other trials used placebo as test treatment and aimed to show the standard treatment was 
no better than placebo. The BRIDGE study (Douketis et al., 2015) aimed to prove no 
perioperative anticoagulant bridging was not inferior to bridging with low molecular weight 
heparin in patients with atrial fibrillation who would be having a surgical procedure. The 
RAPID trial (Radford et al., 2015) was an oncological trial that aimed to prove no further 
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radiotherapy was not inferior to further radiotherapy in patients with Hodgkin lymphoma. In 
both studies, the investigators claimed that the evidence of the effectiveness of the active 
control was weak and based on observational studies. All these trials contain a placebo arm in 
their design, but still, it is used as an experimental arm in the trial, which is unusual for NI 
trials. The ASPECT-cUTI study (Wagenlehner, Umeh, Steenbergen, Yuan, & Darouiche, 2015) 
was the only study that mentioned the possibility of placebo creep in the chosen dose of active 
control. 
Regarding the population included in the analysis, the regulatory guidelines recommend the 
use of both ITT and PP design, with PP as the primary analysis if the conclusion was different 
between the two populations (FDA, 2016). The combination of ITT and PP analysis was the 
most common type of analysis in 23 trials (62.12%). However, the definitions of the ITT and 
PP population used were not the same across the trials. The use of modified ITT (mITT) 
population was evident in most of the trials, instead of the classical ITT population. Besides, 
the use of the words “as a treated population” to reflect the modified PP was popular too. One 
trial described four different populations (Goldstein et al., 2015);   modified ITT(mITT), ITT 
efficacy (ITT E),  ITT safety (ITT S), and per protocol (PP) population. The disagreement 
between the different regulatory guidelines in the definition of the PP versus ITT populations 
is the main reason for these different definitions (Rehal et al., 2016). Both ITT and PP designs 
have their pros and cons and neither of them is considered as the gold standard for NI trials 
(Rehal et al., 2016). In the case of NI trials using PP, analysis will exclude patients with missing 
data and will give results that are more conservative (chance of concluding the non-inferiority 
of an inferior treatment is low) compared to the ITT design (FDA, 2016). The population 
included in the primary analysis should be predefined in the protocol. Moreover, the methods 
used for handling missing data should be specified in the protocol. In this review, most of the 
trials that used ITT analysis used multiple amputations to handle the missing data. 
4.3.2 NI margin setting  
Table 4.2 presents the characteristics of the NI margin in the reviewed trials. All of the reviewed 
trials reported their NI margin. The methods for determining NI margin were not evident in 
nine (24.3%) trials. In ten (27%) trials, the margin was calculated based on previous studies 
only. Clinical judgement alone was used in six (16.2%) trials. The NI margins were justified 
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based on both clinical judgement and historical trials in nine (24.3%)  trials and based on the 
regulatory guidelines in only three (8.1%) trials.  
There was no explicit calculation formula; none of the trials mentioned fixed margin method 
or synthesis method or any other specific methods. The trials aimed to test the non-inferiority 
only in 27 (73%) trials and aimed to test both the non-inferiority and superiority in ten (27%) 
of the trials. 
Sensitivity analysis was reported in 28 (75.7%) of the trials, and usually this means the use of 
PP or ITT analysis as a second analysis. The interim analysis was reported only in ten (27%) 
of the trials. The risk difference was used as a measure of effect for the NI margin in 31 (83.3%) 
trials, the hazard ratio was used in five trials (13.5%) and one trial (2.7%) used the relative risk 
as a measure of effect. Type I error was determined to be 0.05 in 17 (45.9%) of the studies and 
the power of 80% in 17 trials (45.9%). All trials except one justified the sample size calculation 
(Behringer et al., 2015). 
Additionally, 27  (72.9%) trials reported the use of two-sided 95% CI. Among these, 11 trials 
reported type I error of 0.025 and 12 (32.4%) reported the type I error as 0.05, while six trials 
did not report the type I error. Non-inferiority was concluded in 29 (78.4%) of the trials, among 
which four trials concluded the superiority of the test treatment over the active control in 




Table 4.2 The characteristics of the NI margin 
Category Number of trials (%) 
NI margin Justification 
Based on historical data 10 (27.0%) 
Based on clinical judgement 7 (18.9%) 
Based on both historical data and clinical judgement 8 (21.6%) 
Based on regulation 3 (8.1%) 
Not stated 9 (24.3%) 
Confidence Interval (CI) 
Two-sided 95% CI 27 (73.0 %) 
One-sided 95% CI 4 (10.8%) 
Two-sided 90% CI 3 (8.1%) 
One-sided 90% CI 2 (5.4%) 
One sided 97.5% CI 1 (2.7%) 
Type I error 
0.025 12 (32.4%) 
0.05 17 (45.9%) 
0.1 2 (5.4%) 




4.3.3 Public versus private funding 
Table 4.3 presents the differences between the public and private funded trials. Regarding these 
differences, nine of the trials funded by pharmaceutical companies were cardiovascular trials, 
two of them were anti-infective, others included vaccines, diabetes, rheumatology and 
dermatology. There was a statistically significant difference between the trials funded publicly 
and trials funded by pharmaceutical companies concerning the conclusion. Among the 
privately funded trials, out of 15 trials, ten (66.7%) of them concluded non-inferiority, four 
(26.7%) concluded superiority and only one trial (6.7%) failed to conclude non-inferiority. 
Among the publicly funded trials, 13 out of 18 concluded non-inferiority, six failed to establish 
non-inferiority, and no superiority was concluded (p-value =0.02). 
Regarding the blinding process, there was a statistically significant difference between the 
publicly funded trials and trials funded by pharmaceutical companies. Most of the publicly 
funded trials were open label 18 (94.7%), and only one trial was double-blinded. In contrast, 
40% of private funding trials were open-label trials, 20% were single-blinded, and 40% were 
double-blinded (P-value < 0.01). There were no statistically significant differences between 
the public trials and trials funded by pharmaceutical companies concerning the NI methods or 
the primary analysis.   
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Table 4.3 Differences between public and private funded trials 
 Public trials, N 
(%) 
Private trials, N 
(%) 
Both N (%) 
Type of Trial 
Anti-infective 4 (21.1%) 2.0 (13.3%) 0.0 (0.0%) 
Cardiovascular and haemostasis 2 (10.5%) 9.0 (60.0%) 1.0 (33.3%) 
Oncology 2 (10.5%) 0.0 (0.0%) 1.0 (33.3%) 
Gynaecology 4 (21.1%) 0.0 (0.0%) 0.0 (0.0%) 
Others 7 (36.8%) 4.0 (26.6%) 1.0 (33.3%) 
Methods for determining NI margin 
Historical data 3 (15.8%) 5.0 (33.3%) 2.0 (66.7%) 
Clinical Judgement 4 (21.2%) 2.0 (13.3%) 0.0 (0.0%) 
Both historical data and clinical 
judgement 
8 (42.1%) 1.0 (6.7%) 0.0 (0.0%) 
Based on regulation 1 (5.3%) 2.0 (13.3%) 0.0 (0.0%) 
Not stated 3 (15.8%) 5.0 (33.3%) 1.0 (33.3%) 
Blinding 
Open label 18.0 (94.7%) 6.0 (40.0%) 1.0 (33.3%) 
Single blinding 0.0 (0.0%) 3.0 (20.0%) 1.0 (33.3%) 
Double blinding 1.0 (5.3%) 6.0 (40.0%) 1.0 (33.3%) 
Conclusion 
NI established 13.0 (68.4%) 10.0 (66.7%) 2.0 (66.7%) 
Superiority established 0.0 (0.0%) 4.0 (26.7%) 0.0 (0.0%) 
NI not established 6.0 (31.6%) 1.0 (6.7%) 1.0 (33.3%) 
Type of primary analysis 
ITT 4.0 (21.1%) 5.0 (33.3%) 0.0 (0.0%) 
PP 3.0 (15.8%) 2.0 (13.3%) 0.0 (0.0%) 
Primary ITT and sensitivity as PP 11.0 (57.9%) 5.0 (33.3%) 2.0 (66.7%) 
Primary as PP and sensitivity as ITT 1.0 (5.3%) 3.0 (20.0%) 1.0 (33.3%) 




4.4.1 General Characteristics and NI margin  
The conducting and reporting of NI trials are associated with regulatory and statistical 
challenges and usually this kind of trial is poorly conducted (Rehal et al., 2016), mostly due to 
disagreement between the regulatory guidelines. In this review, the NI trials published in 2015 
in the top four medical journals were used to assess the quality of the published NI trials in 
general and to investigate how the challenges and assumptions of NI trials (the assay sensitivity, 
bias minimising and constancy assumption) were presented in the practical field  of setting and 
conducting the NI trials. 
All regulatory guidelines demanded reporting of the NI margin and its justification by statistical 
and medical judgement. All reviewed trials specified the NI margin used (100%) and the 
chosen margin was justified in 28 trials (75.6%). Only nine trials used both statistical relevance 
and medical judgement to establish the NI margin as recommended by the regulatory guidelines. 
Moreover, even when they did, the justification was ambiguous with little detail and usually 
referred to references that do not clearly state how the margin was chosen. 
Moreover, most of the trials reflected the choice of the margin as based on “investigator 
assumptions” without any further explanations. Two trials justified the use of a wide NI margin 
that was determined by clinical judgement only on the basis of there being no historical data 
available (Bensdorp et al., 2015; Cooper et al., 2015). The subjectivity in the setting of NI 
margin was due to the use of clinical judgement that depended on the clinicians’ opinion rather 
than being evidence-based. All trials that depended on clinical judgement only concluded the 
NI, while only two thirds of the trials that used both statistical and medical judgement 
concluded the non-inferiority. None of the reviewed trials explained or mentioned the method 
used to set the NI margin even in the study protocol that was published online. The NI margin 




The changes in the active control efficacy over time were not reported in most of the trials. 
However, in a trial that assessed the efficacy and safety of FXI-ASO compared to enoxaparin 
as prophylaxis for venous thrombosis after total knee arthroplasty, the investigators considered 
changes in the active control efficacy compared to the placebo and reduced the selected NI 
margin by 50% to account for the retention of enoxaparin effect compared to placebo (Büller 
et al., 2015). 
There was an inconsistency between the type I error used for sample size calculation and the 
confidence interval used for the conclusion. Most of the regulatory guidelines recommend the 
use of two-sided 95% CI with a corresponding one-sided type I error of 0.025 (CHMP, 2005; 
FDA, 2016; Piaggio et al., 2012). In this review, 23 (62.16%) of the trials used the two-sided 
95% CI, 11 of them used the type I error of 0.025 and the other 12 used one-sided type I error 
of 0.05. Both type I error and power of the study should be reported and whether the type I 
error is one-sided or two-sided. Use of two-sided 90% CI is also acceptable if the type I error 
is stated to be one-sided 0.05, as was the case with the CAP-START trial which used two-sided 
90% CI with corresponding one-sided 0.05 type I error (Postma et al., 2015).  
The non-inferiority was established in 29 (78.4%) of the trials. These results could be 
influenced by the fact that trials with positive results are more likely to be published, regardless 
of the study design (superiority or non-inferiority)(Lee, Bacchetti, & Sim, 2008). Out of nine 
trials that tested both superiority and non-inferiority, only four established the superiority of 
the test treatment compared to the active control. Switching from non-inferiority to superiority 
is acceptable by all of the regulatory guidelines and no adjustments are needed for type I error 
(FDA, 2016; Lewis, 2001).  
4.4.2 Public versus private funded trials 
Around half of the reviewed trials were publicly funded trials. Compared to the pharmaceutical 
companies, public funded trials tend to use a more conservative (more controlling for type I 
error) margin and usually compare already existing treatments, not a new treatment, or compare 
two well-known regimens.  
More details regarding sample size, randomisation and blinding can be seen in private funded 
trials since most of the time these trials will be used for drug approval application. However, 
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the way the NI margin was chosen was not clear in two thirds of privately funded trials and 
only one private funded trial used both statistical and clinical judgement to justify the chosen 
NI margin. Fifty-three per cent of the privately funded trials used both ITT and PP analysis 
compared to 63.15% of the publicly funded trials. Only one privately funded trial failed to 
declare the non-inferiority compared to six publicly funded trials. The four trials that concluded 
superiority were privately funded trials. 
One of the reviewed trials that can illustrate the manipulation of NI margin and the conclusion 
is the PROCEED II trials (Ardehali et al., 2015). This trial was a prospective, open-label, 
multicentre, randomised non-inferiority trial, funded by Trans Medics (the manufacturing 
company for Organ Care system). The trial aimed to assess the “clinical outcomes” of the 
Organ Care System compared to the standard cold storage of human donor hearts for 
transplantation. The test treatment was the Organ Care System, and the active control was the 
standard cold storage of human donor hearts. Both efficacy and safety endpoints were 
determined. The primary endpoint was 30-day graft survival with 10% difference as non-
inferiority margin. Both ITT as primary analysis and PP analysis were performed. The 
investigators justified the use of a cold storage system as the standard care. Sample size 
calculation was based on an NI margin of 10% difference, with the use of a normal 
approximation test, and a one-sided α level of 0.025; the inclusion of 54 patients per treatment 
group would provide 80% power. The final sample size was 64 patients in each arm. 
Regarding the role of funding the investigators stated (Ardehali et al., 2015):  
“The funder of the study had a role in study design and data collection. The authors were 
responsible for data interpretation, data analysis, and writing of the report.” 
The results were for the ITT analysis (128 patients were included) of the 30-day patients, and 
graft survival rates were 94% (n = 63) in the Organ Care System group (T) and 97% (n = 61) 
in the standard cold storage group (C), (difference 2·8%, one-sided 95% upper confidence 
bound 8.8; P=0·45) (Ardehali et al., 2015).   
For the PP analysis 121 patients were included in the final analysis; the 30-day patients and 
graft survival accounted for 93% in the Organ Care System group (T) and 97% in the cold 
storage group (difference 3.4%, one-sided 95% upper confidence bound 9.9; P-value = 0·39). 
69 
 
The incidence of severe rejection in the Organ Care System was 11 (18%) compared to nine 
(14%) in the standard group (between-group difference was four, 95% CI (-8; 17, p-value = 
0.52). In their conclusion, the authors (Ardehali et al., 2015) stated: 
“In conclusion, our findings show that the clinical outcomes of donor hearts adequately 
preserved with the Organ Care System platform are non-inferior to the outcomes of those 
preserved with standard cold storage. Evaluation of the metabolic assessment capability of the 
Organ Care System requires further study.” 
 There was a discrepancy between the protocol and the actual conducting of the study; in their 
protocol, the investigators stated that the PP analysis would be the primary analysis for this 
study (TransMedics, 2008). However, ITT analysis was the actual primary analysis for this 
trial without any protocol amendments. In PP analysis, the upper limit of 95% CI was 9.9, and 
the cut-off point was 10% (it is not clear if it is considered clinically acceptable to declare non-
inferiority of the Organ Care System); the P-value for non-inferiority was not statistically 
significant. Moreover, for the other secondary points, there were no statistically significant 
differences between the groups, i.e. no additional benefits for the Organ Care System over the 
standard treatment were reported. Even with all these serious considerations, the authors still 
concluded the non-inferiority of the test treatment compared to the standard treatment. 
As mentioned earlier, publicly funded trials tend to be more conservative (more controlling for 
type I error) in choosing the NI margin. For example, in a publicly funded trial that aimed to 
compare azithromycin (T) versus doxycycline (C) for urogenital chlamydia trachomatis 
infection (Geisler et al., 2015), the aim was to conclude the non-inferiority of azithromycin (1 
g in one dose) to doxycycline (100 mg twice daily for seven days). The primary endpoint was 
treatment failure (efficacy). The study was a two arms parallel study with a sample size of 567 
patients, as an open-label study. Both treatments had already been tested and recommended by 
the Centre for Disease Control in the USA (CDC). Previous studies had been conducted to 
investigate the efficacy of both treatments. An interim analysis was used to recalculate the 
sample size. The primary analysis was per protocol analysis. A non-inferiority margin of 5% 
difference was chosen. Regarding the NI margin setting the investigators stated that 
“This non-inferiority study was designed to test the null hypothesis that the absolute rate of 
azithromycin treatment failure would be at least 5 percentage points higher than the absolute 
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rate of doxycycline treatment failure against the alternative hypothesis that there would be no 
difference between regimens, with a failure rate of 3% for both (a rate that was based on the 
results of the meta-analysis).” 
 Regarding their justification of using NI margin of 5%, the author stated:  
“The decision to use the difference cut off of 5 percentage points was based on the reported 
high cure rates for both treatments.” 
In terms of clinical judgement, the investigator stated:  
“this difference was considered by the investigative team to be an appropriate cut-off to 
establish the clinical non-inferiority of azithromycin to doxycycline.” 
In the results, the doxycycline group had no treatment failure compared to five (3.2%; 95% CI, 
0.4 to 7.4%) patients in the azithromycin group. The observed difference in failure rates was 
3.2%, with an upper boundary of the 90% CI of 5.9 percentage points, which exceeded the pre-
specified absolute 5-percentage cut-off point for establishing the non-inferiority of 
azithromycin. The non-inferiority margin of 5% is considered conservative (chance of 
concluding the non-inferiority of an inferior treatment is low) compared with the 10% margin 
difference recommended by FDA regulations (FDA, 2016).  
The chief investigator was contacted by email and asked for the reason for using this 
conservative margin (Geisler, 2016), and the answer was: 
“The reason for using the smaller non-inferiority margin of 5% was because the anticipated 
treatment failure rate for both regimens was only 3 %. Also, typically for a drug to be 
recommended first-line by CDC, it should have an efficacy of 95% or higher.” 
The evidence from the trial is that azithromycin is not a newly introduced treatment; instead it 
is a well-established treatment for urogenital tract infections, and the trial was not funded by 
the manufacturing company. Moreover, for other benefits of using azithromycin rather than 
doxycycline, the compliance rate was higher for the azithromycin group compared to 
doxycycline. For adverse events, 23% of participants in the azithromycin group had adverse 
events compared to 27% in the doxycycline group. The use of a conservative margin (more 
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control for type I error) could be the reason for the failure to establish the non-inferiority of 
azithromycin compared to doxycycline. The use of only per protocol for analysis reduced the 
chance of establishing the non-inferiority.  
4.4.3 Comparison with other reviews 
All included trials reported the NI margin. The rate of justification was higher in this review 
(75.4%) compared to the other similar reviews; in systematic reviews of NI trials that were 
published in high impact journals between 2010 and 2015 (Rehal et al., 2016) the rate of 
reporting the NI margin was 98% and the rate of  justification was 45%.  
Wangg et al. stated that 97.8% of the trials reported the NI margin and only 45% justified the 
NI margin used (Wangge et al., 2010), while Schiller et al. stated that 94% of the reviewed 
trials reported the NI margin and only 23% justified the used NI margin (Schiller, Burchardi, 
Niestroj, & Kieser, 2012). However, the Schiller review included all NI trials published in 2009 
regardless of the quality of the published journal. The rate of justification was even lower (20%) 
in Henanff et al. (Le Henanff, Giraudeau, Baron, & Ravaud, 2006) who reviewed the NI trials 
in 2003, 2004 before the publication of the CONSORT statement in 2006 (Piaggio, Elbourne, 
& Altman, 2006). The reason for improvement could be the fact that the included journals in 
this review were the top four medical journals, which had stringent guidelines for publication.  
Concerning the population included in the analysis, 23 (62.16%) of the trials in this review 
used both PP and ITT analysis, which was higher than Wangge et al. (Wangge et al., 2010) 
who reported that 42% used both analyses. Also,  it is higher than Schiller et al.’s (Schiller et 
al., 2012) finding that 42% of the trials used both ITT and PP. The reason for this high rate 
could be that this review is the most recent one. 
Most of the trials in this review used two-sided 95% CI, which was a similar finding to previous 




This review reflects the publication of NI trials in high impact journals only and the results of 
this review cannot be generalised to other low impact journals. Second, only one reviewer 
extracted and reported the results of this review, which increased the chance of bias due to 
subjectivity, especially in regard to the methods used for NI margin justification. However, 
using the top four medical journals and the most recent year (at the time of review) will present 
a good picture of the quality of published NI trials. 
4.5 Summary 
Comparing with previous reviews, there was an improvement in the reporting within published 
NI trials (Le Henanff et al., 2006; Rehal et al., 2016; Schiller et al., 2012; Wangge et al., 2010). 
This improvement can be seen in the percentage of reporting of the NI margin and reporting of 
methods for setting the margin. However, the reporting of NI trials in the top medical journals 
is still not compatible with the regulatory guidelines, especially in terms of blinding, the 
population included in the analysis, and reporting and justification of the NI margin used.  
This chapter found that around sixty per cent of the trials that justified the NI margin used 
historical evidence in their justification of the NI margin, which reflects the importance of 
historical information in setting the NI margin. Most of them justified the use of active control. 
However, the subjectivity of using clinical judgement only was high since the medical 
judgement for setting the NI margin was hard to investigate due to its subjectivity.  
Up to this point, this thesis has investigated the importance of historical data in the designing 
phase of the NI trial and choosing the appropriate active control in Chapter 2. Chapter 3 
reviewed the available regulations regarding the NI trials and concluded that the only method 
recommended by the regulation is the fixed margin method, which compares a confidence 
interval from historical placebo-controlled trials with the confidence interval from the NI trial. 
In the current chapter, it was explained that around sixty per cent of the included NI trials that 
justified their NI margin based this on the historical data either alone or in combination with 
clinical judgement. 
The conclusion from all these chapters is that the historical placebo-controlled trials have a 
critical role in designing, setting, and analysis of NI trials, which was evident from the available 
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literature (Chapter 2), from regulatory guidelines (Chapter 3) and in practice (Chapter 4). 
Moreover, it was concluded that any changes in the treatment difference between the placebo 
and active control in the placebo-controlled trials would lead to biased estimation and false 
conclusion of non-inferiority of an inferior experimental treatment (Chapter 2). 
The next chapter of this thesis will investigate the changes in the treatment differences between 
the placebo and the active control over time (the constancy assumption). The correlations 
between the year of publication and the treatment effect will be measured in Chapter 5, 
followed by a regression analysis of these changes to build a predictive model to estimate the 
treatment effect based on the year of publication in Chapter 6. Chapter 7 will review the 
available methods to adjust the NI margin, then Chapter 8 will apply both adjusted and non-
adjusted methods for setting the NI margin in an NI trial. Chapter 9 will present the final 






Chapter 5 Changes in Treatment Response over Time 
5.1 Introduction  
The setting of NI margin depends heavily on an indirect comparison between the test treatment 
and the placebo from historical placebo-controlled trials that compare the placebo with the 
active control used in the NI trial. The primary assumption regarding the NI margin setting is 
the constancy of the active control effect over time compared to placebo and the assay 
sensitivity of the active control. Moreover, the main problems with indirect comparison are the 
presence of bio-creep and placebo creep, as discussed in Chapter 2. 
As mentioned in Chapter 2 (section 2.3.5), there is an argument regarding the constancy 
assumption and changes in the active treatment and placebo over time. Many studies have 
demonstrated improvement of the placebo response over time in different therapeutic areas 
(Julious & Wang, 2008; Walsh, Seidman, Sysko, & Gould, 2002) and they have argued that 
could be the reason for the violation of the constancy assumption and the presence of placebo 
creep.  
The changes in the treatment effect can be seen in the effect of aspirin as a painkiller. Aspirin 
has been used as a painkiller for more than a hundred years. If a clinical trial conducted in 1950 
that compared aspirin to a placebo concluded the efficacy of aspirin as a painkiller and the 
same trial was repeated in 2018, would the difference between aspirin and placebo stay the 
same? In addition, if there was a difference, would it be due to the improvement of the placebo 
effect (due to the improvement of the general care or other circumstances) or due to a reduction 
in the efficacy of the aspirin as a painkiller? Moreover, what if the aspirin was used as an active 
control in an NI trial in 2020? Would it be valid to assume that the efficacy of aspirin in 1950 
was the same as in 2020? For the 2020 NI trial would the constancy assumption and assay 
sensitivity both hold? Alternatively, would they change over time?  
Assuming that the effect of placebo improves over time and at the same time the effect of active 
control decreases over time, based on that assumption, the use of historical placebo-controlled 
trials to estimate the effect of placebo in the present time will be biased toward non-inferiority 
if no adjustment for the time is made. This chapter will investigate if there any changes in the 
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placebo and active control effects over time using the Cochrane reviews of placebo-controlled 
trials published in 2015/2016.  
The review will investigate the effect of year of publication (as a proxy to the time of trial 
conducting) on the difference between the active treatment and the placebo (effect size) over 
time by measuring the weighted correlation between standardised mean difference and year of 
publication in different therapeutic areas. In addition, it will investigate the effect of year of 
publication on placebo and active treatment responses after controlling for sample size. 
First, the methods used for reviewing the Cochrane reviews will be explained in Section 5.2. 
The results will be presented in Section 5.3. Three examples from the included reviews will be 
presented in Section 5.4 to illustrate the effect of year of publication on the treatment effect. 
Finally, discussion and conclusions will be presented on the main findings from this review. 
5.2 Methods 
5.2.1 Study design and data collection 
This study is an overview of the Cochrane systematic reviews of placebo-controlled trials 
published in the Cochrane database from January /2015 to December /2016.  
The inclusion criteria for selecting the relevant systematic reviews are: 
 Cochrane reviews of placebo-controlled trials 
 Defined as placebo-controlled trials by the review’s author regardless of the type of 
control group used (placebo, no treatment, usual care) 
 Meta-analysis was performed.  
 The meta-analysis included at least four placebo-controlled trials. 
 Meta-analyses published in 2015-2016 
The exclusion criteria are: 
 Reviews that were withdrawn from publication 
 Over reviews or reviews that included active-controlled trials 
 Reviews containing three or fewer trials 
 Reviews where meta-analysis was not performed 
 Reviews where all trials were conducted in the same year 
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The main reason for choosing reviews published between 2015 and 2016 was that these reviews 
would be the most recent ones and include all recent updates. Already conducted meta-analyses 
of the published systematic reviews was chosen to ensure similarity between the trials in the 
treatments used and the measure of effect, thereby ensuring that these trials can be compared 
to each other (this is usually the same case for the historical trials that were used in setting the 
NI margin). The chosen number of trials included was four or more trials because the aim was 
to exclude the last trial and predict its effect estimate from the remaining trials in the meta-
analysis using the included reviews (Chapter 6). Moreover, including less than four trials could 
lead to more extreme results, especially when measuring the partial correlations.  
Rayyan (Ouzzani, Hammady, & Fedorowics, Zbys, Elmagarmid, 2016), a web-based 
systematic review manager, was used to conduct the systematic review and retrieve the needed 
information. The keyword used in the primary search in the title and abstract was “placebo”, 
the abstracts were reviewed, and the inclusion and the exclusion criteria were applied.  
From each included review, information regarding Cochrane ID, publication year, Cochrane 
group, and medical speciality was retrieved. From each review, the first meta-analysis was 
chosen as the data point in the analysis unless it had no meta-analysis or had less than four 
trials. If the first meta-analysis could not be chosen, the next meta-analysis with more trials 
was chosen. If in any meta-analysis, the subgroups shared the weight in the study, they were 
included as one analysis. If the weight of the study was not shared between the subgroups, only 
the subgroup with the largest number of trials was included.  
From each included meta-analysis, information regarding the year of publication, number of 
trials included, type of control group used, the active treatment used, total number of patients, 
weight of each trial, total number of patients in the placebo and active treatment group, placebo 
and active treatment effect, measure of effect used, type of analysis (fixed or random), and 
heterogeneity were retrieved. Besides, the main estimate and 95% CI, and the last trial’s main 
estimate and 95% CI were retrieved, as well as information regarding the risk of bias and the 




5.2.2 Standardising the difference 
There was a need to obtain a standardised measure of effect to compare both the binary data 
and numerical data. For the binary data, the measure of effect was transferred to the odds ratio 
and then the standardised mean difference (SMD) was calculated from the odds ratio 
(Borenstein, Hedges, Higgins, & Rothstein, 2009) using the formulae below to convert the 
effect sizes to SMD 
𝑆𝑀𝐷 = 𝐿𝑜𝑔 𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 ×
√3
𝜋
     (5.1) 
𝑉𝑠𝑚𝑑 = 𝑉𝑙𝑜𝑔𝑜𝑑𝑑𝑠𝑟𝑎𝑡𝑖𝑜 ×
3
𝜋2













 ,     (5.3) 
where V denotes the variance of the log odds ratio, A is the number of events in the treatment 
group, B is the number of no events in the treatment group, C is the number of events in the 
control group and D is the number of no events in the control group. 
For continuous data, the measure of effect was the mean difference that was transformed into 
the SMD using Borenstein et al. (2009) 
𝑆𝑀𝐷 =
𝑋1̅̅ ̅̅ −𝑋2̅̅ ̅̅
𝑆𝑤𝑖𝑡ℎ𝑖𝑛













,      (5.6) 
Where 𝑆𝑤𝑖𝑡ℎ𝑖𝑛 is the within-groups standard deviation, pooled across groups, S1 is the 
standard deviation of the placebo group, S2 is the standard deviation of the control group, 
n1 is the sample size of the control group, n2 is the sample size of the active treatment 




5.2.3 Statistical analysis 
The correlation coefficient was used in previous studies to measure the association between 
the year of publication and the effect size (Julious & Wang, 2008; Walsh et al., 2002). In this 
analysis, the correlations (both for all trials in general and by the meta-analysis) between the 
year of publication and the SMD, placebo and active treatment and sample size were measured. 
Moreover, partial correlations were adjusted for the sample size between the year of publication 
and SMD, placebo, and active treatment was measured to assess the relationship between the 
year of publication as a proxy to the time of trial conducting and the effect size and the response 
of placebo and the active treatment, all in relation to the sample size. The year of publication 
was used as a proxy for the year of trial conducting, since this was the most appropriate and 
available information from all trials and was used in most of the literature as a proxy for year 
of conducting the trial (Agid et al., 2013; Julious & Wang, 2008; Walsh et al., 2002).  
A parametric (Pearson) correlation and non-parametric (Spearman) correlation between the 
SMD and year of the trial’s publication was calculated. The reviews included both reviews 
with positive (healing, improvement, etc.) and adverse outcomes (death, relapse, pain intensity). 
To perform one scale of measure, the SMD for the reviews of negative outcomes was 
transformed into a positive outcome, and then the correlations were calculated. All reviews 
presented in this chapter reported a positive outcome. As a sensitivity analysis, the absolute 
SMD was used too instead of transformation (the results from the absolute SMD are presented 
in Appendix C).  
The correlation is considered weak if the correlation coefficient is from [0 , 0.3], moderate if 
the correlation coefficient  is [0.3, 0.5], and a correlation coefficient of more than 0.5 is 
considered a strong correlation (Burns & Grove, 2007). The aim of subdividing the correlations 
into weak, moderate and strong correlations was to demonstrate the percentage of correlations 
that fell into these two categories regardless of the sign of the correlation.  
For the illustrated examples presented in this chapter, pairwise meta-regression with the year 
of publication as a covariate was used to assess the effect of year of publication on the main 
estimate of treatment difference between the placebo and the active treatment using the bubble 
plot. Pairwise meta-regression is a pairwise meta-analysis that can be adjusted for covariates. 
It was used in the literature to assess the effect of different covariates in the changes of placebo 
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effect over time in different therapeutic areas (Agid et al., 2013; Khan et al., 2017, 2018b, 
2018c); more details about the pairwise meta-regression will be presented in Chapter 7. 
SPSS version 24 (IBM Corp, 2016) was used to collect and analyse the data. Each meta-
analysis was treated as a separate SPSS data file then all these databases were aggregated in 
one SPSS file and organised by Cochrane ID. For the meta-regression, the R meta-package was 
used for the analysis (Schwarzer, 2007). 
5.3 Results 
5.3.1 Data extraction   
Following systematic reviews conducted in the Cochrane database, 684 titles were identified 
to have a placebo term in the abstract or the title. Of these, 289 titles were excluded after 
reviewing the abstract, and 98 titles were excluded after a secondary assessment of the review 
(reviewing the manuscript). The final sample included 236 reviews for analysis. Figure 5.1 
represents the flow diagram for the data extraction process. 
The main reasons for exclusion in the full-text article assessment were: three or fewer trials in 
the review (238 reviews); 53 reviews had no trials; 56 reviews had one trial; 69 had only two 
trials in the review; and 60 reviews had three trials. In 138 reviews, data could not be pooled 
for meta-analysis. 
Additionally, 59 reviews had the wrong study design: 52 were for active-controlled trials; two 
reviews were NMA; and five reviews were overviews of Cochrane reviews. Four reviews used 
non-medical treatment; four reviews were withdrawn from publication; three reviews had 




Figure 5-1 Flowchart for the process of data extraction  
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5.3.2 Characteristics of the included reviews 
In total, 2489 placebo-controlled trials from 236 meta-analyses were included in the final 
analysis. Among the meta-analyses, 155 (65.4%) measured negative outcomes, and 82 (34.6%) 
measured positive outcomes. Primary meta-analysis was used in 152 reviews (64.1%). The 
median number of trials was seven trials, and the mean was 9.9 trials, with a minimum number 
of four trials and a maximum of 51 trials. 
 The years of trial conducting ranged from 1931 to 2016. The year difference ranged from one 
year to 80 years. Among the included meta-analyses, 76 (32.1%) used mean difference as the 
measure of effect. The risk ratio was used in 131 (55.3%), the odds ratio in 27 (11.4%) of the 
meta-analyses, and the risk difference in only three meta-analyses (1.3%). The most common 
outcome measured was pain, 30 (12.17%), followed by death, 26 (11%), in the included meta-
analyses. The median sample size was 1160 participants with IQR (interquartile range) (494 - 
2229), the minimum sample size was 105 and the maximum was 43290 participants. 
Additionally, 103 (43.5%) meta-analyses used the fixed effect model and 134 (56.5%) used the 
random effects model. 
Figure 5.2 demonstrates the relation between the number of trials in the meta-analyses and the 
used model. The mean number of trials for the fixed effect model meta-analyses was 9.8 
compared to 11 trials in the random effects meta-analyses. However, the difference was not 
statistically significant. 
 




Increasing the sample size was associated with more positive results. Specifically, 170 (72%) 
of the included meta-analyses concluded statistically significant results and only 66 (28%) 
failed to reject the null hypothesis. Among meta-analyses with 4-7 trials, 66.4% had 
statistically significant results compared to 78.1% of the meta-analyses containing more than 
seven trials. The mean number of trials in the meta-analysis with statistically significant results 
was 11.34 compared to eight trials for the meta-analyses with non- statistically significant 
results (p-value = 0.012). 
Regarding the different types of control group included in the analysed meta-analyses (Figure 
5.3), 42.4% of the included meta-analysis defined the control group as a placebo, placebo or 
no treatment was used in 24.2% of the reviews, and 17.8% defined control group as placebo or 
no treatment or usual care.  
 
 




Table 5.1 explains the different Cochrane groups included in the review. There were 17 
different therapeutic areas; the most frequently occurring was Gynaecology and Obstetrics with 
37 (15.6%) reviews.  
Table 5.1 Distribution of the reviews by Cochrane groups 
 Cochrane group Frequency 
Pain, Palliative and Supportive Care Group 22.0 (9.3%) 
Pregnancy and Childbirth Group 20.0 (8.5%) 
Gynaecology and fertility group 15.0 (6.4%) 
Heart Group 13.0 (5.5%) 
Anaesthesia, Critical and Emergency Care Group 11.0 (4.7%) 
IBD Group 11.0 (4.7%) 
Musculoskeletal Group 10.0 (4.2%) 
Stroke Group 9.0 (3.8%) 
Kidney and Transplant Group 9.0 (3.8%) 
Airway group 8.0 (3.4%) 
Hypertension Group 8.0 (3.4%) 
Acute Respiratory Infections Group 7.0 (3.0%) 
Infectious Disease Group 7.0 (3.0%) 
Vascular Group 7.0 (3.0%) 
Common Mental Disorders Group 6.0 (2.5%) 
Drugs and Alcohol Group 5.0 (2.1%) 
ENT Group 5.0 (2.1%) 
Neonatal Group 5.0 (2.1%) 
Neuromuscular group 5.0 (2.1%) 
Schizophrenia Group 5.0 (2.1%) 
Skin Group 5.0 (2.1%) 
Upper GI and Pancreatic Diseases Group 5.0 (2.1%) 
Developmental, Psychosocial and Learning Problems Group 3.0 (1.3%) 
Epilepsy Group 3.0 (1.3%) 
Wounds Group 3.0 (1.3%) 
Hepato-Biliary Group 3.0 (1.3%) 
Tobacco Addiction Group 3.0 (1.3%) 
Bone, Joint and Muscle Trauma Group 2.0 (0.8%) 
Cystic Fibrosis and Genetic Disorders Group 2.0 (0.8%) 
Dementia and Cognitive Improvement Group 2.0(0.8%) 
Eye and Vision Group 2.0 (0.8%) 
Haematological Malignancies Group 2.0 (0.8%) 
Incontinence Group 20 (0.8%) 
Metabolic and Endocrine Disorders Group 2.0 (0.8%) 
Movement Disorders Group 2.0 (0.8%) 
Other groups 7.0 (3.0%) 
Total 236.0 (100.0%) 
IBD; inflammatory bowel disease 
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All included reviews included the risk of bias assessment following the author view. 
Randomisation, blinding, attrition, and reporting were all included in the assessment of the risk 
of bias. Regarding bias, 20.3% of the reviews were considered at high risk, 55.7% had a 
moderate risk of bias, in 9.7% of the reviews the risk of bias was hard to assess, and only 14.3% 
were considered to have a low risk of bias. The quality of evidence was reported for most of 
the reviews in the summary of findings box. The quality of evidence reflects the author’s 
confidence in the estimate of effect. Only 19.8% of the reviews had high quality of evidence, 
36.5% had moderate quality, while 43.5% of the reviews had low to very low quality of 
evidence (Table 5.2).  
 
Table 5.2 Risk of bias and quality of evidence 
Risk of Bias Frequency, N (%) Quality of Evidence Frequency, N (%) 
 High 48.0 (20.3%) Very Low 19.0 (8.1%) 
Moderate 131.0 (55.5%) Low 84.0 (35.2%) 
Low 34.0 (14.4%) Moderate 87.0 (36.9%) 
Unclear 23.0 (9.7%) High 47.0 (19.9%) 
Total 236.0 (100.0%) Total  236.0 (100.0%) 
 
The heterogeneity measured in 𝐼2was reported for all reviews and ranged from 0 per cent to 99 
per cent. The heterogeneity was defined as mild if 𝐼2 < 30%, moderate if,  30% ≤ 𝐼2 ≤ 50% 
and considerably high if 𝐼2 > 50%  (Whitehead, 2002). Half of the meta-analyses had mild 
heterogeneity, with 74 meta-analyses having  𝐼2 = 0%; 32.2% of them had considerably high 
heterogeneity; and only 17.8% had moderate heterogeneity. The heterogeneity was higher, with 
statistical significance, for meta-analyses that used a random effects model and for meta-






5.3.3 Results of Correlations 
Correlations between the year of publication and sample size, placebo effect, active treatment 
effect, SMD were obtained. Partial correlations between the year of publication and placebo 
effect, active treatment effect, SMD after controlling for the sample size were obtained. Both 
Pearson and Spearman correlations were obtained. Correlations were measured for the 2489 
trials in general and then individually for each meta-analysis. The results for parametric and 
non-parametric correlations were similar. The results regarding Spearman correlation are 
presented in Appendix C.   
5.3.3.1 Correlations between total sample size and year of trial publication 
For all included trials the correlation between the sample size in a trial and the year of 
publication was positively correlated with the Pearson correlation, 0.038, 95% CI [0.006; 
0.086], and the Spearman correlation was 0.15, 95% CI [0.0116; 0.194]. Regarding the meta-
analyses included, in 179 (75.5 %) meta-analyses the correlation between the year of 
publication and the sample size was a positive correlation with the median correlation = 0.2. In 
72.5% of the included meta-analyses, the Spearman correlation between the sample size and 
the year of publication was a positive correlation with mean correlation = 0.28 (Figure 5. 4).  
 




5.3.3.2 Correlation between the SMD and the year of publication 
The correlations for the reviews with negative outcome were transformed to positive outcomes 
to present one scale of measure. Regarding all included trials in general, the year of publication 
was negatively correlated with SMD, with Pearson correlation of - 0.013, 95% CI [-.055; 0.03] 
and Spearman correlation of - 0.048, 95% CI[ -.085; -0.007]. Regarding meta-analyses, 58.2% 
of the meta-analyses had a negative correlation between the standardised mean difference and 
the year of publication. The median correlation was - 0.12, mean was - 0.083 and the standard 
deviation (SD) = 0.43. For the Spearman correlation, the median was - 0.11, mean was - 0.087 
and SD = 0.43. (Figure 5.5) 
Regarding the partial Pearson correlation after controlling for the sample size, 56.8% of the 
reviews had a negative correlation between the year of publication and the SMD after 
controlling for the sample size. The median correlation was - 0.093, mean was - 0.059, and SD 
was 0.48 (Table 5.3 and Figure 5.6).  
Table 5.3 Correlation and the partial correlation between SMD and the year of 
publication 
Correlation Pearson correlation  Partial correlation  
Strong Negative 47.00 (19.90%) 48.00 (20.30%) 
Moderate Negative 38.00 (16.10%) 26.00 (11.00%) 
Weak Negative 53.00 (22.50%) 60.00 (25.40%) 
Weak Positive 45.00 (19.10%) 44.00 (18.60%) 
Moderate Positive 32.00 (13.60%) 25.00 (10.60%) 
Strong Positive 21.00 (8.9 0%) 33.00 (14.00%) 








Figure 5-5 Pearson Correlation between standardised mean difference and the year of 
publication 
 






5.3.3.3 Correlation between the placebo response and the year of publication 
As mentioned earlier, the correlations for the reviews with negative outcome were transformed 
into positive outcomes. In 58.6% of the reviews there was a positive correlation between the 
placebo response and the year of publication (Table 5.4). The median correlation was 0.09, 
mean was 0.07, and SD was 0.44. Regarding the Spearman correlation, the median was 0.06, 
mean was 0.05, and the SD was 0.44 (Figure 5.7).  
Table 5.3 Correlation between the placebo response and the year of publication 
Correlation Pearson correlation, N (%) Partial correlation, N (%) 
Strong Negative 29.0 (12.9%) 34.0 (15.1%) 
Moderate Negative 16.0 (7.1%) 23.0 (10.2%) 
Weak Negative 47.0 (20.9%) 50.0 (22.2%) 
Weak Positive 60.0 (26.7%) 47.0 (20.9%) 
Moderate Positive 35.0 (15.6%) 28.0 (12.4%) 
Strong Positive 38.0 (16.9%) 43.0 (19.1%) 
Total 226.0 (100.0%) 225.0 (100.0%) 
 
A partial correlation after controlling for the sample size was obtained in 226 reviews. In 52.2% 
of the reviews there was a positive correlation between the year of publication and the placebo 
response after controlling for the sample size. The median correlation was 0.05, mean was 0.04, 
and SD was 0.44. These results mean that increasing the year of publication will increase the 
placebo response, i.e. placebo response improved over time (Figure 5.8). There were no 
differences between the Pearson and Spearman correlations (Appendix C). Reviews in which 




Figure 5-7 Pearson Correlation between placebo and year of publication 
 





5.3.3.4 Correlation between the active treatment response and the year of publication 
The correlations for the reviews with negative outcome were transformed to positive outcomes 
to present one scale of measure between the negative and positive reviews. In 52% of the 
reviews there was a negative correlation between the active treatment response and the year of 
publication (Table 5.6). The median correlation was - 0.04, mean was - 0.02, and SD was 0.43. 
The median Spearman was - 0.10, mean was - 0.05, and SD was 0.43 (Figure 5.9).  
The partial Pearson correlation after controlling for the sample size was obtained in 226 
reviews. In 51.7% of the reviews there was a negative correlation between the year of 
publication and the active treatment response after controlling for the sample size. The median 
correlation was - 0.03, mean was - 0.02, and SD was 0.43 (Figure 5.10). There were no 
differences between the Spearman and the Pearson correlations (appendix C). 
Table 5.4 Correlations between the active treatment and the year of publication 
Correlation Pearson correlation  Partial correlation  
Strong Negative 34.00 (15.10%) 43.00 (19.10%) 
Moderate Negative 31.00 (13.80%) 35.00 (15.60%) 
Weak Negative 51.00 (22.70%) 38.00 (16.90%) 
Weak Positive 58.00 (25.80%) 51.00(22.70%) 
Moderate Positive 18.00 (8.00%) 18.00 (8.0%) 
Strong Positive 33.00 (14.70%) 40.00 (17.80%) 




Figure 5-9 Pearson Correlation between the active treatment and the year of 
publication 
 





The obtained correlations and partial correlations were affected only by the number of trials 
included in the analysis; meta-analyses with a smaller number of trials had the strongest 
correlations (SMD, placebo and active treatment) on both sides (positive and negative). The 
relation between the SMD correlations and the placebo correlations was in the opposite 
direction, while the relation between the active treatment correlations and the SMD correlations 
was in the same direction for both the Pearson and partial correlations (Figure 5.5 and Figure 
5.6). These results indicate that the active treatment, not the placebo, had the main impact on 
the changes of the SMD response over time. 
 
Figure 5-11 Matrix scatter plot showing the correlations between placebo, active 




Figure 5-12 Matrix scatter plot showing the partial correlations between placebos, 
treatment, SMD and the number of trials in the meta-analysis  
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5.4 Illustrated examples 
Three meta-analyses (from the included 236 meta-analyses) were selected to illustrate the 
changes in the treatment response and placebo response over time in this section. The first 
meta-analysis (Adams, Sekhon, & Wright, 2015) was selected because it was from the 
cardiovascular therapeutic area, which was the most common in this review and the least 
studied in the literature regarding the changes in placebo effect over time. Additionally, it used 
an objective outcome measure, depending on the changes of total cholesterol in the blood, and 
finally, it included a large number of trials with a 20-year difference in the publication years. 
The second review (Enthoven, Roelofs, Deyo, Van Tulder, & Koes, 2016) was chosen because 
it used a subjective outcome measure (pain) with a smaller number of trials included and range 
of publication years of over 20 years.  The third review (Se et al., 2016) related to the prevention 
of depression, and both the therapy and the outcome were measured subjectively. 
5.4.1 Atorvastatin for lowering lipids 
This review was published in 2015 and aimed to assess the effects of various doses of 
atorvastatin on body lipids (total serum cholesterol, low-density lipoprotein (LDL), high-
density lipoprotein (HDL) and triglycerides) in individuals with and without evidence of 
cardiovascular disease. It included 296 trials in total (242 before and after trials and 54 placebo-
controlled trials), with 38,817 patients in total. The main conclusion was that atorvastatin 
decreases total blood cholesterol and LDL-cholesterol in a linear dose-related manner. In 
general, the evidence from this review is considered as high-quality evidence and the risk of 
bias is considered as moderate (Adams et al., 2015). 
The meta-analysis used in this example contains 24 placebo-controlled trials published from 
1995 to 2014. The total sample size was 1902 participants. The active treatment was 
atorvastatin 10 mg. The mean difference of cholesterol reduction was the outcome 
measurement (negative outcome), and the fixed effect meta-analysis model was used to 
calculate the estimate. The final estimate was a statistically significant difference between the 
atorvastatin and the placebo in reduction of total cholesterol (mean difference (MD) = -25.44, 





Figure 5-13 Forest plot of the effect of atorvastatin on lowering blood cholesterol 
 
After transformation from negative to a positive outcome, there was a strong positive 
correlation between the sample size and the year of publication (r = 0.79, p-value = 0.03). This 
means that recent trials have a larger sample size than old ones. The correlation between the 
placebo and year of publication was a non- statistically significant moderate positive 
correlation (r = 0.33, p-value = 0.10). This correlation did not change after controlling for the 
sample size, the partial correlation was moderate positive correlation (r = 0.33, p-value = 0.13). 
The effect of placebo on lowering the cholesterol level was improved over time.  
The correlation between the atorvastatin and the year of publication was a statistically 
significant strong negative correlation (r = - 0.63, p-value < 0.01). The partial correlation after 
controlling for the sample size decreased but was still strong negative correlation (r = - 0.612, 
 P-value < 0.01). 
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In 1995, the atorvastatin decreased the cholesterol level by 30.30 mg/dl compared to 23.30 
mg/dl in 2014. The correlation between the SMD and year of publication was a strong negative 
correlation (r = - 0.65, p-value < 0.01). After controlling for the sample size, the partial 
correlation was also strong negative correlation (r = - 0.66, p-value <0.01). The difference 
between atorvastatin and placebo was decreased over time, even after controlling for the 
sample size (Figure 5.8).  
 
Figure 5-14 Bubble plot of the estimate mean difference between the atorvastatin and 
placebo by year of publication  
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5.4.2 Non-steroidal anti-inflammatory drugs for chronic low back pain (2016) 
This review aimed to assess the effects of non-steroidal anti-inflammatory drugs (NSAID) 
among people with chronic back pain. It includes 13 trials in total (six trials are placebo-
controlled trials; the other seven trials are active-controlled trials). Included in total were 1354 
participants with follow up between nine days and 16 weeks. The main conclusion was that 
NSAID effectively reduced pain and disability associated with low back pain compared to 
placebo. In general, the evidence from this review is considered as low-quality evidence and 
the risk of bias is considered as a moderate risk (Enthoven et al., 2016). 
The meta-analysis used in this example contains six placebo-controlled trials published from 
1982 to 2013. The total sample size was 1354 participants. The active treatment was different 
types of NSAID, and the outcome of interest was a reduction in the pain intensity from the 
baseline (negative outcome). The mean difference was the outcome measurement, and the 
random effect model was used to calculate the estimate. The final estimate was a statistically 
significant difference between the NSAID and the placebo in reduction of pain intensity (mean 
difference (MD) = - 6.97, 95% CI [-10.74; -3.19]) (Figure 5.9).  
 
Figure 5-15 Forest plot of the effect of NSAID on the reduction of pain intensity 
compared to placebo (size of the bubble reflects the sample size)  
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There was a strong non- statistically significant positive correlation between the sample size 
and the year of publication (r = 0.52, p-value = 0.26). That means recent trials have a larger 
sample size than old ones. The Spearman correlation was the same (r = 0.54, p-value = 0.26).   
The correlation between the placebo and year of publication was a non- statistically significant 
moderate positive correlation (r = 0.36, p-value = 0.48). That means the efficacy of placebo to 
reduce the pain was increased over time; this correlation did not change after controlling for 
the sample size, the partial correlation was a moderate positive correlation (r = 0.34, p-value = 
0.57). The correlation between the NSAID and the year of publication was a weak negative 
correlation (r = - 0.04, p-value = 0.90). The Spearman correlation was a moderate negative 
correlation (r = -0.45, p-value = 0.33). These correlations indicate that the efficacy of NSAID 
decreased with time. The partial correlation after controlling for the sample size changed to a 
weak positive correlation (r = 0.003, p-value= 0.9).  
The correlation between the SMD and year of publication was a strong negative  correlation (r 
= - 0.83, p-value = 0.04). After controlling for the sample size, the partial correlation was also 
a strong negative correlation (r = - 0.92, p-value = 0.03). The difference between the NSAID 
and placebo was decreased over time, even after controlling for the sample size. The difference 
between NSAID and placebo was decreased over time, even after controlling for the sample 
size (Figure 5.10).  
 
Figure 5-16 Bubble plot of the estimate mean difference by year of publication 
(size of the bubble reflects the sample size)  
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5.4.3 Cognitive behavioural therapy (CBT), third‐wave CBT and interpersonal therapy (IPT) 
based interventions for preventing depression in children and adolescents 
This review was published in 2016 and aimed to investigate the effectiveness of evidence‐
based psychological interventions (including cognitive behavioural therapy (CBT), 
interpersonal therapy (IPT) and third wave (CBT)) in preventing the onset of the depressive 
disorder in children and adolescents (Se et al., 2016).  
The primary outcome was depression diagnosis at medium-term follow up (up to 12 months), 
based on 32 trials with 5965 participants. The treatment used was a psychological, behavioural 
interventional therapy, not a physical drug therapy. The risk difference was the measure of 
treatment effect used with the random effects model, which was subjectively measured. Two 
subgroups were included in the analysis (Targeted and Universal).  
The result was a statistically significant reduction of the risk of having a diagnosis of depression 
for participants receiving an intervention compared to those receiving no intervention (risk 
difference (RD) ‐ 0.03, 95% CI [‐0.05; ‐0.01], P-value = 0.01) (Figure 5-17). The year 
difference was 21 years, from 1993 to 2014 — the outcome measure in this study. 
Both treatment groups were healthy at the beginning of the study. The aim was to assess the 
efficacy of this treatment in preventing depression but not in treating patients who had already 
been diagnosed with depression.  
There was a moderate non- statistically significant positive correlation between the sample size 
and the year of publication (r = 0.25, p-value = 0.17). That means recent trials have a larger 
sample size than old ones. The Spearman correlation was the same (r = 0.17, p-value = 0.36). 
The correlation between the placebo and year of publication was a non- statistically significant 
weak positive correlation (r = 0.24, p-value = 0.2). That means the efficacy of the placebo was 
increased over time. This correlation did not change after controlling for the sample size, the 
partial correlation was weak positive correlation (r = 0.26, p-value = 0.12). 
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The correlation between the CBT (active treatment) and the year of publication was weak 
positive correlation (r = 0.06, p-value = 0.13). The Spearman correlation was weak positive 
correlation (r = 0.18, p-value = 0.33). The partial correlation after controlling for the sample 
size changed to weak positive correlation (r = 0.15, p-value = 0.43).  
  
 






The correlation between the SMD and year of publication was a weak negative  correlation (r 
= - 0.15, p-value = 0.42). After controlling for the sample size, the partial correlation was also 
weak negative correlation (r = - 0.08, p-value = 0.6). The difference between the CBT and 
placebo was decreased over time even after controlling for the sample size (Figure 5-18). 
 
Figure 5-18 Bubble plot for the changes in the risk difference by year of publication 
(size of the bubble reflects the sample size) 
 
5.5 Discussion and conclusion  
A review of the Cochrane reviews of placebo-controlled trials was performed in this chapter. 
The aim was to investigate the effect of changes over time (year of publication) on the 
difference between the active and control treatment (placebo) by measuring the correlation 
between the SMD and the year of publication.  
The correlations of the SMD varied from strong positive correlations in 21(8.9%) reviews to 
strong negative correlations in 47(19.9%) reviews. The median correlation between SMD and 
year of publication was skewed toward the negative, with a weak negative correlation of -0.1. 
Even though the correlation is considered weak, its negative sign refers to the inverse 
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relationship between the SMD and the year of publication. That means the difference between 
the active treatment and placebo was larger in older trials compared to the most recent ones.  
There was one review study that also investigated this issue. Rattehalli et al. assessed the effect 
of antipsychotics to treat schizophrenia (the rate of drop out) using 12 clinical trials from 1992 
to 2014. The correlation between the standardised mean difference and year of publication was 
-0.35, which means that the difference between the placebo and active treatment decreased 
over time. 
Most of the published studies concentrate on the placebo response over time. The results of 
this review were similar to  Agid et al. (Agid et al., 2013),   We et al. (We et al., 2012) , Nielsen 
(Nielsen, 2016),  Linde et al. (Linde et al., 2016) and Hm et al. (Hm et al., 2009) in assessing 
the placebo effect over time. The current review showed that the correlation between the 
placebo and the year of publication was a positive correlation of 0.07, which reflects the 
positive relationship between the placebo and the year of publication.  
The strongest correlations were between the sample size and year of publication, with a mean 
correlation of 0.2. That means the sample size in the meta-analysis increased with increase in 
the publication years. For the effect size of the active treatment itself, the correlation was -0.05. 
These results reflect a decrease in the effect of the active treatment over time, which was larger 
in older studies than the recent ones. 
Putting all of this together, the results from this chapter indicate a decrease in the effect size of 
the active treatment and increase in the effect size of the placebo that led to decrease in the 
difference (SMD) between the active treatment and placebo. These results were illustrated by 
the three included examples that explain the changes in the treatment differences between the 
active treatment and the placebo. These correlations varied from strongly positive to strongly 
negative. The only factor affecting the results was meta-analyses with a smaller number of 
trials that had extreme correlations.  
The three included examples concluded that the changes in the SMD were due to the changes 
in both the placebo (improvement) and the active control (reduction), with the changes being 
more apparent in the active control than the placebo.   
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There has always been an argument that the improvement in the placebo effect group is due to 
changes in the population and the standard treatment (Kamper & Williams, 2013). However, 
in this review the changes were noticed even for therapeutic areas that used objective outcomes.  
In the first illustrated example, the outcome measure was the total cholesterol level in the blood, 
and the improvement in the placebo group over time was quite clear in   comparison to the 
atorvastatin group. That means the improvement was not due to the placebo effect only; instead 
it was due to changes in the adjuvant treatment and due to the regression to the mean phenome. 
The type of placebo included did not affect the results of the correlations.  
The changes in the sample size over time were clear too. Regarding the sample size, 75.8% of 
the included reviews had a positive correlation between the year of publication and sample size, 
which means that recent studies tend to have a larger sample size than the oldest ones. These 
results are considered as a proof that the changes in the placebo and active treatment responses 
were due to regression to the mean, changes in the population and the improvement in the 
adjuvant treatment, but not due to the effect of the placebo itself.  
The fact that larger studies are the most recent ones raises another argument regarding the type 
of model that should be used in a meta-analysis. A fixed effect model depends on the sample 
size and gives more weights for larger studies, which are usually the recent ones. While a 
random effects model gives more weights for the smaller (older) studies to account for any 
possible heterogeneity. In my opinion, in the case of NI trials, where the boundaries of the 
confidence interval are more important than the point estimate, using a fixed effect model may 
be more preferred than the random effect model since it will give more weight to the most 
recent studies (the larger ones). This hypothesis will be investigated in Chapter 6. 
This review used published data only, which could be considered as a limitation for the 
generalisability of the results since published trials are usually trials with positive results (H. 
Rothstein et al., 2005). Moreover, in this review, 72% of the included meta-analyses have 
statistically significant positive results. This could increase the possibility of publication bias. 
However, this kind of data (published trials) is usually used in the indirect comparison 
situations, either in general or in the estimation of the NI margin from the historical data. That 
means this review is very relevant to the real situation in NI trials.  
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The use of the year of publication as a surrogate for the year of trial conducting could be 
considered as a limitation for this review. That is because the meta-analyses used hadalready 
been published and it was difficult to find the actual year of trial conducting, especially for the 
older trials. Another limitation was that some of the included meta-analyses had the smaller 
sample size of four trials. This could affect the reliability of the results. However, the 
parametric and non-parametric results were both similar. 
Subdividing the correlations to strong, moderate and weak correlations could also be 
considered as a limitation of this review. However, the aim of this categorisation was to 
demonstrate the strength of the correlations regardless of their direction, since the median and 
mean correlations were weak in general. 
Different therapeutic areas, different treatments, and different types of placebo groups were 
included in this review, which is considered as a strength for this review. Overall, regarding 
the treatment difference between the active control and placebo, 58.5% of the included meta-
analyses had either a moderate or strong correlation with time. That means the constancy could 
be assumed in only 41.5% of the included meta-analyses. Adjusting to the sample size, 
improved the percentage of constancy to 44%, but constancy was still lacking in more than half 
of the included meta-analyses. For the placebo response, the constancy assumption held in 47.5% 
and this was reduced to 43.2% after controlling for the sample size. The active control effect 
was constant in 48.4% of the included meta-analyses and this proportion was reduced to 40% 
after controlling for the sample size, which means the sensitivity of the active control was not 
constant.  
These results indicate that assuming constancy of the treatment difference between the active 
control and placebo and assuming that the sensitivity of the active control will not change over 
time will lead to a biased estimate of the treatment effect. In the case of the non-inferiority the 
trial, this will lead to the conclusion of the non-inferiority of an inferior test treatment.  
These results highlight the importance of time changes in the case of indirect comparisons 
between different treatments, especially in the case of NI trials, which depend heavily on the 
indirect comparison between the placebo (P), and the experimental treatment (T) via the active 
treatment (C) assuming the constancy. In the next chapter, the magnitude of the changes in the 
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treatment difference will be studied using a regression model and aiming to predict the 






Chapter 6 Incorporating Time in the Estimation of the 
Treatment Effect Based on Historical Trials  
6.1 Introduction 
The main aim of the thesis is to quantify the non-inferiority margins when using retrospective 
data to inform the decision, and their effect on the analysis of NI trials. Chapter 5 found that 
the changes (reduction) in the treatment difference between the placebo and active treatment 
were due to improvement in the placebo response and decrease in the active treatment response 
over time. This chapter will investigate factors that affect the prediction of a future trial based 
on the available historical information using a weighted linear regression model. 
The detailed objectives will be presented in Section 6.2, followed by the methods used to 
formulate the dataset, build and validate the regression model in Section 6.3. The results will 
be presented in Section 6.4, followed by the discussion and conclusion in Section 6.5. 
6.2 Aim and objectives 
This chapter aims to investigate factors that affect the estimate of a future trial based on the 
available historical trials using the weighted linear regression to predict the standardised mean 
difference in a trial based on the standardised mean difference from a meta-analysis of previous 
trials.  
The objectives are 
 To compare the results of the point estimate using both fixed and random models 
 To assess the relationship between the point estimate (SMD) of a future trial (SMDlt) 
and the point estimate (SMD) of a meta-analysis of retrospective trials (SMDdl)  
 To assess the relationship between the point estimate (SMD) of a future trial (SMDlt) 
and the characteristics of the meta-analysis of previous trials  
 To build a regression model of prediction using SMDlt as the response variable  




6.3.1 Formulating the dataset  
A dataset was formulated from the previously collected reviews (236 Cochrane reviews (meta-
analyses) used in Chapter 5) to form a database for the analysis in this chapter. The included 
reviews are those with more than three trials conducted in different years after deleting the last 
trial(s). The excluded reviews were the reviews with only two trials remaining after removing 
the most recent trial (last trials), and reviews where all trials were conducted in the same year.   
The database contains the original estimate of the treatment effect from this meta-analysis and 
95% CI and the significance level, the SMD and its 95% CI for all trials in the meta-analysis, 
the calculated SMD after deleting the last trial(s) and its 95% CI, and the SMD for the last trial 
(s). It also includes the number of trials included in each meta-analysis, year difference between 
the last trials and first trials, and year difference between last trial and most recent trial after 
deleting the last trial. Other general information regarding the therapeutic area, active treatment, 
the original measure of effect used, heterogeneity, risk of bias, level of evidence, type of 
placebo and number of patients is included in the analysis. The unit of analysis is the meta-
analysis not the trials. 
For each meta-analysis in our database, three standardised mean differences were calculated: 
 The SMD for all trials included in the original meta-analysis (SMD) 
 The SMD for all trials included in the original meta-analysis, excluding the most recent 
(last) trial(s) (SMDdl) 
 The SMD for the most recent (future) trial(s) (SMDlt) 
Some of the included reviews had more than one last trial (most recent). There were two 
possible approaches to overcome this problem. The first approach was to use the most recent 
trial by its month of publication to determine the last trial. Other trials that were published in 
the most recent year but earlier in that year were included with the meta-analysis after deleting 
the last trials (SMDdl). Even with this approach, there were trials conducted in the same month 
or the same trials were used twice in the meta-analysis. For these reviews, a meta-analysis of 
these last trials was conducted, and the pooled estimate of the standardised mean differences 
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from all these trials was used. Using this approach, the changes in the same year could be 
measured.  
The second approach was to calculate the SMDlt when there was more than one last trial in a 
review; a meta-analysis for all last trials published in the same year (the type of model used 
(FE or RE) was applied in accordance to the original model used in the meta-analysis of all 
trials). The pooled estimate of the standardised mean differences from these trials was used as 
the point estimate of the last trial (SMDlt).  
To investigate the effect of using the random and fixed models in the estimate of the meta-
analysis and its 95% CI, both random and fixed effect models were applied in addition to the 
main model used in the meta-analysis. According to the model used, there will be a dataset for 
the original model, a dataset for a fixed model and a dataset for a random model.  
Six different datasets were formulated based on the analysis approach for dealing with multiple 
last trials and model used in the meta-analysis (Table 6.1). 
Dataset 1:  This dataset had SMDdl from the previous trials and for SMDlt (meta-analysis 
for the reviews with more than one trial) + the original model used (fixed or 
random). 
Dataset 2 :  Based on the analysis, this dataset had SMDdl from the previous trials and for 
SMDlt (meta-analysis for the reviews with more than one trial) + fixed effect 
model. 
Dataset 3:  Based on the analysis, this dataset had SMDdl from the previous trials and for 
SMDlt (meta-analysis for the reviews with more than one trial) + random effect 
model. 
Dataset 4:  This dataset had SMDdl from the previous trials and for SMDlt from only one 
last trial (the most recent one by month) + the original model used (fixed or 
random). 
Dataset 5:  Based on the analysis, this dataset had SMDdl from the previous trials and for 




Dataset 6:  Based on the analysis, this dataset had SMDdl from the previous trials and for 
SMDlt from only one last trial (the most recent one by month) + random effect 
model.  
Table 6.1 Different used datasets 
Data Model Used Type of last trial included 
Dataset 1 Original Model 
used in the 
review 
SMDdl: all trials in the meta-analysis excluding all 
last trials 
SMDlt: an estimate from a meta-analysis of the last 
trials (if more than one last trial included) and the 
estimate of the last trial if there is only one trial  
Dataset 2 Fixed Model 
Dataset 3 Random Model 
Dataset 4 Original Model 
used in the 
review 
SMDdl: all trials in the meta-analysis excluding only 
the most recent last trial 
SMDlt: an estimate from the most recent last trial  
Dataset 5 Fixed Model 
Dataset 6 Random Model 
 
6.3.2 The effect of the model used 
As mentioned in earlier chapters (Sections 2.4, 5.6) the choice between the fixed and random 
effects model could influence the setting of the NI margin. Although the random effects model 
accounts for heterogeneity, it gives more weight for smaller “older trials” compared to the fixed 
effect model.  
To investigate the effect of using the random and fixed models on the estimate of meta-analysis 
and its 95% CI, both random and fixed effect models were applied in addition to the main 
model used in the meta-analysis. The differences between the fixed or random effects models’ 
datasets were investigated using the Bland Altman plots as a measure of agreement between 
the SMD for all trials from the fixed and random datasets (Bland & Altman, 1999). The Bland 
Altman is the recommended measure for the comparison between two different methods 




6.3.3 Building the weighted regression model  
For the predictive model, Dataset 1 was the most realistic dataset. In dataset one the model was 
the original model in the review, and the meta-analysis with more than one last trial was treated 
equally by using a meta-analysis to estimate the SMDlt compared to dataset four which used 
the month of publication as a surrogate for the chosen trials, and this is usually inaccurate. 
Datasets 2, 3, 5, 6 used either fixed or random models, which reduced the chance of 
generalisability of the predictive model. For all these reasons, dataset 1 was chosen to be the 
dataset for the development of the predictive model. 
The main aim of this chapter is to investigate if it is possible to predict the estimate of a trial 
based on a meta-analysis of previous similar trials using the regression model. Regression is 
considered as the most frequently used method for prediction. It is considered a powerful and 
more flexible method (Kutner, Nachtsheim, Neter, & Li, 2005). Due to the nature of the 
outcome variable available from the constructed dataset, a multiple linear regression model 
will be the appropriate model to use to construct the predictive model.  
Dataset 1 will be divided randomly using R into 75% training dataset that includes 168 meta-
analyses to build a regression model and 25% test dataset that includes 56 meta-analyses to test 
and validate the model. A model will be developed to predict the values of SMDlt (dependent 
variable), using the SMDdl as the independent variable and the year of the predicted trial (Ylt), 
the year of last trial publication (Ydl) and year of first trial (Y1) as co-variables in the model. 
In addition, the year differences between the first and last year in the meta-analysis of historical 
trials and the year of the predicted trials will be tested as possible co-variables in the model.  
The independent variable (SMDdl) used in the model is constructed from a meta-analysis of 
several trials, and because of that, each case in the dataset will have a different weight according 
to the sample size of the meta-analysis. For this reason, using weighted multiple regression 
(WLS) will be more appropriate than using multiple linear regression (Solon, Haider, & 
Wooldridge, 2015). Weighted regression will give each meta-analysis its proper amount of 
influence over the parameter estimate. Based on the fact that the sample size is increasing by 
time with the median correlation between sample size and year of publication of 0.2 (Section 
5.5.4.1), the model will be weighted for the total sample size of the historical trials (Ndl).  
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The multiple linear regression model used is represented in the equation (6.1) (Kutner et al., 
2005)  
𝑌𝑖 = 𝛽0 + 𝛽1𝑥𝑖1+𝛽2𝑥𝑖2+ ⋯ + 𝛽𝑝−1𝑥𝑖,𝑝−1 + ɛ𝑖  (6.1) 
where Y is the response variable, 𝛽0, 𝛽1, 𝛽2 … … + 𝛽𝑝−1 are the parameters,  𝑥𝑖+𝑥𝑖2, … … . 𝑥𝑖,𝑝−1 
are the predictors, ɛ𝑖 is the measurement error N(0. 𝜎
2) and i= 1… n. 
For the weighted least square, the coefficients of estimates can be calculated using equations 
(6.2) and equation (6.3)  
𝛽𝑖 =
∑ 𝑤𝑖 ∑ 𝑤𝑖𝑥𝑖𝑌−∑ 𝑤𝑖𝑥𝑖 ∑ 𝑤𝑖𝑌
∑ 𝑤𝑖 ∑ 𝑤𝑖𝑥𝑖
2−(∑ 𝑤𝑖𝑥𝑖)
2   (6.2) 
𝛽0 =
∑ 𝑤𝑖𝑌−𝑏 ∑ 𝑤𝑖𝑥𝑖
∑ 𝑤𝑖
  (6.3), 
where 𝑤𝑖 is the weight for each case (meta-analysis) in the model. The model will be weighted 
for the total sample size of the historical trials (Ndl). 
The model adequacy will be checked by checking the assumptions of multiple regression model 
(Montgomery, Peck, & Vining, 2006): (1) the relation between the dependent variable and the 
independent variable is linear; (2) the error (ɛ)has zero mean with constant variance; (3) the 
errors (ɛ)  are uncorrelated and normally distributed; (4) for the weighted regression, the 
weights must be known (Ndl). The model adequacy check will include residual analysis, a test 
of lack of fit, looking for high leverage and influence observation, and checking for outliers.  
As a secondary objective for building the regression model, the agreement between the 
predictors and the observed values of the last trial estimate will be measured using a Bland-
Altman plot (Bland & Altman, 1999). The results are presented in Appendix D. 





6.3.4 Validation of the regression model 
The model validation is necessary to check if the model will work successfully in the real 
working environment (Montgomery et al., 2006). A proper validation should include checking 
if the regression coefficients’ signs and magnitude are reasonable. The stability of the 
regression coefficients should be investigated. Also, the prediction performance of the model 
should be checked (Montgomery et al., 2006). Different methods could be used for validation 
of the regression models, and these include bootstrapping and cross-validation. 
Bootstrapping  is one of the most common methods used to provide an accurate estimate, 
especially when the size of the sample data is considered small (Kutner et al., 2005).  In this 
chapter, bootstrapping will be used to validate the weighted linear regression built from the 
training data set.  
Cross-validation is one of the most common methods for validation of regression models 
(Kutner et al., 2005). Two approaches are available depending on the sample size of the original 
data. The first approach is used when rich datasets are available and involves dividing the 
dataset into 3 parts: training (50%), validation (25%) and test sets (25%). The model will be 
fitted using the training set. The validation set will be used to assess the prediction error rate. 
The test set is used to assess the general error of the final model. The other approach, which is 
used in case where the available dataset is not too large (as in the current case), is to divide the 
data into a training set (75%) and test set (25%), then the model will be built using the training 
set and cross-validated and tested using the test dataset.  
There are other methods for cross-validation, including leave one out cross validation 
(LOOCV), K-fold cross-validation or the repeated K-fold cross-validation. However, 
interpretation of the results should be done with caution since the root mean squared error 
(RMSE) calculated from these methods tends to be higher in the case of weighted regression 
(Kutner et al., 2005). The dataset used for model prediction comprises only 224 meta-analyses. 
On that basis, the decision was made to cross-validate using a training and test dataset and the 





6.4.1 Characteristics of the included meta-analyses (whole dataset)  
Out of the 236 meta-analyses included in the previous analysis, only 224 were included in the 
final analysis. Twelve meta-analyses were excluded from the analysis.  
 Six were excluded because the remaining trials after deleting the last were conducted 
in the same year, and that meant there would be no year difference between the trials. 
  In five meta-analyses only two trials remained after deleting last trials, and since the 
aim was to include at least 3 trials in the meta-analysis, it was decided to remove these 
trials.  
 In one meta-analysis, the three remaining trials were conducted in the same year, so 
there was no treatment difference between the trials.  
It was identified that 172 (76.8%) meta-analyses had only one trial as last trials; 34 (15.2%) 
had two trials as last trials; ten (4.5%) had three last trials; six (2.7%) had four trials as last 
trials; and two meta-analyses had six trials as last trials. After choosing the most recent trial 
from the last trials, 218 meta-analyses had one last trial and six reviews had two trials 
described as last trials (Figure 6.1).
 
Figure 6-1 Number of trials 
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From 224 reviews included, 111 reviews were published in 2016, 113 reviews in 2015. The 
total number of trials included in each of the meta-analyses ranged between 4 and 51 trials, 
with a mean number of 10.31 trials, SD = 7.5, and a median of 8 trials. The total sample size 
ranged from 105 to 43290 patients, the median being 1244 patients and IQR (526-2251). 
The year of publication ranged from 1931 to 2016 with the year difference between the oldest 
and the most recent trials varying from two years’ difference to 80 years’ difference. The 
difference between the last trial and trial before it ranged from one to 24 years. 
Risk ratio was the measure of effect in 125 (55.8%) of the reviews, the mean difference was 
used as a measure of effect in 72 (32.1%) of the reviews, 24 (10.7%) reviews used the odds 
ratio and four (1.3%) reviews used risk difference as the measure of effect. A fixed effect model 
was used in 96 reviews and random effect model in 128 reviews (Figure 6.2). Heterogeneity 
was statistically significantly higher when the random effect model was used, with mean 𝐼2= 
40.48% compared to 23.7% for fixed effect models. There was no difference in the number of 
trials included in the analysis between fixed and random models, with the mean number of 
trials 10 and 11 trials, respectively. 
 
 




Regarding the placebo type, 92 (41.1%) of the reviews defined the control group as (placebo) 
only, while 56 (25%) reviews used (Npno treatment or placebo) as the control group. Forty-
two (18.8%) of the reviews defined the control group as (placebo, usual care or no treatment) 
and 15 (6.7%) defined it as (usual care or placebo), nine (4%) reviews as usual care, eight 
(3.6%) as no treatment, and in two reviews no treatment or usual care was used. 
Regarding the risk of bias, 32 (14.3%) of the reviews had low risk of bias, 125 (55.8%) had 
moderate risk of bias, 47 (21%) had high risk of bias and in 20 (8.9%) of the reviews the risk 
of bias was described as unclear. Regarding the quality of evidence, the evidence was very low 








Table 6.2 Mean and Standard deviation for SMD, SMDdl, SMDlt for six different 
datasets 
 SMD (mean, SD) SMDdl (mean, 
SD) 
SMDlt (mean, SD) 
Dataset 1 -0.059 (0.580)  -0.062 (0.600) -0.078 (0.770) 
Dataset 2(fixed) -0.052 (0.550) -0.055 (0.590) -0.072 (0.750) 
Dataset 3 (random) -0.063 (0.600) -0.06 (0.620) -0.067 (0.820) 
Dataset 4 -0.059 (0.580) -0.061 (0.60) -0.067 (0.820) 
Dataset 5(fixed) -0.052 (0.550) -0.053 (0.580) -0.067 (0.820) 
Dataset 6(random) -0.063 (0.600) -0.063 (0.620) -0.067 (0.820) 
SD= standard deviation, SMD: the standardised mean difference of all trials, SMDdl: a standardised mean difference of all trials after 
deleting the last, SMDlt: a standardised mean difference of the last trial (s). 
Regarding the differences in the estimate from the different datasets extracted, there was no 
statistically significant difference between these datasets (Table 6.2). The mean SMD for the 
total trials using method one or method two for data extraction (mentioned earlier in 6.4.1) was 
similar for the original model and using either fixed or random model. For the comparison 
between the different models, (fixed and random) datasets one, two, and three will be used. For 
the model prediction, dataset one will be used. From Table (6.2), the estimate from the last trial 
is smaller than the estimate of the previous trials regardless of the type of model used or the 
type of last trial extraction. Moreover, the point estimates were higher than both the SMDdl 
and SMDlt. The estimate from the fixed models was higher (closer to zero) than the estimate 
from the random models for SMD, SMDdl and SMDlt.  
Regarding the Cochrane group, in total, 42 different groups were included in the analysis. 
Twenty meta-analyses (8.9%) were from the pregnancy and childbirth group, 19 (8.4) were 
from the pain and palliative supportive group, 14 (6.2%) from the gynaecology group, 13(5.8 %) 
from the heart group, while the other groups varied between 11 and one meta-analyses. 
Concerning the therapeutic area, 33 (14.7%) meta-analyses were cardiovascular, neurology and 
obstetrics and gynaecology accounted for 26 (11.6%) each, 21 (9.3%) were infections, 20 
(8.9%) were psychiatry, 19 (8.4%) were gastroenterology. Additionally, anaesthesia accounted 
for 18(8%) meta-analyses, nutrition accounted for 12 (5.3%), respiratory and urology 
accounted for 10 (4.4%) meta-analyses each, 8 (3.6%) were orthopaedics and 22 (9.8%) of the 
meta-analyses were distributed in other therapeutic areas.  
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6.4.2 The effect of type of model on the estimate of SMD 
Paired sample t-test was used to test if the differences between these the two models were 
statistically significant or not. In general, there was no statistically significant difference in the 
SMD estimated from the fixed or random model with the mean SMD for the fixed models -
0.05, 95% CI [-0.13; 0.021] compared to -0.06, 95% CI [-0.14; 0.017] for the random models 
with mean difference between the two models -0.01 and 95% CI [-0.044; 0.025]. However, 
there was a statistically significant difference in the length of the 95% CI, with mean width for 
the fixed model =0.89, 95% CI [0.79; 0.98] and the random model = 0.98 with 95% CI [0.88; 
1.08], the mean difference in the length between the random and fixed model was 0.09, 95% 
CI [0.064; 0.14]. 
Figure (6.4) illustrates the differences in frequency distribution for SMD between the fixed and 
random model. The distribution of the random effects model was wider than that of the fixed 
effect model; this reflects the wider confidence interval for the random model compared to the 
fixed model. The point estimate from both models was similar.  
 




The Bland-Altman plot was used to assess the agreement for the point estimates and the 95% 
CI boundaries to test the agreement between the fixed and random model. Figure (6.5) 
represents the Bland Altman plot for the agreement between the fixed and random models for 
the point estimate, the width of the 95 % CI and the upper and the lower boundaries of the 95 % 
CI in accordance to the heterogeneity and the sample size (N). Figure (6.6) represents the Bland 
Altman plot for the agreement between the fixed and random models for the point estimate, the 
width of the 95 % CI and the upper and the lower boundaries of the 95 % CI in accordance to 
the heterogeneity and the total number of trials included.  
For the point estimate, the average of difference (bias) = -0.01, SD =0.1 and the limit of 
agreement (LOA)was- 0.23; 0.21. For the width of the 95% CI the absolute distance between 
the lower and upper limits of the confidence interval was used to measure the width of the 95% 
CI From the graph, , the average of difference (bias) = -0.09, SD =0.2 and the limit of agreement 
was - 0.5; 0.31. 
For the agreement between the 95% CI boundaries of the fixed and random model, regarding 
the upper boundaries of the 95% CI the average difference (bias) = -0.07, SD =0.17 and the 
limit of agreement was - 0.41; 0.25. For the lower limits of the 95% CI, the average difference 
(bias) = 0.09, SD =0.17 and the limit of agreement was - 0.24; 0.43.  
From the figures (6.5 and 6.6), there was good agreement between the point estimates of the 
fixed and random model, with the smaller average difference of -0.01 and narrower limit of 
agreement of (- 0.23; 0.21). The agreement was less for the boundaries of the 95 % CI and the 
width of the 95% CI, with the averages of the difference of the upper, lower and width being 
0.07, 0.09 and -0.09 respectively and the LOA being wider.  
For the point estimate, there is a clear agreement between the fixed or random model in the 
case of the meta-analysis with mild heterogeneity, larger sample size, and a larger number of 
trials, this conclusion based on the graphs only. When the heterogeneity of the meta-analysis 
increases, the agreement is less apparent, and the difference between the two models is 
statistically significant. These results support the finding from the literature that the random 
effect model accounts for heterogeneity but cannot explain it, while the fixed effect model does 
not account for heterogeneity (Cooper, Sutton, Morris, Ades, & Welton, 2009; DerSimonian 





Figure 6-5 Bland-Altman graph for agreement between random and fixed models 
(According to the heterogeneity of the model, the size of the bubble represents the sample size in the meta-analysis) 
 
Figure 6-6 Bland-Altman plot for agreement between random and fixed model 




6.4.3 Prediction of the SMD of the last trial from a meta-analysis of previous trials  
6.4.3.1 Description of data used for analysis (training data set) 
The dataset of 224 meta-analyses was randomly divided into two datasets using R sampling 
process: the training dataset that included 75% of the whole dataset (168 meta-analyses) and 
the test dataset that contained 56 meta-analyses. Regarding the outcome variable, the SMD of 
the predicted trial (SMDlt), the mean (SD) = -.11 (0.75), the Min, Max = (-3.61; 2.28). 
Regarding the independent variable, the SMD from the historical trials (SMDdl), the mean (SD) 
= -0.07 (056), Min, Max= (-2.39; 1.3).  
Table (6.3) represents the differences between the three datasets in regard to the variables that 
will be used in building and testing the regression model.  
Table 6.3 Differences between the whole, training and test datasets used for analysis 
Comparison Whole dataset Training data Test data 
Number of reviews 224.00 168.00 56.00 
SMDdl Mean (SD) -0.06 (0.60) -0.07 (.56) -0.03 (0.70) 
Median -0.11 -0.16 -0.04 
Min; Max -2.39; 3.25 -2.39; 1.30 - 1.31; 3.25 
SMDlt Mean (SD) - 0.07 (0.77) - 0.11 (0.75) 0.04 (0.80) 
Median - 0.05 - 0.08 0.04 
Min; Max - 3.61; 2.46 - 3.61; 2.28 -1.31; 3.25 
Sample size 
(Ndl) 
Mean (SD) 2389.00(4879.00) 2166.00 (4289) 3057.00(6330.00) 
Median 934.00 1002.00 842.00 
Min; Max 67.00; 38862.00 67.00; 34996.00 111.00; 3886.00 
Number of 
trials (Kdl) 
Mean (SD) 9.46 (8.10) 9.50 (8.63) 9.16 (6.40) 
Median 7.00 7.00 6.05 
Min; Max 3.00; 50.00 3.00; 50.00 3.00;28.00 
Y meta Mean (SD) 15.53 (11.30) 15.6 (11.90) 15.25 (9.30) 
Median 13.00 12.50 13.00 
Min; Max 1.00; 75.00 1.00; 75.00 3.00; 46.00 
Y2 Mean (SD) 19.10 (11.50) 19.13 (12.13) 19 (9.70) 
Median 16.00 15.00 17.00 
Min; Max 1.00; 75.00 2.00; 80.00 5.00; 48.00 
Y3 Mean (SD) 3.57 (3.50) 3.50 (3.75) 3.80(9.30) 
Median 2.00 2.00 3.00 
Min; Max 1.00; 24.00 1.00; 24.00 1.00; 3.00 
First year  Min; Max 1931; 2013 1931; 2013 1966; 2007 
Recent year  Min; Max 1965; 2015 1965; 2015 1982; 2015 
Predicted year  Min; Max 1977;2016 1977; 2016 1990; 2016 
SMDdl: SMD from the historical trials, SMDlt: SMD for the predicted trial, Ndl: sample size of the meta-analysis, Kdl: number 
of trials included in meta-analysis, Ymeta: year difference in meta-analysis, Y2: year difference between the first trial and the 




6.4.3.2 Building the regression model 
The sample size of 224 was considered small. For that reason, to obtain a valid model across 
validation was used to develop and test the model. The developed model was based on 75% of 
the data as a training dataset and test and validated on the remaining 25% of the data. The 
results of the final training model included 168 meta-analyses that were randomly selected, and 
the final tested model contained the remaining 56 meta-analyses (Table 6.3).  
The mean (SD) year difference in the historical meta-analysis was 15.6 (12.5) years with a 
minimum of one and maximum of 75 years. The mean (SD) number of trials in the meta-
analysis was 9.5 (8.6) and the median was seven trials with a minimum of three trials and 
maximum of 50 trials. Regarding the sample size for the meta-analysis, the mean number of 
participants was 2,166 (4,289), the median was 1,002, the minimum number was 67 and the 
maximum number was 34,996.  
A weighted multiple regression model was built using the 75% training dataset that was 
constructed randomly from the full dataset to test if the SMD of the last trial (SMDlt) could be 
predicted from the SMD of the previous meta-analysis (SMDdl) and what changes there would 
be in the SMDdl. The model included the SMD of the last trial as the dependent variable 
(SMDlt), SMD from the previous meta-analysis as the independent (predictor) variable 
(SMDdl). The covariates tested in the model were the year difference between the last trial and 
the oldest trial in the meta-analysis of previous trials (Y1), year difference between predicted 
trial and the trials before (Y2), and the year difference in the meta-analysis of the previous 
trials (Y3). Additionally, the year of publication of predicted trial (Ylt), the year of the first and 
last trial in the meta-analysis of the previous historical trials (Y1st, Ydl) and the number of 
trials in the previous meta-analysis (Kdl). The model was weighted by the sample size of the 
previous meta-analysis (Ndl). Stepwise regression was used, and only variables that 
statistically significantly affected the SMDlt were presented in the final model. Table 6.4 
illustrates the results of the weighted regression model using the training dataset. 
The final fitted regression model was  




Table 6.4 Summary of the results of the regression model 
Model B Std. Error Beta    t Significance 95% CI of  β 
(Constant) 30.320 10.689  2.830 0.005 (9.210; 51.420 
SMDdl 0.920 0.065 0.747 14.236 < 0.001 (0.792; 1.047) 
Ymeta -0.005 0.002 -0.116 -2.223 0.028 (-0.009 ;-0.001) 
Ylt -0.015 0.005 -0.149 -2.833 0.005 (- 0.026; - 0.005) 
Weighted Least Squares Regression weighted by the sample size of the historical meta-analyses. Dependent Variable: SMDlt; Standardised 
mean difference of predicted trial, Ymeta: year difference between first and last trials in the meta-analysis, SMDdl= Standardised mean 
difference of historical trials, Ylt= year of publication of the predicted trial  
The model indicated that the SMD from the meta-analysis of the previous trials (SMDdl), year 
difference in the historical meta-analysis and the year of the predicted trial (Ylt) explains only 
55.1% of the variance in the model (Adjusted 𝑅2= 0.551, F statistics for overall significance 
= 69.175, p-value <0.0001). The point estimate of the meta-analysis of historical trials (SMDdl) 
statistically significantly predicted the SMD of the future trial (β = 0.92, 95% CI (0.79; 1.05)), 
for each unit increase in SMDdl the SMDlt increased by 0.92 units (i.e. the SMD of any future 
trial will be 0.92 of the point estimate of previous trials after controlling for the other variables). 
The year difference between the oldest and most recent trial in the meta-analysis of previously 
conducted trials affected the SMD of the future trial. For every one year increase in the 
difference in the meta-analysis, the SMD of the future trial will be decreased by -0.005 (β = - 
0.005, P-value = 0.028). The year of the predicted trial (Ylt) statistically significantly affected 
the estimate of the future trial (SMDlt) (β= - 0.015, P-value = 0.005). For each year increase in 
the future trial, SMD will be reduced by 0.015.  
A similar model was built using the whole dataset (for comparison). The results of the whole 
dataset can be presented as  
𝑌(𝑆𝑀𝐷𝑙𝑡) = 36.140 + 0.881 × (𝑆𝑀𝐷𝑑𝑙) − 0.008 × (𝑌𝑚𝑒𝑡𝑎) − 0.018 × (𝑌𝑙𝑡) (6.5) 






6.4.3.3 Checking the regression model adequacy 
Figure 6.7 and Figure 6.8 illustrate the diagnostic plot for the regression model. There were no 
possible outliers in the model. The residuals were normally distributed. Regarding the 
collinearity, both the variance inflation factor and the tolerance level were low, and that 
indicates multicollinearity was not a concern in the model. The assumption of independent 
errors was met when the Durbin-Watson value was  2.2 (Kutner et al., 2005). 
The scatter plot of predicted values against the residuals showed that the data met the 
assumptions of homogeneity of variance and linearity. There was a random pattern in the plot 
for the predicted and the residual values.  
 










6.4.3.4 Regression model validation 
6.4.3.5 Bootstrapping of the regression model  
Bootstrapping was used as a method of validation in the training dataset. From the sample data 
1000 repeated samples were drawn, and the results of this bootstrapping are given in Table (6.5) 
According to the table below, the level of bias in the included variables was very low. The 
biased corrected 95% CIs were similar to the original model except for the year difference that 
had a borderline p-value of 0.054. 
Table 6.5 Bootstrapping for the regression model of the training dataset 
 B 
Bootstrapping  
Bias Std. Error Sig.(2-tailed) 
BCa 95% CI 
 
Constant 30.316 -1.066 11.911 .005 (7.988; 49.323) 
SMDdl .920 .003 .077 .001 (0.760; 1.075) 
Ylt -.015 .001 .006 .005 (-0.028; -0.001) 
Ymeta -.005 .000 .003 .054 (-0.011; -0.001) 
Bootstrap results are based on 1000 bootstrap samples, SMDdl: Mean standardised difference from the 
meta-analysis, Yet: the year of predicted trial, Ymeta: year difference in the meta-analysis, BCa 95% CI: 
bias-corrected and accelerated 95% CI  
6.4.3.6 Regression model validation 
As mentioned earlier, 75% of the data was used to build the model (training data). The next 
step will be to test and validate the model on the remaining 25% of the data (test data). The 
developed model from the training set was used to predict the SMDlt in the test data set. The 
predictive model from the training set was given in equation (6.4)  
This model (Equation 6.4) was used to predict SMDlt from the test dataset. The correlation 
between the predicted values and the observed values of the SMDlt in the test dataset was 0.7, 
which is a strong positive correlation (Figure 6.9).  𝑅2 = 0.4, which means that the model 
explained 40% of the variation in the test data. The Root Mean Squared Error (RMSE) was 0.6, 
and the Mean Absolute Error (MAE) was 0.4. Both of these are considered low, and that means 





6.5 Summary and discussion 
6.5.1 Main findings and interpretation 
This chapter investigated the effect of using either a fixed or random model in the final estimate 
of the meta-analyses. Using the data set from Chapter 5, the meta-analyses were examined 
using both random and fixed models to compare the results. There was no statistically 
significant difference between the point estimates in the meta-analyses using a fixed or random 
model; however, the 95% CI was statistically significantly wider using random effect models 
compared to the fixed effect model. Using the Bland Altman plot to measure the agreement 
between the two models obtained a high degree of agreement between the two models in regard 
to the point estimate; this agreement was less in the case of the 95% CI boundaries and the 
width of the 95% CI.  
Figure 6-9  Scatter plot between the predicted values using the training model 
and SMDlt from testing dataset 
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Heterogeneity with the meta analysis, the number of trials and the total sample size of the meta-
analysis all had effects on the agreement between the fixed and random model; meta-analyses 
with higher heterogeneity, small overall sample size and a small number of trials showed less 
agreement between the estimates from the two models. This may be due to smaller studies 
having higher heterogeneity when compared to larger ones (IntHout, Ioannidis, Borm, & 
Goeman, 2015).  
In NI trials, the NI margin was formulated using the boundaries, not the point estimate. Thus, 
setting the NI margin based on the fixed or random model could lead to different margins, 
especially for a meta-analysis with a smaller number of trials and smaller sample size. The 
random effects model will use a wider 95% CI with extreme boundaries, which could lead to 
the conclusion of non-inferiority of an inferior treatment. Moreover, the results in Chapter 5 of 
this thesis indicated that smaller studies tend to be earlier studies. Thus, in the context of this 
thesis with respect to NI trials, it can be concluded that using a random-effects model to 
estimate the effect of active control compared to placebo will give more weight to the older 
heterogeneous small studies that could lead to a biased estimate of the effect of the active 
control over placebo. For both these reasons, the recommendation is to use a fixed effect model 
for the situation where this is going to inform a determination of non-inferiority limit 
consequence by indirect comparison. 
The primary aim of this chapter was to build a model to predict the point estimate of a trial 
based on previously available trials. The model was built using data from 2310 trials from 224 
meta-analyses of placebo-controlled trials from the different medical fields and multiple linear 
regression that was weighted for the sample size of the meta-analyses. The main predictor for 
the point estimate of a trial was the point estimate of previous trials; year differences in the 
meta-analysis and the year of the predicted trial were the other co-variables in the model. 
The three main variables that affect the estimate of any future trial were the estimate from the 
meta-analysis of previous trials, the year difference in the meta-analysis and the year of the 
predicted trial. Increase of one unit in the point estimate of the historical meta-analysis will 
lead to an increase in the predicted estimate of the future trial by 0.92. For the year difference 
in the meta-analysis, for each year increase in difference, the predicated estimate will be 
reduced by 0.005. For the year of prediction, for each year increase in the prediction, the 
predicted estimate will be reduced by 0.015. The model created in this chapter takes into 
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consideration both the estimate from previous trials and the year differences between the trials, 
and that will lead to a more accurate estimate than using the results from the regular meta-
analysis.  
The results from this model support the results from Chapter 5 and other literature (Ioannidis 
& Lau, 2001) that concludes the treatment effect is not constant over time. These results 
highlight an important issue of the bias that could arise from using the estimate of historical 
meta-analysis for indirect comparison without any further adjustment. It also highlights the 
need for the most appropriate estimate of effect and raises the question of whether using the 
results from the most recent, more extensive, trials would be better for estimating the real 
treatment effect than the overall results, especially in the context of this thesis (Borzak & 
Ridker, 1995). 
In summary, the estimate from the meta-analysis of the historical trial can explain only 55% of 
the estimate of the future even after adjusting for the time and the year difference in the meta-
analysis. However, it is an excellent predictor of the estimate of any future trial. Using meta-
analysis of retrospective trials to predict the estimate of future trial or using it in indirect 
comparison will introduce bias since, as mentioned earlier, its predictive power is only 55%. 
According to our results, the difference between the estimate from a meta-analysis of historical 
trials and the predicted trial will be in the range of (0.79; 1.047). This difference is affected by 
the year of publication of the future trial and the year difference in the meta-analysis of 
historical trials. For each year increase, the prediction of the estimate will be reduced by 0.015 
and for each year increase in the difference between the years of the first and last trials in the 
meta-analysis the prediction will be decreased by 0.005. These differences could be seen as 
small differences even though they arestatistically significant. However, the fact that a 
standardised difference was used in the range from (-3, 3) indicates that these differences are 
considered moderate changes and should be considered.  
In the case of NI trials, usually  the estimate from the historical placebo-controlled trials is used 
as the estimate of the treatment difference between the putative placebo and the active control 
in the NI trial, with a degree of adjustment in the case of the fixed margin approach by using 
the upper or the lower limit of the 95% CI. However, according to the results of this chpater, 
the used estimate is a biased estimate and does not reflect the actual efficacy of the active 
control compared to the putative placebo in the NI trial, since the actual estimate will be 
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different by 0.92 (0.79; 1.047). Moreover, the conducting year of NI trials and the time 
difference in the meta-analysis will also affect the predictor of the estimate in the predicted 
trial.  
6.5.2 Strengths and limitations  
The main strength of the model developed in this chapter is that it comes from different 
therapeutic areas and could be viewed as a general model. Moreover, it takes into consideration 
the year difference between the oldest and the planned trial (where the placebo effect needs to 
be predicted) and the year of the planned trial. 
The main limitation of the model is the use of transformed data. Transformation of the point 
estimate from odds or risk ratio to the standardised mean difference could lead to a reduction 
in the power of prediction for this model, even though our estimate will contribute to reducing 
the bias in the case of NI trials.  
Splitting the dataset into training and test datasets was used for model validation. This method 
was chosen due to the relatively small sample size. However, other methods for validation, 
including leave one out cross validation and K-fold cross validation, were used and are 
presented in Appendix D2. Some points were considered as posssible outliers; however, 
removing these points from the analysis did not change the results of the regression model and 
for that reason the decision to keep these points was taken.  
Trials with positive findings tend to be published more frequently than trials with no findings 
(Rothstein et al., 2006). For the dataset used in this chapter, the risk of publication bias was 
higher since only published data (meta-analyses) were used in the final model. In addition, 
trials with negative findings tend to be published later than trials with  positive findings 
(Rothstein et al., 2006) and using the year of trial publication as a surrogate for the trial conduct 
year could impact the results. 
6.5.3 Implications for the thesis aims and objectives  
In NI trials, historical trials are usually used to set the NI margin, using the upper or lower part 
of the 95% CI in the case of a fixed margin effect. Two conclusions can be drawn from this 
chapter in regard to NI trials. First, the fixed effect model is the recommended model to use in 
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the case of NI trials since its 95% CI is narrower and it gives less weight for smaller older 
studies. Second, in this chapter, it was found that the treatment effect in a future trial would 
range from 0.79 to 1.047 of the treatment effect of historical trials. That means, in NI trials, the 
constancy should not be assumed; instead, it should be assessed and according to that the NI 
margin should be formed.  
In the next chapter, a review of the possible methods that can be used to assess the constancy 
and adjust for a time in the setting of the NI margin will be conducted, followed by the 






Chapter 7 Methods for Adjusting for Time in Non-
Inferiority Trials 
7.1 Introduction 
Reviewing the literature in Chapter 2 and the review of the NI trials in Chapter 4 resulted in 
the conclusion of the importance of using the historical information in setting the NI margin 
for indirect comparison, with more than 50% of reviewed trials depending on the historical 
trials in setting the NI margin.  
Chapter 2 highlighted the assumptions regarding the NI trials that include the constancy 
assumption and assay sensitivity of the active control and controlling for the placebo effect. 
Violation of these assumptions will lead to a biased estimate from the NI trials that could lead 
to a conclusion of the non-inferiority of an inferior treatment. The changes in the effect sizes 
of the placebo and the active control and treatment difference were studied in Chapters 5 and 
6. All of these results confirm the importance of incorporating time changes in setting the NI 
margin.  
In the context of this thesis, the aim of this chapter is to develop criteria to select a method to 
set an adjusted NI margin for time changes. To review the available methods to set and adjust 
for a covariate (time) in the NI trials with choosing the appropriate methods for adjusting for 
the time in indirect comparisons.   
Criteria for the best performance will be formulated based on the literature review in Chapters 
2 and 3 and the results of Chapters 5 and 6. These criteria will be applied to the different 
methods. In the following chapter, the chosen method will be applied to data from the placebo-




7.2  Criteria for a good performance method 
The main aim in the NI trial is to establish the non-inferiority of the tested treatment compared 
to active treatment by an indirect conclusion of the superiority of the tested treatment to the 
placebo. Any chosen method to set the adjusted NI margin should maintain the three main 
assumptions in the NI trial (Julious, 2011): 
 Assay sensitivity: the chosen active control is the most efficient available treatment 
 Bias minimising: the differences between the historical placebo-controlled trials and 
the NI trial are minimum (the same endpoint, similar population characteristics, etc...) 
 Constancy assumption: the efficacy of the active control is the same in the placebo-
controlled trials and the NI trial. 
It is proposed that the criteria for the chosen method include adjusting for any possible 
covariates, including all possible active controls that can be used in the design and the analysis 
phase of the NI trial. These criteria are based on the assumptions and methodological needs 
concerning NI trials to produce accurate and reliable results that are adjusted for any possible 
biases (FDA, 2016), and on the findings from the literature review in Chapter 2, the regulations 
in Chapter 3 and the results of Chapters 5 and 6.  
 
7.2.1 Adjusting for any possible covariates while setting the NI margin 
From the results of Chapters 5 and 6, it was found that the time changes affect the estimate of 
any future trials based on the results from the meta-analysis of the historical trials. Adjusting 
for the time difference between the placebo-controlled trials and the NI trial will reduce the 
possibility of biases. Moreover, accounting for time differences between the NI trials and the 
historical trials is also essential for the constancy assumption.  
7.2.2 Including all possible active controls 
In most therapeutic areas, there is more than one possible active control (standard treatment). 
Comparing all possible active controls in the designing phase and while setting the NI margin 
is essential for the assay sensitivity of the active control and including all relevant trials in the 
analysis to compare these active controls together or against the placebo will ensure the 
sensitivity of the chosen active control.  
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7.2.3 The phases of the NI trial 
Setting the NI margin in the design phase is one of the most important regulatory and 
methodological challenges concerning the NI trial. The chosen method should be used in the 
designing phase to choose the active control, to set the sample size of the NI trial and to set the 
NI margin. In the analysis phase, the same method should be used to compare the results from 
the current NI trial and historical trials, to estimate the efficacy of the tested treatment compared 
to placebo and to rank all possible treatments compared to placebo.   
7.2.4 Type of data 
Two types of data can be used in the case of NI trials to compare the results from the NI trial 
and the historical trials: individual patient-level data (IPD) and aggregated data (AD). IPD is 
preferred to the AD in the case of indirect comparison. However, IPD is not available most of 
the time, especially from the historical placebo-controlled trials. Any used method should be 
able to handle both the IPD and AD in the case of hard to reach IPD. 
7.2.5 Computational flexibility   
A method that can be used in both Frequentist and Bayesian approaches and that offers ease of 
use and coding is preferred.  
 
Table 7.1 gives a summary of the developed criteria. 
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Table 7.1 Criteria for the best performance method 
Criteria  Description 
Adjusting for Co-variables   Adjusting for the differences between the including 
trials, to minimise the biases originated from the 
difference between the NI trial and the placebo-
controlled trials. Adjusting for time differences to 
ensure the constancy assumption  
Including more than one 
active control 
 
To ensure the assay sensitivity assumption  
Can be used both for the 
designing phase and the 
analysis phase of NI  
 
For the designing phase to calculate the sample 
size, and set the NI margin. For the analysis phase 
to compare the results from the NI trial and other 
placebo-controlled trials and rank the included 
treatments. 
Can handle both the IPD 
and AD data 
 
In the case of historical trials, usually, it is difficult 
to have access to the patient data level 
Computational flexibility   Using both the Frequentist and Bayesian approach 
and with availability of software to conduct the 
analysis 
 
7.3  Methods for adjusted non-inferiority margin  
7.3.1 Adjusted regulatory approaches 
This approach was built according to the predictive model developed in Chapter 6. The 
predicted estimate for a future trial from previous historical trials depends on the point estimate 
from the meta-analysis, the year differences in the meta-analysis and the year of the future 
predictive trial. 
𝑌(𝑆𝑀𝐷𝑙𝑡) = 30.32 + 0.92 × (𝑆𝑀𝐷𝑑𝑙) − 0.005 × (𝑌𝑚𝑒𝑡𝑎) − 0.015 × (𝑌𝑙𝑡)  
The parameters in this model have min and max-predicted years of 1977 and 2016. The year 
difference in the meta-analysis ranged from one to 75 years, and the SMD from the historical 
trials ranged from (-2.39 to 1.3). Using this model, the estimate for any future trial can be 
predicted. This estimate will be adjusted for the time differences between the NI trial and the 
historical trials.  
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For the fixed margin approach, either the main predicted estimate (more reliable) or the worst 
limit of the predicted 95% CI) can be used. For the synthesis method, the adjusted predicted 
estimate and its 95% CI can be incorporated in the 95% CI from the NI trial.  
The differences between the adjusted regulatory and the non-adjusted regulatory approaches 
(discussed in Chapter 2) are illustrated in Table 7.2. The main advantage for this method is that 
it adjusts for time and can predict the estimate of the future trial based on the historical trials, 
the year difference in the historical meta-analysis, in addition to the year of predicted trial. The 
main limitation for this proposed approach is that it cannot compare more than three treatments 
(only one active control will be included), cannot adjust for any other difference between the 
trials, is limited to the year 2016 and cannot be used beyond this limit. Moreover, the 
predictivity of this model was only 55.1%. 
 
Table 7.2 Comparison between the adjusted and non-adjusted regulatory approaches 





Adjusting for Co-variables   No Adjust for time only 
 




Used in the designing and 
analysis phase of NI  
 
Yes Yes 
Can handle both the IPD 
and AD data 
 
Yes Yes 
Computational flexibility   Yes No 
 





7.3.2 Pairwise meta-regression for adjusting for time  
Meta-regression was introduced as a method to explain the heterogeneity in the pairwise meta-
analysis (Thompson & Sharp, 1999). Usually, meta-regression compares two treatments 
(pairwise meta-regression) with adjusting for any possible covariates between the trials. The 
meta-regression model is a meta-analysis model that includes study level covariates to test the 
impact of covariates for statistical significance (Hoaglin et al., 2011). In a pairwise meta-
analysis, including co-variables or effect modifiers could reduce biases introduced by 
heterogeneity or inconsistency between treatment comparisons (Hoaglin et al., 2011). Usually, 
meta-regression is not recommended if the number of studies included is less than ten (Higgins 
& Green, 2008), especially when there are multiple covariates in the model. If the number of 
studies is small, multiple covariates are not recommended in meta-regression  (Borenstein, 
Hedges, 2009). This could be considered as a limitation for the meta-regression. However, it 
has been used for a smaller number of studies (Dranitsaris, Jelincic, & Choe, 2011) with caution 
to include only one covariate at the time.  
The general principles of meta-regression are the same as those for the regression models. The 
effect estimate is the dependent (outcome) variable, and the characteristics of the study (the 
potential effect modifiers or covariates) are the independent variables. The difference between 
regular regression models and meta-regression models is that in the latter the included studies 
are weighted (Thompson & Sharp, 1999). 
The obtained coefficient from the meta-regression model will affect the size of the main 
estimate of “the outcome variable” changes by the co-variables. The p-value from the 
coefficient of the covariate indicates whether the difference is statistically significant or not. 
Both fixed and random effects models can be used. 
Pairwise meta-regression has been used in NI trials to include covariates in the analysis.  Eckert 
& Falissard (2006) used a pairwise meta-regression to compare the direct and indirect estimate 
between escitalopram and venlafaxine anti-depressant treatments using six placebo-controlled 
trials that compared escitalopram versus placebo and four comparing venlafaxine and placebo 
to indirectly compare venlafaxine and escitalopram (to establish non-inferiority of escitalopram 
to venlafaxine). The covariates included in the model were age, gender repartition, and severity 
at baseline.  
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The results from the indirect comparison were compared to the results from the two non-
inferiority trials that compared venlafaxine and escitalopram. Eckert et al. concluded that the 
direct and indirect comparison results were both the same; the type of model used was not 
stated clearly (Eckert & Falissard, 2006). 
Dranitsaris et al. (2011) used meta-regression to compare dalteparin to enoxaparin indirectly 
with the presence of the common comparator (placebo). They compared the results from five 
placebo-enoxaparin trials and four dalteparin-placebo trials to estimate the indirect treatment 
effect of dalteparin and enoxaparin compared to placebo. They used the active treatment as the 
primary independent variable, and the estimate from the trials compared to placebo (relative 
risk) as the outcome variable. The type of model used was not stated clearly. Moreover, they 
were able to adjust for the duration of therapy, treatment schedule, geographical region and the 
year of randomisation (Dranitsaris et al., 2011). Dranitsaris et al. concluded that meta-
regression is considered as an appropriate method for adjusted indirect comparison in the case 
of the presence of the common comparator (placebo) (Dranitsaris et al., 2011).  
Witte et al. (2011) used pairwise meta-regression to design an NI trial for supportive treatments 
in kidney transplantation (Witte, Schmidli, O’Hagan, & Racine, 2011). They proposed a 
random effect meta-regression and used each treatment as covariates in the model. They 
suggested the use of fixed margin or synthesis approaches to set the NI margin. In this study, 
there were no other covariates in the model apart from the treatments.  
Meta-regression has been used to measure the changes in the placebo response over time in 
multiple therapeutic areas (Furukawa et al., 2018; Khan et al., 2017, 2018a, 2018b). In all these 
studies, the changes in placebo response over time were confirmed, using the year of 
publication as a covariate in the regression model.  
Based on these studies, and in the context of this thesis to adjust for a time while setting a NI 
margin from the indirect comparison, pairwise meta-regression could be used in the designing 
phase of the trial as an alternative to the unadjusted pairwise meta-analysis to test for the 
constancy first and then to predict the active treatment response compared to the placebo in the 
year of NI trial conducting. This method could lead to a more accurate NI margin that takes 
into consideration the changes in the efficacy of the active control compared to placebo over 
time. The steps for the proposed method are: 
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1- Meta-regression of the placebo-controlled trials that compare the active treatment to 
placebo is conducted with the year of publication as a covariate in the regression model 
(if the year of trial conducting is available for all trials it is better to use that instead of 
the year of publication). 
2- The constancy assumption will be assessed based on the bubble plot of the estimated 
effect size. 
3- If the constancy assumption holds, then the estimate and the 95% CI from the pairwise 
meta-analysis will not be different from the estimate from the meta-regression and can 
be used to set the NI margin. 
4- If the constancy assumption does not hold, then the predicted estimate adjusted for the 
time of NI trial conducting and the 95% CI should be used to set the NI margin.  
Table 7.3 The methodology selection criteria for pairwise meta-regression 
Criteria Meta-regression 
Adjusting for co-variables   Yes  
Including more than one active control No 
Used in the designing and analysis phase of NI  Limited (only in the designing 
phase) 
Can handle both the IPD and AD data Yes 
Computational flexibility   Limited 
Can rank the included treatments No 
 
This method will lead to assessment of the constancy assumption and to setting an adjusted NI 
margin that accounts for any possible changes in the treatment effect over time. The main 
limitation of this method would be that the number of included historical trials should be ten 
or more. Moreover, this method cannot be used if there is more than one active control, and it 
is limited to the designing phase of the NI trial and cannot be used in the analysis phase. Table 




7.3.3 Network meta-regression 
A network meta-regression approach could be used to adjust for covariates or effect modifiers 
in a network meta-analysis model. This approach became popular in recent years as a preferred 
method to adjust for covariates in indirect comparison (Cooper et al., 2009; Donegan, Welton, 
Tudur Smith, D’Alessandro, & Dias, 2017; Eckert & Lançon, 2006; Liang et al., 2014).  
Network meta-regression is a newly developed approach used to explain and control for the 
heterogeneity and inconsistency in the network meta-analysis (mixed treatment comparison) 
by adjusting for possible effect modifiers in the network meta-analysis.  
Until now, only Bayesian frames are available for network meta-regression. Different software 
is available for analysis, including WIN Bugs, SAS, STATA, and gemtc R package 
(Valkenhoef & Kuiper, 2016).  
Similar to the pairwise meta-regression, network meta-regression is not recommended if the 
number of included studies is less than ten (Higgins & Green, 2008). This is considered as the 
most critical drawback regarding the network meta-regression model due to concern over low 
power of the analysis if the number of trials is small compared to the number of included 
comparisons (Cooper et al., 2009).  The advantage of using the network meta-regression over 
the pairwise meta-regression is that more than one active treatment can be included in the 
comparison, while the pairwise meta-regression can handle only two treatments. Moreover, 
network meta-regression can be used in both the designing phase to set the NI margin based 
on different active controls and in the analysis phase by incorporating the NI trial in the network 
of analysis. Moreover, the network meta-regression can be used when there are no direct 
placebo-controlled trials that compare the active treatment and the placebo. 
Cooper et al. (2009)  introduced three possible mixed treatment comparison methods (network 
meta-regression models) with co-variables depending on the type of regression coefficient used 
in the model  (Cooper et al., 2009).  
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Model 1: The regression coefficient for each treatment is different  
This model assumes that each treatment by covariate interaction for the comparison between 
the active treatment and the control is different and unrelated. Equation 8.1 illustrates the 
framework of network meta-regression when the coefficient is independent   
𝑟𝑗𝑘~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑝𝑗𝑘, 𝑛𝑗𝑘)𝑓𝑜𝑟 trial 𝑗, treatment 𝑘 
𝑙𝑜𝑔𝑖𝑡 (𝑝𝑗𝑘 = {
𝜇𝑗𝑏               𝑏 = 𝐴, 𝐵, 𝐶 𝑖𝑓 𝑘 = 𝑏
𝜇𝑗𝑏 + 𝛿𝑗𝑘𝑏   𝑖𝑓 𝑘 𝑎𝑙𝑝ℎ𝑎𝑏𝑒𝑡𝑐𝑎𝑙𝑙𝑦 𝑎𝑓𝑡𝑒𝑟 𝑏
 
𝛿𝑗𝑏𝑘~𝑁𝑜𝑟𝑚𝑎𝑙 (𝑑𝑏𝑘 + 𝛽𝑏𝑘𝑋𝑗, 𝜎
2)~𝑁𝑜𝑟𝑚𝑎𝑙(𝑑𝐴𝑘 − 𝑑𝐴𝑏 + (𝛽𝐴𝑘 −
𝛽𝐴𝑏)𝑋𝑗, 𝜎
2),
                    
                 𝑑𝐴𝐴, 𝛽𝐴𝐴 = 0      (8.1) 
Where 𝜇𝑗𝑏 is the log odds ratio in trial j compared to baseline treatment b, 𝛽𝑏𝑘  is the change 
in the log odds ratio of an event per unit change in covariate 𝑋𝑗 for treatment k relative to 
control treatment b, 𝛿𝑗𝑏𝑘 is the trial log odds ratio of k compared to b, 𝑑𝑏𝑘 is the pooled log 
odds ratio for the treatment k relative to b if a covariate 𝑋𝑗 =0, number of r of treatments in the 
network = k and the number of relative treatments is k-1. 
 
Model 2: The regression coefficient is exchangeable: this model assumes all interactions of 
treatment by covariates are different but related, equation (8.2).  
𝑟𝑗𝑘~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑝𝑗𝑘, 𝑛𝑗𝑘)𝑓𝑜𝑟 trial 𝑗, treatment 𝑘 
𝑙𝑜𝑔𝑖𝑡 (𝑝𝑗𝑘 = {
𝜇𝑗𝑏               𝑏 = 𝐴, 𝐵, 𝐶 𝑖𝑓 𝑘 = 𝑏
𝜇𝑗𝑏 + 𝛿𝑗𝑘𝑏   𝑖𝑓 𝑘 𝑎𝑙𝑝ℎ𝑎𝑏𝑒𝑡𝑐𝑎𝑙𝑙𝑦 𝑎𝑓𝑡𝑒𝑟 𝑏
 
𝛿𝑗𝑏𝑘~𝑁𝑜𝑟𝑚𝑎𝑙 (𝑑𝑏𝑘 + 𝛽𝑏𝑘𝑋𝑗, 𝜎
2)~𝑁𝑜𝑟𝑚𝑎𝑙(𝑑𝐴𝑘 − 𝑑𝐴𝑏 + (𝛽𝐴𝑘 − 𝛽𝐴𝑏)𝑋𝑗, 𝜎
2) 
Where  𝛽𝐴𝑘~𝑁𝑜𝑟𝑚𝑎𝑙(𝐵, 𝜎𝐵




Model 3: The regression coefficient is shared (common)    
𝑟𝑗𝑘~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑝𝑗𝑘, 𝑛𝑗𝑘)𝑓𝑜𝑟 trial 𝑗, treatment 𝑘 
𝑙𝑜𝑔𝑖𝑡 (𝑝𝑗𝑘 = {
𝜇𝑗𝑏               𝑏 = 𝐴, 𝐵, 𝐶 𝑖𝑓 𝑘 = 𝑏
𝜇𝑗𝑏 + 𝛿𝑗𝑘𝑏   𝑖𝑓 𝑘 𝑎𝑙𝑝ℎ𝑎𝑏𝑒𝑡𝑐𝑎𝑙𝑙𝑦 𝑎𝑓𝑡𝑒𝑟 𝑏
 
𝛿𝑗𝑏𝑘~ {
𝑁𝑜𝑟𝑚𝑎𝑙 (𝑑𝐴𝑘 + 𝛽 𝑋𝑗, 𝜎
2)~𝑁𝑜𝑟𝑚𝑎𝑙(𝑑𝐴𝑘 − 𝑑𝐴𝐴 + 𝛽𝑋𝑗, 𝜎
2)𝑖𝑓 𝑏 = 𝐴
𝑁𝑜𝑟𝑚𝑎𝑙(𝑑𝑏𝑘, 𝜎
2)~𝑁𝑜𝑟𝑚𝑎𝑙(𝑑𝐴𝑘 − 𝑑𝐴𝑏 , 𝜎
2)                              𝑖𝑓 𝑏 ≠ 𝐴
 
where 𝑑𝐴𝐴, 𝛽𝐴𝐴 = 0         (8.3) 
The way of choosing between these three models depends on the nature of covariates and the 
number of trials available per comparison, since in the case of model one the number of 
comparisons will be higher compared to model 3 ( Cooper et al., 2009). The model’s goodness 
of fit should decide which coefficient to use by comparing the deviance information criterion 
(DIC) with low DIC preferred. Moreover, the interpretation and the usefulness of the model to 
the clinician should be taken into consideration (Cooper et al., 2009). For the purpose of this 
thesis, the shared model will be used. 
There was not enough literature regarding the use of network meta-regression in general or in 
the case of NI trials. A search of the Web of Science for publications with network meta-
regression in their titles returned only 15 publications, starting from the year  2012. The peak 
was in 2018 with seven publications. Moreover, there was only one study regarding the 
conducting of network meta-regression in NI trials (Kent et al., 2018). 
Kent et al. used network meta-regression to choose the appropriate active control, to set the 
non-inferiority margin and to calculate sample size for the future NI trial based on the network 
meta-regression on the available data for endovascular abdominal aortic aneurysm (Kent et al., 
2018).  They used the follow-up time as a co-variable in the model and they adjusted for what 




The limitations regarding this method are the reducing power of analysis when the number of 
covariates increases. Even though there were no minimum limits of the number of trials that 
should be included in the analysis, the power of the analysis for the network meta-regression 
reduced as the number of studies decreased (Cooper et al., 2009). Most published studies 
include only one covariate at a time  in the analysis, and only the Bayesian approach is available.  
Table 7.4 summarises the methodological criteria for the network meta-regression 
Table 7.4 Methodological criteria for the network meta-regression 
Criteria Network Meta-regression 
Adjusting for Co-variables   Yes 
Including more than one active control Yes 
Used in the designing and analysis phase of NI  Yes 
Can handle both the IPD and AD data Yes 
Computational flexibility   Limited (no Frequentist 
approach) 
Can rank the included treatments Yes 
 
7.3.4 Methods depending on IPD data  
Different methods were introduced to adjust for covariates in indirect comparison in general 
and in the case of NI trials; some of these methods depend on the use of individual patient data 
(IPD) from the available trials to adequately adjust for any possible effect modifiers like age 
and gender (Phillippo et al., 2018). The most commonly used methods are the Matching 
Adjusted Indirect Comparison (MAIC) (Ishak, Proskorovsky, & Benedict, 2015; Signorovitch 
et al., 2012, 2010) and Simulated Treatment Comparison (STC) (Caro & Ishak, 2010; Ishak et 
al., 2015). Both of these methods depend on the availability of the individual patients’ data and 
the presence of a common comparator to generate an indirect comparison that is adjusted for 
any possible effect modifiers. The calculation is done either by reweighting the treatment effect 
of the AB trial  and applying it in the AC trial in the MAIC or to simulate the AB treatment 
effect in the AC trial in the STC method (Phillippo et al., 2018). 
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Both methods could be applied in the case of NI trials since in these trials the active control is 
the common comparator between the placebo and the test treatment. However, both methods 
adjust for only patients-based covariates, not for trials-based covariates. In this case, they 
cannot adjust for time differences (year of publication) on the patient level. The availability of 
IPD data is another consideration because IPD is not usually available from all historical data.   
Nie & Soon (2010) presented a covariate-adjusted regression model to assess the constancy 
assumption in NI trials and set a justified margin when the constancy assumption was violated 
(Nie & Soon, 2010). However, their model depends on the availability of IPD data and cannot 
be applied to aggregated population data (AD). Moreover, it adjusts only if the constancy 
assumption is violated and depends mainly on the historical data to test the constancy 
assumption (Xu, Barker, Menon, & D’Agostino, 2014).  This model was modified by Xu et al. 
(2014)  to modify the covariate adjustment using both fixed and synthesis methods in one and 
two stage approaches using the IPD, not the aggregated population data (AD) (Xu et al., 2014). 
Table 7.5 summarises the methodological criteria for the IPD methods. 
 
Table 7.5 Applying the selection criteria for the IPD based methods 
Criteria IPD 
Adjusting for Co-variables   Limited (patients based only) 
Including more than one active control Limited  
Used in the designing and analysis phase of NI  Yes 
Can handle both the IPD and AD data No 
Computational flexibility   Yes 





When setting NI margins using the regulatory approaches, there is no adjustment for the 
changes in the placebo and active treatment effect over time. However, using a fraction of the 
effect size of the active control fixed margin could be considered as an approach for adjustment.  
Adjusting for covariates in individual patient data (IPD) level is another approach to  
adjustment for covariates in indirect comparison using  MAIC or STC methods. However, the 
IPD usually is not available for all trials, especially the older trials in the case of NI trials. 
Regarding the aggregated data, both pairwise meta-regression and network meta-regression 
could be used to adjust for indirect comparison in NI trials. However, pairwise meta-regression 
can be used only in the designing phase of the trial and can include only one active control.  
The use of network meta-regression could be promising in the case of NI trials for many reasons. 
First, it could adjust for the time  (year of publication) or any other possible effect modifiers or 
confounders between the historical trials and NI trials. Second, it can include all possible active 
controls in the network to compare the efficacy of the test treatment with different available 
treatments and placebo. Third, network meta-regression could rank the treatment according to 
best treatment and can compare the estimate from both the direct and indirect comparison in 
the same networks. The drawbacks of network meta-regression are the need for a large number 
of trials to include more comparisons and its susceptibility to ecological bias, as well as its 
lower power to detect differences (Phillippo et al., 2018). Moreover, only the Bayesian 
approach is available until now. Table 7.6 reflects the differences between the different 
methods for setting the NI margin.  
In summary, for the purpose of this thesis (adjusting for the time in case of indirect comparison), 
network meta-regression is considered the best method, followed by the pairwise meta-
regression. Network meta-regression and pairwise meta-regression will be applied and 
compared using the available data from the review in Chapters 5 and 6. 
As mentioned earlier, IPD methods cannot be applied for adjusting for time. However, it could 
be applied for adjusting for the patients level data, which indirectly could account for the 
differences in time between the trials. Moreover, the major limitation for the IPD  methods is 
the shortage of patients level data, especially for the older placebo-controlled trials. The 
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proposed adjusted regulatory approach and the IPD methods cannot be used due to the 
limitations mentioned earlier. 
In the next chapter,  two reviews from the Cochrane reviews of placebo-controlled trials that 
were discussed in Chapters 5 and 6 will be used. Pairwise meta-regression will be used to assess 
the constancy by including the year of publication as a covariate in the model. then an adjusted 
NI margin will be calculated from the output of the pair-wise meta-regression. Different M2s 
will be constructed based on different percentages of M. The sample size of the hypothetical 
NI trial will be calculated based on the selected NI margin (M2).  Network meta-regression 
will be used for the analysis of the hypothetical NI trial based on the different NI margins 
proposed.  









1- Adjusting for Co-variables   Limited Yes Limited Limited 
Including more than one 
active control 
No Yes No Limited 
Used in the designing and 
analysis phase of NI  
Limited (Design) Yes Yes Yes 
Can handle both the IPD and 
AD data 
Yes Yes Yes No 
Computational flexibility   Limited No Limited Yes 
Can rank the included 
treatments 







Chapter 8 Applying the Proposed Adjusted Method for 
Setting and Analysis of NI Trials 
8.1 Introduction 
Chapter 7 reviewed the possible methods that can be used to adjust for a time in the case of NI 
trials. Criteria for methods that can be used to adjust for a time in the case of indirect 
comparison were also developed based on the assumptions of NI trials (assay sensitivity, bias 
minimising and constancy assumption), and the ability to adjust for time and the ease of use. 
Th conclusion was that pairwise meta-regression in the designing phase and network meta-
regression in the analysis phase were the recommended methods to use for adjusting for a time 
in indirect comparison.  
This chapter aims to propose a new method of using the pairwise meta-regression for assessing 
the constancy assumption and setting the NI margin in the designing phase (using adjusted 
fixed margin approach), and the network meta-regression to indirectly compare the placebo 
response to the test treatment with the year of conducting as a covariate  in the analysis phase. 
Moreover, the changes in the used percentage of M1 to form M2 and the effect of year of 
conducting on the 50% of M1 will be discussed. 
The chapter is structured as follows. In Section 8.2, the methods for the setting and the analysis 
will be presented. This will be followed in Section 8.3 by introducing the first case study 
(atorvastatin for lowering lipids) where the constancy does not hold. The second case study 
(lidocaine for reducing propofol-induced pain) will be presented in Section 8.4. Finally, a 
summary and recommendations will be provided in Section 8.5. 
8.2  Methods  
8.2.1 Selection of the case studies 
The two cases were selected from the Cochrane reviews used in Chapter 5, based on the 
correlations between the SMD and the year. In the first case study, the correlation was a strong 
negative correlation (constancy assumption does not hold), and in the second case study, the 
correlation was a weak positive correlation (constancy assumption does hold). Both case 
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studies have a similar number of trials, one of them depended on the objective measure 
(cholesterol reduction) and the other one depended on a subjective measure (pain intensity), 
and the year difference in both cases was over twenty years. 
In each case study, it will be hypothetically assumed that a new treatment (T) has been 
developed and needs to be tested for non-inferiority compared to the active treatments 
(atorvastatin and lidocaine in the first and second case studies, respectively) in the year 2020. 
Theoretically, if a new treatment (T) is developed, the aim will be to conclude the non-
inferiority of this new treatment (T) compared to the active control (C). The use of a placebo 
in any future trial is not acceptable due to ethical reasons. In both case studies, several placebo-
controlled trials that compare the active control (C) to placebo (P) were identified. The aim 
now is to assess the constancy of the efficacy of the active control compared to the placebo and 
indirectly to compare the efficacy of the test treatment with that of the placebo. 
8.2.2 Assessing the constancy 
In each case study, a pairwise meta-regression will be used to assess the constancy assumption 
by including the year of publication as a covariate in the model. This will assess whether the 
treatment difference (point estimate) changed over time or not. The fixed effect pairwise meta-
regression will be conducted using the R gemtc (Valkenhoef & Kuiper, 2016). Markov Chain 
Monte Carlo (MCMC) simulation method will be used to calculate the posterior distributions. 
The number of iterations will be 20,000, there will be one thinning interval, four chains, and 
the sample size per chain will be 20,000. Half normal priors will be used to cover a range of 
plausible values, and they seem reasonable for a wide range of diseases and treatments 
(Schmidli et al. , 2012).  
8.2.3 Setting the NI margins 
For each case study, two NI margins will be calculated. The unadjusted NI margin, assuming 
the constancy holds, will be calculated using the lower limit of the 95% CI of the meta-analysis 
of the placebo and active treatment.  
The adjusted NI margin will be calculated from the pairwise meta-regression that adjusts the 
result for the year of trial conduction. The adjusted non-inferiority margin will be calculated 
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using the fixed margin approach with an adjusted 95% CI from the placebo-controlled trials in 
the year of NI trial conducting.  
8.2.4 Setting the hypothetical non-inferiority trials  
For each case study, two hypothetical NI trials tocompare the active treatment (C) with the test 
treatment (T) will be formulated. The sample size for the first trial will be calculated based on 
the unadjusted margin and the second one will be calculated based on the adjusted margin.  
 A network meta-regression will be used in the analysis phase to indirectly assess if the test 
treatment was superior to placebo or not (adjusted predictive approach). The results will be 
compared to the unadjusted non-inferiority margin (assuming the constancy). 
To evaluate the efficacy of the use of the 50% of M1 as M2, different percentages of M1 will 
be compared in the year 2020 both when adjusted for time and while the constancy is assumed. 
Moreover, the changes of M2 based on the year of conducting (2025, 2030) will be assessed to 
investigate the validity of using a constant generic 50% of M1 as unadjusted margin. 
The methods for each case study will be explained with more details in sections (8.3 and 8.4). 
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8.3 Atorvastatin for lowering lipids - the constancy assumption does not seem to hold 
8.3.1 Background 
The review was published in 2015 and aimed to assess the effects of various doses of 
atorvastatin on body lipids (total serum cholesterol, low-density lipoprotein (LDL), high-
density lipoprotein (HDL) and triglycerides) in individuals with and without evidence of 
cardiovascular disease. It included 296 trials in total (242 are before and after trials, and 54 
placebo-controlled trials), with 38,817 patients in total. The main conclusion was that 
atorvastatin decreases total blood cholesterol and LDL-cholesterol in a linear dose-related 
manner. In general, the evidence from this review is considered as high-quality evidence and 
the risk of bias is considered as a moderate risk (Adams et al., 2015). This case study was 




The meta-analysis used included 24 placebo-controlled trials published from 1995 to 2014. 
These trials were chosen by the authors of the original review (Adams et al., 2015) and the 
chosen studies (24 studies) were studies which measured the cholesterol level and used an 
atorvastatin dose of 10 mg as an active control.  
The total sample size was 1902 participants, and the fixed effect model was used to calculate 
the estimate. The active treatment was atorvastatin 10 mg, and the outcome of the meta-analysis 
was a reduction in total cholesterol level from the baseline (negative outcome, the more 
negative the better).  
Figure 8-1 Meta-analysis of placebo versus atorvastatin 
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The final estimate was a statistically significant difference between the placebo and the 
atorvastatin in baseline reduction of total cholesterol. The mean difference for placebo versus 
atorvastatin was 25.44, 95% CI (24.5: 26.38) (Figure 8.1).  
 
8.3.2 Assessing the constancy and setting the NI margin 
The twenty-four placebo-controlled trials that compared the placebo to the atorvastatin were 
included in the pairwise meta-regression model. The year of publication was the covariate in 
the model, and the outcome variable was the mean difference between the placebo and the 
atorvastatin. The fixed effect pairwise meta-regression was conducted using the R gemtc 
(Valkenhoef & Kuiper, 2016). Markov Chain Monte Carlo (MCMC) simulation method was 
used to calculate the posterior distributions. The iterations were 20,000, with one thinning 
interval, four chains, and a sample size per chain of 20,000. Half normal priors were chosen to 
cover a range of plausible values, and they seem reasonable for a wide range of diseases and 
treatments (Schmidli et al. , 2012).  
Table 8.1 Results from the fixed effect meta-regression analysis 
 Mean Standard Error 95% CrI 
Mean Difference 25.88 0.49 (24.92; 26.86) 
Year - 4.84 1.24 (-7.29; -2.41) 
Note: the mean difference was in placebo-atorvastatin, Dbar= 61.01, PD=26.01, DIC=87, 𝐼2 = 23% 
Table 8.1 shows the results from the fixed effect of meta-regression analysis. The results of 
meta-regression indicate that the year of publication statistically significantly reduces the 
difference for reduction of the cholesterol level between the placebo and the atorvastatin. Each 
year increase in the publication will reduce the mean difference between the placebo and the 
atorvastatin by 4.84 points (Table 8.1). The results for the random effects meta-regression were 
the same as for the fixed model, and they are presented in tAppendix (E.1.1) 
Assuming the constant variance, the standard error of the point estimate (0.49)  from Table 8.1 
was used to calculate the confidence intervals for predictions. The prediction per year was 
calculated using the predict command in R. 
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95% CI= Mean difference (in a specific year) ± 1.96× Standard error (SE)  (8.1) 
Hypothetically, if a new treatment (Test) is discovered as an alternative to atorvastatin and 
needs to be tested for non-inferiority to atorvastatin in 2020, a non-inferiority trial will be 
designed using the meta-analysis of the historical placebo-controlled trials tocompare the active 
control with placebo: 
The null hypothesis:  H0: 𝜇𝑇 − 𝜇𝐶 ≤  − 𝛿   (8.2) 
The alternative hypothesis: Ha:  𝜇𝑇 − 𝜇𝐶 > −𝛿   (8.3) 
𝛿 is a percentage (50%) of the lower limit of the mean difference between the placebo and 
active control (atorvastatin), C is the active control (atorvastatin), T is the test treatment (test), 
P is the placebo. From the meta-analysis in (Figure 8.1): 
𝜇𝑃-𝜇𝐶 95% CI = 25.44 (24.50; 26.38) and 
𝜇𝐶-𝜇𝑃 95% CI = - 25.44 (- 26.38; -24.50). 
Assuming the constancy, to conclude the non-inferiority of the test treatment (T) compared to 
placebo (P), the lower limit of the 95% CI of the NI trial should be greater than -24.50, or to 
use the 50% to preserve the effect of the active control, the NI margin (M2) should be greater 
than -12.25. The -12.25 is the unadjusted margin assuming the constancy holds (Figure 8.2). 
However, according to the results of the meta-regression (Table 8.1), the year of publication 
has a negative effect on the efficacy of the atorvastatin compared to the placebo (the constancy 
does not hold). The treatment difference between the atorvastatin and the placebo is decreased 
over time. Figure 8.3 represents the bubble plot from the meta-regression analysis. 
Using pairwise meta-regression, assuming the constancy does not hold (Figure 8.3), the mean 
difference between the placebo and the atorvastatin can be extrapolated for 2018, 2019, 2020, 
2025, 2030 (the years the trial will possibly be conducted). The prediction by year was 
calculated from the R predict commands and the 95% CI calculated assuming constant variance 
with standard error (SE) of 0.49  
95 % CI= Mean difference (in specific year) ± 1.96× 0.49. 
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Table 8.2 Estimates of NI margin using the two different constancy assumptions 
Year 𝜇𝐶-𝜇𝑃 (95% CI) M1 M2 
Constancy assumed (estimate from meta-analysis), not adjusted for the year 
2018 - 25.44 (- 26.38; -24.50). -24.50 -12.25 
2019 - 25.44 (- 26.38; -24.50). -24.50 -12.25 
2020 - 25.44 (- 26.38; -24.50). -24.50 -12.25 
2025 - 25.44 (- 26.38; -24.50). -24.50 -12.25 
2030 - 25.44 (- 26.38; -24.50). -24.50 -12.25 
Constancy not assumed (estimate from the meta-regression), adjusted for the year 
2018 -18.79 (-19.72; -17.85) -17.85 -8.93 
2019 -18.29 (-19.35; -17.35) -17.35 -8.67 
2020 -17.79 (-18.73; -16.85) -16.85 -8.43 
2025 -15.30 (-16.22; -14.35) -14.35 -7.17 
2030 -12.80 (-15.30; -11.84) -11.84 -5.90 
𝜇𝐶-𝜇𝑃is the treatment difference between the atorvastatin and placebo, M1, is the NI margin, the upper limit of the 95 % CI 
of 𝜇𝐶-𝜇𝑃,  M2 is the 50% of M1 
 
Figure 8-2 Bubble plot for the mean difference between the placebo and atorvastatin 
when the constancy assumption holds 




Figure 8-3 Bubble plot for the meta-regression of the mean difference between placebo 
and atorvastatin 
(Note: Bubble size reflects sample size, the 95 % CI assuming constant standard error of 0.49) 
Table 8.2 illustrates the difference between the NI margins using the unadjusted 95% CI 
(assuming the constancy) and the 95% CI from the meta-regression (the constancy does not 
hold). To conclude the NI of the test treatment (T) compared to atorvastatin, the lower limit of 
the 95 % CI of the NI trial (𝜇𝑇-𝜇𝐶) should be greater than M2. 
Hypothetically, two NI trials could be designed in 2020, using either the unadjusted margin of 
-12.25 (assuming the constancy) or the adjusted margin of -8.43 (the constancy does not hold). 
Using the formula for sample size calculation (Flight & Julious, 2016):  




    (8.4) 
where d is the pre-specified non-inferiority margin,  𝜎2 is the variance of the mean difference 
(from Figure 8.1 the standard deviation =12),  𝜇𝑇 is the mean cholesterol reduction in the test 
treatment,  𝜇𝐶 is the mean cholesterol reduction in the atorvastatin group,  r is the allocation 
ratio between the treatment and control group, and is assumed to be one. α is a type I error, β 
is a type II error. 
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Assuming the constancy using the unadjusted NI margin of (d= -12.25), the standard deviation 
of 12, Type I error (α) of 0.025 and Type II error (β)  of 0.1, the sample size assuming zero 
mean difference between the test treatment and atorvastatin is 21 participants per arm.  
𝑛𝐶 = 𝑛𝑇 =  
(2) × (12)2 × (𝑍1− + 𝑍1−0.025)
2
1 × ((0) − 12.25)
2  




𝑛𝐶 = 𝑛𝑇=20.15 
𝑛𝐶 = 𝑛𝑇 = 21 
When adjusted for time, the adjusted NI margin in 2020 of - 8.43 and standard deviation of 12, 
Type I error of 0.025 and Type II error of 0.1, the sample size assuming zero mean difference 
between the test treatment and atorvastatin is 43 participants per arm. In 2025, the sample size 
will increase to 59 participants per group and to 87 participants in each arm in the year 2030.  
8.3.3 Analysis of non-inferiority trial based on the unadjusted margin (NI margin > -12.25)  
Suppose the NI trial is conducted in 2020 with a sample size of 21 participants in each arm 
based on an NI margin of -12.25. The aim is to confirm the non-inferiority of the test treatment 
compared to atorvastatin with NI margin > -12.25. 
Network meta-analysis (NMA) will be used to compare the effect of the test treatment and the 
atorvastatin, without adjusting for the time (no adjustment in the setting or the analysis), by 
including the three different treatments (placebo, atorvastatin and the test treatment) in one 
network. Network meta-regression will assess the treatment difference between the placebo 
and the test treatment in 2020 (adjusting for the time in the analysis phase). 
Figure 8.4 represents the network of the three treatments (placebo, atorvastatin, and the test 





Figure 8-4 Network of atorvastatin, placebo and the test treatment 
(Thickness of lines represents the number of trials), circles represent the included treatments, the solid line represents direct 
comparisons, and the dash line represents the indirect comparison) 
 
The gemtc R package for Bayesian network meta-analysis  (Valkenhoef & Kuiper, 2016) was 
used for conducting both the network meta-analysis and the network meta-regression.  Markov 
Chain Monte Carlo (MCMC) simulation method was used to calculate the posterior 
distributions. The iterations were 80,000, with one thinning interval, four chainsand a sample 
size per chain of 40,000, all are the same as those used by Schmidli et al. ( 2012). Half-normal 
prior was used to cover a range of plausible values, and they seem reasonable for a wide range 







Table 8.3 Comparison of the mean difference between the placebo and test treatment 
assuming the constancy 
 𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI trial 
(2020) (95% CrI), SE 
= (3.7) 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), SE = 
(4.22) 
NMR (𝜇𝑇 − 𝜇𝑃) in (2020) 
(95% CrI), SE = (4.22) 
18.5 0.0 (-7.2; 7.2) 25.0 (18.0; 33.0) 18.0 (9.6; 26.0) 
16.5 -2.0 (-9.2; 5.3) 23.0 (16.0; 31.0) 16.0 (7.6; 24.0) 
15.5 -3.0 (-10.0; 4.3) 22.0 (15.0; 30.0) 15.0 (6.6; 23.0) 
14.5 -4.0 (-11.0; 3.2) 21.0 (14.0; 29.0) 14.0 (5.6; 22.0) 
13.5 -5.0 (-12.3; 2.2) 20.0 (13.0; 28.0) 13.0 (4.6; 21.0) 
12.5 -6.0(-13.2; 1.3) 19.0 (12.0; 27.0) 12.0 (3.6; 20.0) 
10.5 -8.0 (-15.3; -0.7) 17.0 (10.0; 25.0) 9.8 (1.5; 18.0) 
8.5 -10.0 (-17.3; -2.7) 15.0 (8.2; 23.0) 1.8 (-0.5; 16.0) 
7.0 -11.4 (-18.5; -4.4) 14.0 (6.8; 21.0) 6.4 (-1.7; 15.0) 
1.5 -17.0 (-24.3; -9.7) 8.5 (1.1; 16.0) 0.8 (-7.5; 9.1) 
0.0 -18.5 (-25.7; -11.2) 6.9 (-0.4; 14.0) -0.7 (-8.9; 7.6) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜇𝑡 − 𝜇𝑐 refers to the mean difference between the active 
control and the test treatment, negative sign means the test treatment is less effective than the active control, SE: Standard 
error, 𝜇𝑡 is the treatment effect in the test group in the NI trial,  
light grey = Failure to conclude NI of T versus C, medium grey = C is superior to T, dark grey =T is not superior to 
placebo.    
 
Table 8.3 illustrates the differences between the placebo and the test treatment, using the NI 
margin of -12.25 to set the sample size of 21. The results from the NMA assume the 
constancy in the analysis phase (no changes by time). The results from the NMR represent 
the predicted results in 2020 (constancy not assumed in the analysis phase).  
The first column in the table illustrates μt (the mean of the test treatment), the second column 
illustrates the results of the NI trial 𝜇𝑇 − 𝜇𝐶 with the light shading referring to failure to 
conclude the non-inferiority of T compared to C and the medium grey shading illustrating 
that the control is even superior to the test treatment. The last column illustrates the results 
from the network meta-analysis that indirectly compared the test treatment (T) with the 
placebo (P) and the dark grey shading illustrates that the test treatment is not superior to the 
placebo.  
From the table (8.3), by assuming the constancy and ignoring the changes of the efficacy of 
the active control (atorvastatin) and the placebo, using the margin of -12.25 the non-
inferiority can be concluded up to four points difference (the efficacy of test treatment is four 
points less than the atorvastatin). The non-inferiority cannot be concluded if the efficacy of 
the test treatment is five points less than the active control.  
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Using NMA (constancy assumed in the analysis phase), the superiority of the test treatment 
compared to the placebo was concluded, up to a mean effect of the test treatment 𝜇𝑡 =1.5 
points (the test treatment was inferior to active control).  
Using the NMR (adjusted for time in the analysis phase), the superiority of the test treatment 
was concluded, with 𝜇𝑡 up to 10.5 points, which is less than the unadjusted one (NMA), but 
still the test treatment was inferior to the atorvastatin.  
 
8.3.4 Analysis of non-inferiority trial based on the adjusted margin (NI margin < -8.43) 
Suppose the NI trial is conducted in 2020 with a sample size of 43 participants in each arm 
based on an adjusted NI margin of -8.43. The aim is to confirm the non-inferiority of the test 
treatment compared to atorvastatin with NI margin greater than - 8.43. The three treatments 
(atorvastatin, test treatment, and placebo) were included in one network (Figure 8.4). NMA 
will be used to compare the effect of the test treatment compared to placebo without any further 
adjustment for time (constancy assumed in the analysis phase). Network meta-regression will 
be used to compare the efficacy of the test treatment compared to the placebo in 2020 (adjusted 
for time in the analysis phase).  
The gemtc R package for Bayesian network meta-analysis  (Valkenhoef & Kuiper, 2016) was 
used for conducting both the network meta-analysis and the network meta-regression.  Markov 
Chain Monte Carlo (MCMC) simulation method was used to calculate the posterior 
distributions. The iterations were 80,000, with one thinning interval, four chains, and a sample 
size per chain of 40,000, all are the same as those used by Schmidli et al. ( 2012). Half-normal 
prior was used to cover a range of plausible values, and they seem reasonable for a wide range 
of diseases and treatments  (Schmidli et al., 2012). 
Table 8.4 illustrates the differences between the placebo and the test treatment, using the NI 
margin of -8.43 to set the sample size of 43. From the results, by adjusting for time (2020), 
the non-inferiority of the test treatment compared to atorvastatin was concluded up to three 
points of difference (the efficacy of test treatment is three points less than that of the 
atorvastatin). The non-inferiority cannot be concluded if the efficacy of the test treatment is 
greater than 3.5 points less than the active control.  
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Using the NMA, (constancy assumed) the superiority of the test treatment compared to 
placebo was concluded even when the mean effect of the test treatment equalled zero. When 
adjusted for the time (NMR) the superiority of the test treatment compared to placebo was 
concluded up to mean effect of test treatment equal to 8.5.   
Table 8.4 Comparison of the mean difference between the placebo and test treatment, 
constancy not assumed 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), SE= 2.58 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), SE= 
2.67 
NMR (𝜇𝑇 − 𝜇𝑃) in (2020) 
(95% CrI), SE= 3.27 
18.5 0.0 (-5.1; 5.1) 25.0 (20.0; 31.0) 18.0 (11.0; 24.0) 
16.5 -2.0 (-7.1; 3.1) 23.0 (18.0; 29.0) 16.0 (9.4; 22.0) 
15.5 -3.0 (-8.1; 2.1) 22.0 (17.0; 28.0) 15.0 (8.4; 21.0) 
14.5 - 4.0 (-9.1; 1.1) 21.0 (16.0; 27.0) 14.0 (7.3; 20.0) 
13.5 -5.0 (-10.1; 0.0) 20.0 (15.0; 25.0) 13.0 (6.4; 19.0) 
12.5 -6.0 (-11.1; -0.9) 19.0 (14.0; 25.0) 12.0 (5.4; 18.0) 
11.5 -7.0 (-12.1; -1.8) 18.0 (13.0; 24.0) 11.0 (4.4; 17.0) 
10.5 -8.0 (-13.1; -2.9) 17.0 (12.0; 23.0) 9.8 (3.4; 16.0) 
8.5 -10.0 (-15.6; -4.9) 15.0 (10.0; 21.0) 7.8 (1.4; 14.0) 
7.0 -11.5 (-16.6; -6.4) 14.0 (8.8; 19.0) 6.3 (-0.1; 13.0) 
1.5 -17.0 (-22.0; -11.9) 8.5 (3.3; 14.0) 0.8 (-5.7; 7.2) 
0.0 -18.5 (-23.6; -13.5) 6.9 (1.8; 12.0) -6.9 (-7.1; 5.7) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜇𝑡 − 𝜇𝑐 refers to the mean difference between the active 
control and the test treatment, negative sign means the test treatment is less effective than the active control. 
Light grey = Failure to conclude NI of T versus C, medium grey = C is superior to T, dark grey =T is not superior to 
placebo  
 
8.3.5 The effect of using different percentages of M1 to set M2 
As mentioned in Chapter 2, M2 is the actual NI margin using a specific percentage of M1. This 
percentage is used to protect the constancy assumption (FDA, 2016). As a common generic 
practice, 50% of M1 is usually used as the M2. However, it is not clear if the use of 50% could 
be an alternative to the assessment of the constancy and the adjustment for time. Table 8.5 
illustrates how the use of a different percentage of M1 could change the results both when 
assuming the constancy and when adjusting for time.  
In 2020, when constancy was assumed (no adjustment for time), using 50% of the M1 instead 
of M1 as a whole, partially to protect the estimate from the conclusion of non-inferiority of an 
already inferior test treatment, the difference between the conclusion of non-inferiority and the 
failure to conclude the superiority to placebo was six points. This difference between the 
conclusion of non-inferiority and failure to conclude superiority to placebo dropped to three 
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points using 60% of M1, 0.5 points using 70% of M1. At 80% of M1, the failure to conclude 
superiority was higher at 12.5 points, while the conclusion of non-inferiority was 11 points 
(difference of -1.5 points); the conclusion was non-inferiority of an already inferior treatment. 
At 90% of M1, and if M1 was used, the non-inferiority would be established for an already 
inferior treatment (Table 8.5).  
Table 8.5 Comparison between the unadjusted and adjusted margins when constancy 
does not hold 
 Constancy Assumed Adjusted for time 
M2 = 50% M1 
NI margin -12.25 -8.43 
Sample size 𝑛1 =𝑛2 21.00 43.00 
NI established up to  𝜇𝑡=14.50 𝜇𝑡=15.50 
NI cannot be concluded 𝜇𝑡=13.50 𝜇𝑡=15.00 
Atorvastatin is superior to test treatment  𝜇𝑡=10.50 𝜇𝑡=13.00 
Test treatment not superior to placebo (2020) 𝜇𝑡=9.00 𝜇𝑡= 7.00 
Test treatment not superior to placebo (NMA) 𝜇𝑡=0.00 𝜇𝑡< 0.00 
M2 = 60% M1 
NI margin -14.70 -10.11 
Sample size 𝑛1 =𝑛2 14.00 30.00 
NI established up to  𝜇𝑡=13.00 𝜇𝑡=14.50 
NI cannot be concluded 𝜇𝑡=12.50 𝜇𝑡=14.00 
Atorvastatin is superior to test treatment  𝜇𝑡= 9.50 𝜇𝑡= 11.50 
Test treatment not superior to placebo (2020) 𝜇𝑡= 10.00 𝜇𝑡= 7.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=1.50 𝜇𝑡< 0.00 
M2 = 70% M1 
NI margin -17.5 -11.79  
Sample size 𝑛1 =𝑛2 11.00 22.00 
NI established up to  𝜇𝑡=11.50 𝜇𝑡= 14.00 
NI cannot be concluded 𝜇𝑡=11.00 𝜇𝑡= 13.50 
Atorvastatin is superior to test treatment  𝜇𝑡=7.50 𝜇𝑡= 9.50 
Test treatment not superior to placebo (2020) 𝜇𝑡=11.00 𝜇𝑡= 8.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=3.00 𝜇𝑡<0.00 
M2 = 80% M1 
NI margin -19.60 -13.48 
Sample size 𝑛1 =𝑛2 8.00 17.00 
NI established up to  𝜇𝑡=11.00 𝜇𝑡= 14.00 
NI cannot be concluded 𝜇𝑡=10.50 𝜇𝑡= 13.00 
Atorvastatin is superior to test treatment  𝜇𝑡=6.50 𝜇𝑡=9.50 
Test treatment not superior to placebo (2020) 𝜇𝑡= 12.50 𝜇𝑡= 9.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=4.50 𝜇𝑡= 0.50 
M2 = 90% M1 
NI margin -22.05 -15.60 
Sample size 𝑛1 =𝑛2 7.00 14.00 
NI established up to  𝜇𝑡=9.00 𝜇𝑡= 12.50 
NI cannot be concluded 𝜇𝑡= 8.50 𝜇𝑡= 11.50 
Atorvastatin is superior to test treatment  𝜇𝑡= 5.50 𝜇𝑡= 9.50 
Test treatment not superior to placebo (2020) 𝜇𝑡=13.50 𝜇𝑡= 9.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=5.50 𝜇𝑡= 1.50 
M2 =  M1 
NI margin -24.50 -16.85 
Sample size 𝑛1 =𝑛2 6.00 11.00 
NI established up to  𝜇𝑡=8.50 𝜇𝑡=12.00 
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NI cannot be concluded 𝜇𝑡=7.50 𝜇𝑡= 11.50 
Atorvastatin is superior to test treatment  𝜇𝑡=4.50 𝜇𝑡= 7.50 
Test treatment not superior to placebo (2020) 𝜇𝑡=6.50 𝜇𝑡= 11.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=14.50 𝜇𝑡= 2.50 
When adjusted for time, the adjusted NI margin using 50% of the M1 leads to 8.5 points 
difference between the conclusion of non-inferiority and failure to conclude the superiority to 
placebo. This difference is reduced to 7.5 points using 60% of M1, 6 points difference using 
70% of M1, 4.5 % using the 80% of M1, 3.5 points using the 90% of M1 and 1.5 points using 
the whole M1 (Table 8.5).  Figures 8.5 and 8.6 illustrate the differences between the use of 
adjusted and unadjusted margins with different percentages of M1. 
Even though using 50% of M1 with the unadjusted margin partially protected from the 
conclusion of non-inferiority of an already inferior test treatment in 2020, this protection was 
similar to 70% using the adjusted margin. The use of an unadjusted margin will increase the 
risk of the conclusion of non-inferiority of an already inferior treatment. The adjusted margin 
was away from the conclusion of non-inferiority of an inferior treatment even with the use of 
the whole M1 instead of a percentage of M1. The use of an unadjusted margin led to a false 
conclusion of non-inferiority of an already inferior test treatment to placebo with the 70% of 
M1. Using the adjusted margin led to a larger sample size of the planned NI trial. 
In 2025, the picture was changed; assuming the constancy and using the NI margin of -12.25 
with sample size of 21 led to failure to conclude the non-inferiority with treatment effect of the 
test treatment (𝜇𝑡 = 13.5). The superiority of the test treatment compared to placebo cannot be 
established at 𝜇𝑡 = 12, with the difference between the two being 1.5 points only. The use of 
50% of M1 while assuming constancy did not protect against the conclusion of non-inferiority 
of an already inferior treatment.  
By increasing the year difference between the last historical trial and the year of NI trial 
conducting, the gap between the failure to conclude non-inferiority and failure to conclude the 
superiority of the test treatment to the placebo was increased. By the year 2030 (15 years 
difference), the non-inferiority of the test treatment was established up to 𝜇𝑡 = 14.5, while 
there was failure to establish superiority to placebo at 𝜇𝑡 = 15. In other words, i the non-
inferiority of an already inferior treatment was concluded by assuming the constancy without 
any further adjustment. Moreover, the use of a 50% fraction of M1 did not protect against the 




Figure 8-5 Comparison between the different percentages of M1 using the adjusted 
margin (constancy does not hold) 
 
Figure 8-6 Comparison between the different percentages of M1 using the unadjusted 
margin (constancy assumed) 
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Table 8.6 Comparison between the unadjusted and adjusted margins for years 2020, 2025, 
2030 
 Constancy Assumed Adjusted for time 
2020 
NI margin -12.25 -8.43 
Sample size 𝑛1 =𝑛2 21.00 43.00 
NI established up to  𝜇𝑡=14.50 𝜇𝑡=15.50 
NI cannot be concluded 𝜇𝑡=13.50 𝜇𝑡=15.00 
Atorvastatin is superior to test treatment  𝜇𝑡=10.50 𝜇𝑡=13.00 
Test treatment not superior to placebo (NMR) 𝜇𝑡=9.00 𝜇𝑡= 7.00 
Test treatment not superior to placebo (NMA) 𝜇𝑡=0.00 𝜇𝑡< 0.00 
2025 
NI margin -12.25 -7.17 
Sample size 𝑛1 =𝑛2 21.00 59.00 
NI established up to  𝜇𝑡=14.50 𝜇𝑡=16.00 
NI cannot be concluded 𝜇𝑡=13.50 𝜇𝑡=15.50 
Atorvastatin is superior to test treatment  𝜇𝑡=10.50 𝜇𝑡= 13.50 
Test treatment not superior to placebo (NMR) 𝜇𝑡=12.00 𝜇𝑡= 8.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=0.00 𝜇𝑡< 0.00 
2030 
NI margin -12.25 -5.90  
Sample size 𝑛1 =𝑛2 21.00 87.00 
NI established up to  𝜇𝑡=14.50 𝜇𝑡= 16.25 
NI cannot be concluded 𝜇𝑡=13.50 𝜇𝑡= 16.00 
Atorvastatin is superior to test treatment  𝜇𝑡=10.50 𝜇𝑡= 13.50 
Test treatment not superior to placebo (NMR) 𝜇𝑡=15.00 𝜇𝑡12.50 
Test treatment not superior to placebo (NMA) 𝜇𝑡=0.00 𝜇𝑡<0.00 
When adjusting for time, in 2025, the sample size was increased to 59 participants per arm and 
the NI margin was -7.17. The non-inferiority of the test treatment compared to the placebo was 
concluded up to 𝜇𝑡= 16.00, while the superiority to placebo was concluded up to 𝜇𝑡 = 8.5. In 
2030, the sample size increased to 87 participants per arm and the NI margin was    -5.90. The 
non-inferiority of the test treatment compared to the placebo was concluded up to 𝜇𝑡= 16.25, 
while the superiority to placebo was concluded up to 𝜇𝑡 = 12.5. (Table 8.6) 
In summary, in the case where the constancy assumption does not hold, assuming the constancy 
and using the unadjusted margin could lead to the conclusion of non-inferiority of an already 
inferior treatment. The use of a predefined percentage of 50 % M1 instead of the whole M1 
cannot protect from the conclusion of non-inferiority of an inferior test treatment, especially 
when the time difference between the last historical trial and the NI trial is increased. The use 
of a 50% fraction of M1 cannot be a replacement for the adjustment for the constancy. Using 
the adjusted margin reduces the chances of the conclusion of the non-inferiority of an inferior 
treatment regardless of the fraction of the M1 used. In the case of an NI trial, the adjusted 
margin for time should be used to set M1; M2 should be a matter of clinical judgement and 
based on the adjusted M1, not used as a tool for protection of the constancy assumption.   
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8.4 Using lidocaine for reducing propofol‐induced pain on the induction of anaesthesia in 
adults - the constancy assumption seems to hold 
8.4.1 Background 
This review was updated in 2016. It aimed to investigate the efficacy and adverse effects of 
lidocaine in reducing high-intensity pain during propofol injection. The review includes 82 
multicentre placebo-controlled trials. The quality of evidence is graded as high quality. The 
main meta-analysis used in this example includes 23 trials. These trials were chosen based on 
the dose group (low dose group trials). The year difference ranged from 1988 to 2010. The 
results indicate that the incidence of high-intensity pain in the control group (placebo) was 
higher than in the lidocaine group (low dose group). The odds of high-intensity pain in the 
placebo group were 5.16 times higher than in the lidocaine group, 95% CI (4.14; 6.42) 
(Euasobhon et al., 2016). Figure 8.7 represents the meta-analysis for the comparison between 
the lidocaine and the placebo. 
 
Figure 8-7 Meta-analysis of the pain intensity in placebo versus lidocaine 
169 
 
8.4.2 Assessing the constancy and setting the NI margin 
From Chapters 5 and 6, it was concluded that the use of a fixed effect model is recommended 
in the case of NI trials since it gives less weight to the extreme older trials compared to the 
random effects model, which will give more weight for smaller studies with extreme results. 
For that reason, the fixed effect model will be used. The results of the random effects model 
will be presented in the Appendix (E.3). 
Fixed effect pairwise meta-regression was conducted using the R gemtc (Valkenhoef & 
Kuiper, 2016). Markov Chain Monte Carlo (MCMC) simulation method was used to 
calculate the posterior distributions. The iterations were 20,000, with one thinning interval, 
four chains, and a sample size per chain of 20,000. Vague priors used were the same as those 
used by Schmidli et al. ( 2012).  
Table 8.7 Results of meta-regression of placebo versus lidocaine 
 Estimate Standard Error 95% CrI 
Log odds ratio  1.68 0.11 1.46; 1.91) 
Year 0.10 0.20 (-0.32; 0.50) 
Note: the log odds ratio was between placebo versus Lidocaine, Dbar= 48.86, PD=25.33, DIC=74.20, 𝐼2 =
8 % 
The 23 placebo-controlled trials that compared the placebo to the lidocaine were included in 
the pairwise meta-regression model. The year of publication was the co-variable in the model, 
and the outcome variable was the log odds ratio between the placebo and the lidocaine.  
The results of meta-regression indicate that the year of publication does not affect the point 
estimate (Table 8.7). Over the 22 years of trial conducting, the effect estimate for the odds of 
pain in the lidocaine group compared to placebo was constant over time and the effect of the 
year of publication was not statistically significant (Table 8.7).  
Figure 8-8 represents the bubble plot from the fixed effect meta-regression. Based on the meta-
regression, the constancy assumption does hold, and the treatment difference between the 
placebo and the lidocaine is constant over time. 
Figure 8.9 would represent the bubble plot if the constancy were assumed and without any 




Figure 8-8 Bubble plot for the changes in the odds ratio per year  
(Constancy not assumed) 
 
 
Figure 8-9 Bubble plot for changes in odds ratio (constancy assumed) 
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Table 8.8 Estimates of NI margin using the adjusted and unadjusted methods 
Year OR (𝜋𝑃/𝜋𝐶) 95% CI  M1 M2(1/2 log M1) 
Constancy assumed (estimate from meta-analysis), not adjusted for the year 
2018 5.16 (4.14; 6.42) 4.14 2.03 
2019 5.16 (4.14; 6.42) 4.14 2.03 
2020 5.16 (4.14; 6.42) 4.14 2.03 
2025 5.16 (4.14; 6.42) 4.14 2.03 
2030 5.16 (4.14; 6.42) 4.14 2.03 
Constancy not assumed (estimate from the meta-regression), adjusted for the year 
2018 5.26 (4.22; 6.55) 4.22 2.05 
2019 5.27(4.23; 6.57) 4.23 2.06 
2020 5.28 (4.24; 6.58)  4.24 2.06 
2025 5.40 (4.30; 6.68) 4.30 2.07 
2030 5.43 (4.36; 6.77) 4.36 2.09 
Suppose in 2020, a new treatment (test) is developed to reduce the pain intensity during 
propofol injection. To conclude the non-inferiority of the new treatment compared to lidocaine, 
an NI trial will be designed and conducted in 2020  
The null hypothesis:  H0: 𝑂𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 𝜋𝑇/𝜋𝐶 ≥   𝛿   (8.5) 
The alternative hypothesis: Ha:  𝑂𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 𝜋𝑇/𝜋𝐶 <  𝛿  (8.6) 
Where 𝛿 is the percentage (50%) of the lower limit of the 95% CI between the placebo and 
active control (lidocaine), C is the active control (lidocaine), T is the test treatment (test), and 
P is the placebo.  
The prediction by year was calculated from the R predict commands and the 95% CI was 
calculated using the standard error (SE) of 0.11 from Table 8.7 
 95% CI= Mean difference (in specific year) ± 1.96× 0.11 
Table 8.8 illustrates the calculations of the NI margins using the unadjusted 95% CI (assuming 
the constancy) and the 95% CI from the meta-regression (the constancy does not hold). There 
was a slight increase in the NI margin even though the constancy assumption over the 22 years 
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was evident. Increasing the odds ratio means an increase in the pain intensity, which means a 
decrease in the efficacy of the active control (lidocaine) to reduce the pain compared to placebo.  
Hypothetically, an NI trial could be designed in 2020, using either the adjusted margin of 2.06 
or the non-adjusted margin; the NI margin 2.03 could be used to calculate the sample size. 
Using the formula for sample size calculation (Wang, Chow, & Li, 2002) 












)   (8.7) 
1- With the unadjusted NI margin of 2.03, using the formula (8.7), where d is the NI 
margin (d = 2.03), Type I error of 0.025 and Type II error of 0.1, 𝜋𝑇 is the 
proportion in the treatment group and 𝜋𝐶 is the proportion of the control group.  
The sample size assumes equal relative effects between both treatments (rate of 




 = 329 
𝑛𝑇 = 𝑛𝐶 = 329 
2- With the adjusted margin of 2.06, using the formula (8.2) NI margin (odds = 2.06), 
Type I error of 0.025 and Type II error of 0.1, the sample size assuming equal 
relative effects between both treatments (rate of failure of both groups = 0.15) based 




 = 316 
 𝑛𝑇 = 𝑛𝐶 = 316 
In the year 2025, the sample size will be reduced to 310 participants per arm and in 2030 the 
sample size will be 305 participants per arm. 
8.4.3 Analysis of non-inferiority trial based on the unadjusted NI margin >2.03 
Suppose the NI trial is conducted in 2020 with a sample size of 329 participants in each arm 
based on NI margin of odds ratio less than 2.03. The aim is to confirm the non-inferiority of 
the test treatment (Test) compared to lidocaine with NI margin less than 2.03. 
The null hypothesis ∶  H0: the upper limit of the 95 CI( πT/πC) ≥ 2.03 
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The alternative hypothesis ∶  Ha: the upper limit of the 95 CI πT/πC < 2.03 
With the constancy assumption holding for this review, the NI margin < 2.03 will be used for 
both the network meta-analysis (unadjusted analysis) and the network meta-regression (for 
the year 2020). A network composed of the three treatments (lidocaine, placebo, and test 
treatment) will be formulated (Figure 8.10). Network meta-analysis (NMA) will be used to 
compare the efficacy of the test treatment compared to the placebo without any further 
adjustment. A network meta-regression (NMR) will be used to assess the efficacy of the test 
treatment compared to placebo in 2020. The gemtc R package for Bayesian network meta-
analysis  (Valkenhoef & Kuiper, 2016) will be used in the analysis for both the NMA and 
NMR. Markov Chain Monte Carlo (MCMC) simulation method was used to calculate the 
posterior distributions. The iterations were 80,000, with one thinning interval,  four chains, 
and a sample size per chain of 40,000, all are the same as those  used by Schmidli et al. 
( 2012). Normal half priors used were the same as those used by Schmidli et al. ( 2012).
 
Figure 8-10 Network of lidocaine, placebo and the test treatment 
(Thickness of lines represents the number of trials), circles represent the included treatments, the solid line represents direct 















Table 8.9 Comparison of the odds ratio between the placebo and test treatment assuming 
the constancy 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) (95% CrI),SE=0.22  
NMA,  OR (𝜋𝑃/𝜋𝑇) 
(95% CrI),SE= 0.22 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) (95% CrI), SE= 0.41 
15.00% 1.0 (0.65; 1.53) 5.31 (3.29; 8.62) 6.28 (2.87; 14.00) 
17.00% 1.10 (0.72; 1.67) 4.87 (3.02; 7.87) 5.75 (2.59; 12.9) 
19.00% 1.32 (0.88; 2.00) 4.01 (2.53; 6.39) 4.70 (2.13; 10.50) 
20.00% 1.40 (0.94; 2.11) 3.80 (2.41; 6.00) 4.40 (1.99; 9.76) 
21.00% 1.51 (1.01; 2.27) 3.54 (2.23; 5.54) 4.14 (1.89; 9.45) 
23.00% 1.68 (1.13; 2.50) 3.18 (2.01; 4.99) 3.74 (1.70; 8.29) 
25.00% 1.89 (1.28; 2.81) 2.83 (1.80; 4.41) 3.27 (1.52; 7.34) 
30.00% 2.41 (1.65; 3.55) 2.20 (1.42; 3.41) 2.56 (1.19; 5.50) 
35.00% 3.05 (2.11; 4.47) 1.75 (1.12; 2.69) 2.04 (0.94; 4.45) 
40.00% 3.75 (2.59; 5.49) 1.42 (0.91; 2.19) 1.67 (0.77; 3.63) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜋𝑡/𝜋𝑐 refers to the odds ratio between the test treatment 
and the active control, the 𝜋𝑝/𝜋𝑡 refers to the odds ratio between the placebo and the test treatment odds ratio >1 indicates 
worse outcome (high pain intensity). 
Light grey = Failure to conclude NI of T versus C, medium grey = C is superior to T, dark grey =T is not superior to 
placebo 
 
Table 8.9 illustrates the results of using the unadjusted margin. When assuming the 
constancy, a non-inferiority margin of 2.03 will be used with a sample size of 329 
participants in each arm. The non-inferiority of the test treatment compared to lidocaine was 
established up to a failure rate (failure to reduce pain) of 19% compared to a failure rate of 
15% in the lidocaine group. The non-inferiority could not be established with a failure rate of 
20%. Moreover, the inferiority of the test treatment compared to the active control (lidocaine) 
was evident at a failure rate of 21%. With a failure rate of 35%, the superiority of the test 
treatment compared to placebo could not be established using the network meta-regression 
(adjusting for time) or with a failure rate of 40% in the case of network meta-analysis (no 
adjusting for time).  
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8.4.4 Analysis of non-inferiority trial based on the adjusted NI margin >2.06 
Suppose the NI trial was conducted in 2020 with a sample size of 320 participants in each arm 
based on NI margin of OR < 2.06. The aim is to confirm the non-inferiority of the test treatment 
(Test) compared to lidocaine with NI margin of 2.06 
The null hypothesis ∶  H0: the upper limit of the 95 CI πT/πC ≥ 2.06 
The alternative hypothesis ∶  Ha: the upper limit of the 95 CI πT/πC < 2.06 
The network meta-analysis and network meta-regression were conducted using the gemtc R 
package for Bayesian network meta-analysis  (Valkenhoef & Kuiper, 2016). Markov Chain 
Monte Carlo (MCMC) simulation method was used to calculate the posterior distributions. The 
iterations were 80,000, with one thinning interval, four chains, and a sample size per chain of 
40,000, all are the same as those used by Schmidli et al. ( 2012). Vague priors used were the 
same as those used by Schmidli et al. ( 2012). 
The network meta-analysis will compare the three treatments together with no consideration 
for the time either in the designing phase (unadjusted NI margin) or the analysis phase (no 
Covariates included in the model) and will evaluate the efficacy of the test treatment compared 
to placebo in general (without adjustment). The network meta-regression was used to evaluate 
the efficacy of the test treatment compared to placebo in 2020.   
When adjusting for time, a non-inferiority margin of 2.06 will be used with a sample size of 
316 participants in each arm.  
Table 8.10 illustrates the results of using the adjusted margin. The non-inferiority of the test 
treatment compared to lidocaine was established up to failure rate (failure to reduce pain) of 
19% compared to a failure rate of 15% in the lidocaine group. The non-inferiority could not be 
established with a failure rate of 20%. Moreover, the inferiority of the test treatment compared 
to the active control (lidocaine) was evident at a failure rate of 21%. With a failure rate of 35% 
the superiority of the test treatment compared to placebo could not be established using the 
network meta-regression (adjusting for time) or with a failure rate of 40% in the case of network 
meta-analysis (no adjusting for time). 
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Table 8.10 Comparison of the odds ratio between the placebo and test treatment, the 
constancy not assumed (NI margin =2.06) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) (95% CrI) 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
(95% CrI) 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) (95% CrI) 
15.00% 1.0 (0.64; 1.55) 5.31 (3.27; 8.67) 6.24 (2.80; 14.10) 
17.00% 1.15 (0.75; 1.76) 4.63 (2.86; 7.48) 5.42 (2.47; 12.30) 
19.00% 1.34 (0.88; 2.04) 3.98 (2.51; 6.38) 4.70 (2.10; 10.60) 
20.00% 1.42 (0.94; 2.14) 3.75 (2.49; 6.40) 4.61 (2.06; 10.30) 
21.00% 1.50 (1.00; 2.27) 3.54 (2.22; 5.66) 4.13 (1.88; 9.19) 
23.00% 1.68 (1.13; 2.52) 3.18 (2.00; 5.01) 3.73 (1.69; 8.44) 
25.00% 1.86 (1.25; 2.80) 2.85 (1.80; 4.50) 3.63 (1.51; 7.54) 
30.00% 2.41 (1.64; 3.59) 2.21 (1.41; 3.43) 2.60 (1.17; 5.83) 
35.00% 3.03 (2.07; 4.49) 1.75 (1.12; 2.71) 2.07 (0.94; 4.43) 
40.00% 3.78 (2.60; 5.56) 1.41 (0.90; 2.19) 1.64 (0.75; 3.62) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜋𝑡/𝜋𝑐 refers to the odds ratio between the test treatment 
and the active control, the 𝜋𝑝/𝜋𝑡 refers to the odds ratio between the placebo and the test treatment odds ratio >1 indicates 
worse outcome (high pain intensity), SE is the standard error. 
Light grey = Failure to conclude NI of T versus C, medium grey = C is superior to T, dark grey =T is not superior to 
placebo 
 
8.4.5 The effect of different percentages of M1 to set M2 
When the constancy assumption holds, both the adjusted and the unadjusted margin yield the 
same results. The sample size was larger using the unadjusted margin. In the case of constancy 
assumption hold, using the results from a pairwise meta-analysis of the placebo-controlled 
trials will lead to unbiased results without the need for any further adjustment. In the case of 
constancy assumed (NI margin =2.03), the difference in the failure rate between the conclusion 
of non-inferiority and the failure to conclude superiority was 16 points using the 50% of M1, 
which was similar using the adjusted margin of 2.06 (50% of M1). The difference was reduced 
to 15 points using the 60% of M1 in both cases and by the time of using the whole M1 as NI 
margin the difference was reduced to five points in the unadjusted case and four points with 
the adjusted margin. Table 8.11 and Figures 8.11 and 8.12 compare the two different margins 
when the constancy assumption holds (detailed tables are presented in Appendix E). 
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Table 8.11 Comparison between the adjusted and unadjusted margin when the constancy 
holds 
 Constancy Assumed Adjusted for time 
M2 = 50% M1 
NI margin 2.03 2.06 
Sample size 𝑛1 =𝑛2 329.00 316.00 
NI established up to  Failure rate = 19.00%   Failure rate =19.00%  
NI cannot be concluded Failure rate = 20.00%  Failure rate =20.00%  
Lidocaine is superior to test treatment  Failure rate = 21.00% Failure rate =21.00% 
Test treatment not superior to placebo (2020) Failure rate = 35.00% Failure rate =35.00% 
Test treatment not superior to placebo (NMA) Failure rate = 38.00% Failure rate =38.00% 
M2 = 60% M1 
NI margin 2.35 2.38 
Sample size 𝑛1 =𝑛2 227.00 220.00 
NI established up to  Failure rate = 20.00% Failure rate =20.00% 
NI cannot be concluded Failure rate = 21.00% Failure rate =21.00% 
Lidocaine is superior to test treatment  Failure rate = 23.00% Failure rate =23.00% 
Test treatment not superior to placebo (2020) Failure rate = 35.00% Failure rate = 35.00% 
Test treatment not superior to placebo (NMA) Failure rate = 37.00% Failure rate = 36.00% 
M2 = 70% M1 
NI margin 2.70 2.75 
Sample size 𝑛1 =𝑛2 167.00 162.00 
NI established up to  Failure rate = 21.00% Failure rate =21.00% 
NI cannot be concluded Failure rate =22.00% Failure rate = 22.00% 
Lidocaine is superior to test treatment  Failure rate =25.00% Failure rate = 25.00% 
Test treatment not superior to placebo (2020) Failure rate = 33.00% Failure rate = 33.00% 
Test treatment not superior to placebo (NMA) Failure rate = 38.00% Failure rate =35.00% 
M2 = 80% M1 
NI margin 3.12 3.18 
Sample size 𝑛1 =𝑛2 128.00 124.00 
NI established up to  Failure rate =22.00% Failure rate = 22.00% 
NI cannot be concluded Failure rate =23.00% Failure rate =23.00% 
Lidocaine is superior to test treatment  Failure rate =26.00% Failure rate =26.00% 
Test treatment not superior to placebo (2020) Failure rate = 32.00% Failure rate =30.00% 
Test treatment not superior to placebo (NMA) Failure rate =33.00% Failure rate =33.00% 
M2 = 90% M1 
NI margin 3.59 3.67 
Sample size 𝑛1 =𝑛2 101.00 98.00 
NI established up to  Failure rate = 23.00% Failure rate =23.00% 
NI cannot be concluded Failure rate =24.00% Failure rate =24.00% 
Lidocaine is superior to test treatment  Failure rate = 27.00% Failure rate =26.00% 
Test treatment not superior to placebo (2020) Failure rate = 30.00% Failure rate =30.00% 
Test treatment not superior to placebo (NMA) Failure rate = 32.00% Failure rate =30.00% 
M2 =  M1 
NI margin 4.14 4.24 
Sample size 𝑛1 =𝑛2 82.00 80.00 
NI established up to  Failure rate =25.00% Failure rate =24.00% 
NI cannot be concluded Failure rate =26.00% Failure rate =25.00% 
Lidocaine is superior to test treatment  Failure rate =29.00% Failure rate =28.00% 
Test treatment not superior to placebo (2020) Failure rate =30.00% Failure rate =28.00% 




Figure 8-11 Comparison between the different percentages of M1 using the unadjusted 
margins when the constancy assumption holds 
 
Figure 8-12 Comparison between the different percentages of M1 using the adjusted 
margins when the constancy assumption holds 
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Table 8.12 Comparison between the unadjusted and adjusted margins for years 2020, 
2025, 2030 
 Constancy Assumed Adjusted for time 
2020 
NI margin 2.03 2.06 
Sample size 𝑛1 =𝑛2 329.00 316.00 
NI established up to  Failure rate = 19.00%   Failure rate =19.00%  
NI cannot be concluded Failure rate = 20.00%  Failure rate =20.00%  
Lidocaine is superior to test treatment  Failure rate = 21.00% Failure rate =21.00% 
Test treatment not superior to placebo (NMR) Failure rate = 35.00% Failure rate =35.00% 
Test treatment not superior to placebo (NMA) Failure rate = 38.00% Failure rate =38.00% 
2025 
NI margin 2.03 2.07 
Sample size 𝑛1 =𝑛2 329.00 310.00 
NI established up to  Failure rate = 19.00%   Failure rate =19.00% 
NI cannot be concluded Failure rate = 20.00%  Failure rate =20.00% 
Lidocaine is superior to test treatment  Failure rate = 21.00% Failure rate =21.00% 
Test treatment not superior to placebo (NMR) Failure rate = 35.00% Failure rate = 35.00% 
Test treatment not superior to placebo (NMA) Failure rate = 38.00% Failure rate = 38.00% 
2030 
NI margin 2.03 2.09 
Sample size 𝑛1 =𝑛2 329.00 305.00 
NI established up to  Failure rate = 19.00%   Failure rate =19.00% 
NI cannot be concluded Failure rate = 20.00%  Failure rate = 20.00% 
Lidocaine is superior to test treatment  Failure rate = 21.00% Failure rate = 21.00% 
Test treatment not superior to placebo (NMR) Failure rate = 30.00% Failure rate = 30.00% 
Test treatment not superior to placebo (NMA) Failure rate = 38.00% Failure rate =38.00% 
Table 8.12 illustrates the changes of the treatment effect of the test treatment compared to the 
lidocaine and the placebo in the years 2020, 2025 and 2030. From the table there were no 
differences between the treatment effect assuming the constancy and after adjusting for the 
time. When the constancy is established the use of the proposed method (the adjusted for time 
method) leads to the same results. Moreover, using the adjusted margins leads to reduction of 
the sample size needed to establish the non-inferiority. 
The use of the unadjusted margin leads to a larger sample size and smaller NI margin which 
could be considered as conservative (chance of concluding the non-inferiority of an inferior 
treatment is low) method that could lead to the failure to conclude the NI of an actually non-
inferior test treatment.  
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8.5 Summary and recommendations 
In this chapter, pairwise meta-regression was proposed as a method to assess the constancy and 
set an adjusted NI margin using the year of trial conducting or (publication) as a covariate in 
the model. The network meta-regression was used in the analysis phase to assess the efficacy 
of the test treatment compared to placebo in the year of NI trial conducting. Two reviews from 
the Cochrane reviews discussed in Chapters 5 and 6 were used to validate the proposed method.  
In the first example, the constancy did not hold; the treatment difference between the active 
control (atorvastatin) and the placebo decreased each year. The difference between the 
unadjusted margin of -12.25 and the adjusted margin of -8.43 in 2020 was 3.82 points, which 
increased to 5.08 points in the year 2025, and by 2030 the difference increased to 6.35 points. 
 Using the unadjusted margin of -12.25 led to a smaller sample size of 21 participants compared 
to 43 participants in 2020 with the adjusted margin. Moreover, the distance between the 
conclusion of non-inferiority of the test compared to active control and the failure to conclude 
the superiority of the test treatment compared to the placebo was greater (8.5 points) with the 
adjusted margin of 50% of M1  (-8.43) compared to six points using the unadjusted margin 50% 
M1(-12.25). The difference was the same as when using 70% of the M1 of the adjusted margin 
(Figures 8.5 and 8.6).  
The use of a percentage of the M1 in the case of the unadjusted margin could preserve some of 
the efficacy of the test treatment compared to the active control and partially decreased the 
chance of conclusion of non-inferiority of an inferior treatment in 2020. However, this was not 
constant, as by the year 2030 the use of 50% of M1 as a NI margin did not protect against the 
conclusion of non-inferiority of an already inferior treatment. When the treatment effect of test 
treatment was 14.5, the non-inferiority of the test treatment compared to placebo was 
established, while in fact the test treatment was not superior to placebo.   
It should be noticed that according to the results from Chapter 5, the relation between the year 
and the point estimates was not constant. It varies between a positive and negative correlation, 
with the degree of correlation ranging from strong to weak. That means the use of the generic 
50% without any further assessment of the constancy could lead to biased results if the effect 
of the treatment improved over time.  
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In the first example, by using the adjusted margin the chosen value of M2 could be from 50 % 
of M1 to 100% of M1 based only on clinical judgement. Using the unadjusted margin, the 
clinicians would be forced to choose a NI margin of 50 % or less from M1.  In the example 
above, the use of up to 70% of the adjusted M1 could be considered more appropriate, without 
any fears of violation of the constancy assumption (since the M1 is already based on the 
adjusted margin).  
The situation was different in the second example, where the constancy was assessed and held 
over time. The results using the adjusted and unadjusted methods were almost similar. Also, 
even with the use of M1 as a whole as NI margin, the distance between the conclusion of non-
inferiority and failure to conclude superiority to placebo was still stable. The use of the adjusted 
margin led to smaller sample size and wider margin with the same power to conclude the non-
inferiority of the test treatment compared to the unadjusted margin. That means the use of the 
unadjusted margin leads to more conservative results that could lead to failure to conclude the 
non-inferiority of an actual non-inferior treatment.  
The strength of the proposed method is that it works based on the relation between the treatment 
estimate and the year of publication. When the relation was strong negative, the adjusted 
margin was smaller and the sample size was larger using the adjusted margin. While in the 
second example, where the correlation was weak positive, the adjusted margin was larger and 
the sample size was smaller than the unadjusted ones. In other words, in comparison with the 
traditional methods of using the 50% of M1 to protect the assumption of the constancy, the 
adjusted method using the pairwise meta-regression worked on the base of the magnitude and 
the direction of the relation  between the treatment and the time, not on a fixed percentage of 
M1.  
Designing and conducting NI trials is not straightforward. To reduce the chances of the 
conclusion of non-inferiority of an already inferior treatment, the constancy should be assessed 
not assumed. Pairwise meta-regression should be used in the designing phase to assess the 
constancy of the treatment effect between the placebo and the active control. Based on the 
results of this assessment, both the NI margin and sample size for the future non-inferiority 
trial should be determined based on the year of trial conducting. The percentage of M1 that 
will be used to construct M2 should be based on clinical judgement, not only to secure the 
constancy assumption, and should be a fraction of the adjusted margin.  The chance of 
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conclusion of non-inferiority of an already inferior treatment was reduced significantly using 
the adjusted margin compared to the unadjusted margin, especially when the year differences 
between the NI trial and the historical trials increased. 
An important point that should be considered is the fact that the time between the trial design 
and analysis could vary from one year to up to five years or more. In this case, the year of trial 
analysis should be used to set the NI margin, not the year of trial design. In both examples used 
in this chapter, the NI trial was designed in 2018 and the year of the prediction was 2020 as 
this, not 2018, was the year of the analysis. However, in the cases where the analysis year is 
delayed beyond the planes, the analysis should be further adjusted for this delay whenever 
appropriate.  
Although the use of pairwise meta-regression to assess the constancy will reduce the chances 
of type I error (by reducing the chance of conclusion of non-inferiority of an already inferior 
treatment), there are some situations where the pairwise meta-regression cannot be used. 
Pairwise meta-regression cannot be used if there were no direct placebo-controlled trials that 
compared the active treatment to placebo or if there was more than one possible active control 
to assess. In these cases the alternative will be the network meta-regression.  
Network meta-regression can be used in the designing phase to assess the sensitivity of the 
available active controls, to assess the constancy assumption, to set the NI margin and to 
calculate the sample size for the future non-inferiority trial. The use of network meta-regression 
in the designing phase is beyond the scope of this thesis.  
Another limitation of the use of pairwise meta-regression is the limited power if the number of 
included trials is less than ten trials (Thompson & Higgins, 2002). This fact could affect the 
ability of pairwise meta-regression to assess the constancy. Moreover, the use in this chapter 
of a hypothetical NI trial based on the information from two Cochrane reviews instead of a real 
NI trial could be considered as a limitation of this study.  
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As recomendations, in the designing of an NI trial, the NI margin should be adjusted for time 
regardless of whether the constancy holds or not; the statistical M1 should be based on the 
adjusted NI margin, while the fraction of M1 to formulate M2 should be a matter of clinical 
judgement and based on the adjusted margin M1. 
In conclusion, in the case of indirect comparison in general and specifically in any NI trial, the 
constancy should be assessed not just assumed. Pairwise meta-regression was proposed as a 
possible solution to adjust for time and is considered as the method of choice for assessing the 
constancy, setting a non-inferiority margin, and calculating the sample size in the designing 
phase of the trial. In the analysis phase of the trial, to assess the efficacy of the test treatment 
compared to placebo, a network meta-regression could be used, adjusted for time. Network 
meta-regression may provide a solution for the cases where there are no placebo-controlled 
trials or where there is more than one active control treatment. In conclusion, the proposed 
method works effectively both in cases when the constancy does not hold, as in the first 
example, and when the constancy holds (second example). 
In the next chapter, final discussion and conclusions will be presented along with 






Chapter 9 Discussion and Conclusion 
9.1 Introduction 
In medical practice, the superior placebo-controlled randomised trials are the standard to 
establish the efficacy of a treatment,  compared to the placebo group (Fisher, 1999). However, 
due to changes in medical practice, changes in the patient population and ethical concerns, it 
has become challenging to apply placebo-controlled trials to test a new treatment. In this 
situation, NI trials are the alternative to superiority trials. NI trials depend on indirect 
information from the available historical placebo-controlled trials to establish the superiority 
of the tested treatment to the putative placebo and from that to conclude the non-inferiority 
with the active control (D’Agostino et al., 2003).  
The three critical assumptions regarding the conducting and analysis of NI trials are: A. assay 
sensitivity, B. bias minimising (bio-creep and placebo creep) and C. Constancy assumption. 
These three key assumptions are needed due to the use of indirect comparison between the NI 
trial and available historical placebo-controlled trials (S. A. Julious, 2011). 
Reflecting the challenges and considerations regarding NI trials, the aim of this thesis was to 
quantify adjusted non-inferiority margins when using retrospective data. The objectives of this 
thesis are: 
 To investigate the methodological and regulatory challenges associated with the 
planning, conducting and reporting of non-inferiority trials. 
 To investigate the changes in the placebo and active treatment effects over time and 
their impact on the design and analysis of NI trials. 
 To quantify and model placebo and active treatment responses over time with 
recommendations for retrospective comparison back to placebo. 
 To propose a method for adjusting for time using indirect comparison in NI trials. 
Meeting these objectives will lead at the end to the introduction of the most appropriate method 
to set and analyse NI trials based on the type of available data that will quantify for the changes 
in the treatment effect while making an indirect comparison. 
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Chapters 2 and 3 set the scene for this thesis by describing the methodological and regulatory 
requirement and challenges associated with the design and conducting of the NI trial. The 
systematic review in Chapter 4 of the published NI trials in the top medical journals in 2015 
provided information on how the NI trials are conducted and reported in medical practice and 
quantified the importance of historical information in the designing and reporting of NI trials.  
Chapter 5 and 6 investigated the changes in the treatment effect of placebo and active treatment 
over time and how these changes could affect the prediction of any historical placebo-
controlled trial.  
Chapters 7 and 8 reviewed the possible methods for adjusting for a time in the case of the 
indirect comparisons and proposed a method to set an adjusted NI margin in two case studies 
of hypothetical NI trials. 
This chapter will discuss the main findings from this thesis in the context of the overall thesis 
aims and objectives. Strengths and limations of this thesis will be presented as well as 
recommendations regarding the design and analysis of NI trials. 
9.2 Main findings 
This section will summarise how this thesis addressed the objectives.  
9.2.1 Objective one: Investigate the methodological and regulatory challenges associated 
with the planning, conducting and reporting of non-inferiority trials 
To investigate the methodological challenges associated with the design and analysis of non-
inferiority trials, a literature review of the assumptions, challenges, and methods regarding NI 
trials was conducted in Chapter 2.  
The main findings from Chapter 2 were that, in medical fields, RCTs involve not only drug 
trials, but also include different types of comparisons such as assessing a new treatment, 
comparing surgical and medical approaches, and comparing different doses of the same 
treatment.  
With regard to NI trials, the three main assumptions that should be considered in designing NI 
trials are assay sensitivity (A), Bias minimising ( Placebo creep and Bio-creep) (B), and 
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Constancy assumption (C). Violations of any of these assumptions will lead to a biased NI 
margin and possibly the conclusion of non-inferiority of an inferior treatment. Moreover, 
choosing the appropriate active control and setting the NI margin are the main challenges in 
designing NI trials. 
Regarding the methods for setting the NI margin, the available methods for setting and analysis 
of the NI margin are the regulatory methods (fixed margin and the synthesis methods) and 
predictive methods using the network meta-analysis in the analysis phase. In these methods, to 
control for the changes in the treatment response of the active control (constancy assumption), 
the regulatory approaches methods use both the statistically calculated margin (M1) and the 
smaller clinically significant margin (M2). However, none of the available methods adjusts for 
the changes in the treatment response or any other possible covariates that could be different 
between the retrospective data from the placebo-controlled trials and the non-inferiority trials.  
Different regulatory guidelines were presented in Chapter 3. All of the guidelines set 
recommendations on the appropriate designing and conducting of non-inferiority trials but do 
not impose any enforceable legal responsibilities (FDA, 2016).  There was an apparent 
inconsistency between the guidelines that could negatively affect the quality and reporting of 
NI trials regarding the definitions and population analysis. Moreover, only the fixed margin 
approach was approved as a preferred method for setting NI trials and is described as a 
conservative (chance of concluding the non-inferiority of an inferior treatment is low) approach. 
The FDA non-inferiority guidelines for industry was the most substantial detailed document in 
terms of describing the design, setting and analysis of NI trials (FDA, 2016). In addition, all 
guidelines approve the use of NI design for testing the efficacy but not the safety.  
Chapter 4 aimed to investigate the conducting, analysis and reporting of NI trials in clinical 
practice in regard to the regulatory recommendations. A systematic review of NI trials 
published in 2015 in four top medical journals was conducted. 
 The main findings were that 37 NI trials were published in the JAMA, BMJ, Lancet, and 
NEJM, all of which reported the chosen NI margin. The reporting of NI trials was not 
compatible with the regulatory guidelines, especially in the blinding, the population included 
in the analysis and reporting and justification of NI margin used. Sixty per cent of the included 
trials that reported methods for selection NI margin depended on the historical information 
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alone or in combination with clinical decisions to set the NI margin. Twenty-four per cent of 
the included trials did not state the reason behind choosing the NI margin. 
The importance of historical information in regard to setting the NI margin from indirect 
comparison was established both from the literature in Chapters 2 and 3 and from practice in 
Chapter 4.  
By the end of Chapter 4, it was concluded that setting the NI margin depends on the available 
evidence from the historical placebo-controlled trials. Any possible changes in the efficacy of 
the active control (assay sensitivity, Section 2.4) or in the effect of placebo (placebo creep, 
Section 2.8) or in the treatment difference between the placebo group  and the active treatment 
group (constancy assumption, Section 2.5) will lead to a biased NI margin, which could lead 
to a biased conclusion. The next step was to assess the changes of the treatment effect over 
time. 
9.2.2 Objective two: To investigate the changes in the placebo and active treatment effects 
over time and their impact on the design and analysis of NI trials 
Aiming to investigate the changes in the treatment effect of the placebo group (assess the 
placebo creep) and active treatment over time, an overview of Cochrane reviews of placebo-
controlled trials was conducted in Chapter 5. The correlations between the effect size of a 
placebo group, active treatment group, and the treatment difference (SMD) and the year of 
publication were obtained. Besides, the correlations between the sample size and year of 
publication were obtained. By the end of Chapter 5, it was concluded that the correlations 
between the treatment difference between placebo group and active control group varied from 
strong negative to strong positive. The sample size of a trial is positively correlated with the 
year of publication (R = 0.2), the median placebo effect has a weak positive correlation with 
the year of publication (R = 0.05), the median active control has a weak negative correlation 
with year of publication (R = -0.04), and for the treatment difference (SMD) the median 
correlation was -0.11.   
Even though these median correlations are considered weak correlations, the results indicate 
that, overall, around 58.5% of included reviews had moderate to strong negative correlations 
regarding the treatment difference between the active control and the placebo. It was possible 
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to confirm that the effect size of active control and placebo group and the treatment difference 
between the two are not constant over time. These changes are due to improvement in the 
placebo effect and decrease in the active treatment effect, which serve to decrease the effect 
size of the treatment difference between the two.  
In the case of NI trials, this conclusion means that the constancy assumption about the treatment 
difference between the active control and placebo should not be assumed; instead, it should be 
assessed first, and then the NI margin should be calculated according to the constancy 
assumption. Also, setting NI margin without adjusting for these changes will lead to a biased 
estimate from the NI trial that could conclude either the non-inferiority of an inferior treatment 
or fail to conclude the non-inferiority of an effective treatment.  By the end of Chapter 5, two 
important questions had been raised: first, whether the fixed effect model will be more 
appropriate for use than a random model; second, what will be the effect of time in the 
prediction of any future trial? Both questions were answered in Chapter 6. 
9.2.3 Objective three: To quantify and model placebo and active treatment responses over 
time with recommendations for  retrospective comparison back to the placebo 
To quantify and model the changes in the placebo and active control responses over time, the 
standardised mean difference for the treatment response between the placebo group and the 
active treatment from 224 meta-analyses that were reviewed in Chapter 5 were used to build a 
regression model in Chapter 6.  
The predictive power of the model was 55.9%. The three main variables that affected the 
estimate of any future trial were the point estimate from the meta-analysis of previous trials, 
the year difference in the meta-analysis, and the year of the predicted trial. Increasing one unit 
in the estimate from the meta-analysis of the historical trial will lead to an increase in the 
predicted estimate of the future trial by 0.92. For the year difference in the meta-analysis, 
increasing the year difference will reduce the predicted estimate of the predicted trial; for each 
increase in year difference the predicated estimate will be reduced by 0.005. For the year of 
prediction, for each year increase in the prediction, the predicted estimate of the future trial will 
be reduced by 0.015. As mentioned earlier, all three variables together explain only 55.9% of 
the variability of the model. That means the historical data incorporated in a meta-analysis 
explain only 55.9% of the predicted estimate of any future trial. Using this historical estimate 
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without further adjustment will lead to biased results, especially when the time differences 
between the trials were high, which highlights the need for a method to set NI trials that 
incorporates time (adjust for the time) of trial conducting in the indirect setting of the NI margin. 
By the end of Chapter 6, the importance was confirmed of including time in the analysis of NI 
trials. This inclusion of time will not reflect the changes in time only but could also reflect 
changes in the population characteristics, treatment protocol, and any other changes that can to 
be measured from studying the demographics or the characteristics of the trials.  
Another important conclusion from Chapter 6 related to the type of model used. In NI trials, 
using a random effect model to estimate the effect of active control compared to placebo will 
give more weights to the older heterogeneous small studies, which could lead to a biased 
estimate of the effect of the active control in the current NI trials.  
There was no statistically significant difference between the point estimates from the fixed and 
random models. However, the 95% CI boundaries from the random effects model were 
statistically significantly wider and different from those of the fixed effect model. In terms of 
NI trials, the focus was on the 95% CI boundaries, not the point estimate, and for that reason, 
the use of a fixed effect model in the case of indirect comparison from the meta-analysis of 
historical trials was found to be most appropriate in the case of NI trials. By the end of Chapter 
6, it was concluded that the constancy assumption cannot be assumed; instead, it needs to be 
assessed.  
9.2.4 Objective Four: To propose a method for adjusting for time using indirect comparison 
in NI trials 
To develop a method that could incorporate time in the setting and analysis of NI trials, in 
Chapter 7 of this thesis, possible ways for adjusting for covariates were reviewed, either by 
using individual patient data (IPD) or aggregated data (AD). Criteria for the method of 
adjustment were developed in Chapter 7 based on the conclusions from the previous chapters. 
These criteria include the ability to adjust for covariates (time), ability to be used in the 
designing and the analysis phase of the NI trial, to use aggregated data, to assess the sensitivity 
of the active control, and to offer flexibility and computational ease of use.  
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Pairwise meta-regression was proposed as a new method to assess the constancy assumption 
and to set the NI margin in the case where the constancy assumption does not hold. Network 
meta-regression could be used to assess the constancy assumption and to set the NI margin in 
the case where the constancy assumption does not hold; additionally, the network meta-
regression approach can incorporate different treatments in one network and adjust for any 
possible co-variables at the same time.  
In Chapter 8, pairwise meta-regression was applied in the designing phase of the NI trial and 
network meta-regression in the analysis phase in two different scenarios of non-inferiority trials. 
In the first case the constancy assumption did not hold. In this case, using pairwise meta-
regression, it was possible to assess the constancy, set the adjusted NI margin, and calculate 
the sample size of a future NI trial. Network meta-regression was used to assess the efficacy of 
the test treatment compared to the placebo in the year of NI trial conducting. The obtained 
results indicate that using the unadjusted margin when the constancy does not hold will lead to 
biased results and the conclusion of non-inferiority of an inferior treatment. The use of a fixed 
50% of M1 instead of the whole M1 was partially protective in the case where constancy was 
not assumed in the year 2020. However, it was not protective in the year 2030, with a 15-year 
difference between the historical trials and the NI trial. 
 In the case of the adjusted margin, the use of the whole M1 was away from the false conclusion 
of non-inferiority, while with an unadjusted margin of 70% of M1 there was a false conclusion 
of non-inferiority. In the second case, when the constancy assumption held, the results from 
the adjusted and unadjusted margin were almost similar. Even with the use of 100% of M1, the 
results were away from the false conclusion of non-inferiority.  
The use of the adjusted margin in both cases was protective from the conclusion of non-
inferiority of an inferior treatment.  Moreover, using the adjusted margin was protective from 
the possibility of placebo creep since the adjusted margin will adjust the difference between 
the placebo group and active treatment group. This could be considered as a strength of this 
method, which works in different ways regardless of whether the constancy is assumed or not, 
based on the relation between the time and the treatment effect. In the first example, the NI 
margin was decreased and the sample size was increased progressively each year based on the 
fact that the correlation between the time and the treatment effect was a strong negative 
correlation. The situation was different in the second example, where the NI margin was 
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slightly increased each year and the sample size was slightly decreased because the correlation 
between the time and the treatment effect was a weak positive correlation. This method takes 
into consideration the direction and the magnitude of the changes over time by either increasing 
or decreasing of the treatment difference.  As a conclusion from Chapter 8, M2 should be 
chosen based on the clinical judgement as a percentage of the adjusted margin with the 
possibility of use between 100% and 50%, or even less based on the clinical judgement, and 
should not be obtained to assume (protect) the constancy. 
The main findings from this thesis could be summarised into these points: setting the NI margin 
is the main challenge in a non-inferiority trial; in an NI trial, the constancy should not be 
assumed but instead should be assessed; using a percentage of the active treatment response 
(M2) cannot guarantee the constancy.  
The changes in the treatment effect over time were mainly due to a decrease in active treatment 
effect and not due to the improvement of placebo effect only. Pairwise meta-regression is 
considered as a promising method to assess the constancy, protect from the possibility of 
placebo creep, set the adjusted margin, and calculate the sample size in the designing phase of 
the NI trial. Network meta-regression should be used in the analysis phase of the NI trial to 
assess the efficacy of the test treatment compared to placebo on the year of NI trial conducting. 
The only limitation of the use of pairwise meta-regression and network meta-regression was 
the limited power when the number of trials included was less than ten. 
9.3  Main thesis strengths  
 Although the importance of historical trials in relation to conducting NI trials has been reported 
before, this thesis was among the first to comprehensively incorporate evidence on its 
importance from the literature, regulations and from medical practice. 
To the best of my knowledge, this thesis was the first to conclude that the treatment effect is 
not constant over time. In addition, this thesis was the first to conclude that these changes in 
the treatment effect were not due only to the improvement of placebo response; instead, it was 
a combination of changes in the placebo and the active treatment over time. Even though  a 
reasonable number of publications have investigated changes in the placebo effect over time, 
to the best of my knowledge, this thesis was the first to compare these changes with the changes 
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in the active control response over time and the changes in the main treatment effect over time 
using aggregated data from different therapeutic areas. Moreover, it was the first to incorporate 
the changes in the treatment effect over time into indirect comparison in NI trials specifically.  
To the best of my knowledge, this thesis was the first to use a very comprehensive dataset from 
different therapeutic areas to assess the relation between the time and the treatment effect. The 
overview of Cochrane reviews that was used for studying the correlations in Chapter 5 and 
construction of the weighted regression in Chapter 6 were performed specifically to answer the 
research question of this thesis: How can time affect the setting of the NI margin?). The data 
for correlation included 692,753 patients from 2364 placebo-controlled trial aggregated in 236 
meta-analyses from 44 different Cochrane groups. The data used to build the regression model 
were obtained from 681,163 patients from 2310 trials aggregated in 224 meta-analyses. 
Moreover, a standardised scale (standardised mean difference) was used to measure the 
estimate from this data. For all these reasons, the results from these analyses are generalisable 
for different therapeutic areas, and any placebo-controlled trials using any scale of measures.  
This thesis was the first to estimate the predictivity of the historical trial to estimate a future 
trial. It was also the first to conclude that an increase of one unit in the estimate from the meta-
analysis of the historical trial will lead to an increase of the predicted estimate of the future trial 
by 0.92. Moreover, this thesis was the first to measure the negative effect of the year difference 
between the historical trials and the predicted year of future trial on the predicted estimate of 
the future trial.   
Another important finding from this thesis was that only 55.9% of the predicted estimate of 
any future trial can be predicted from the estimate from the meta-analysis of historical trials 
for the same treatment after adjusting for the year of publication of the future trial and the year 
difference in the historical meta-analysis. These results are considered proof of the changes in 
the treatment effect over time. Usually, these changes are due to population shifts and changes 
in the treatment protocols and due to the general improvement in the quality of life. All of these 
causes cannot be measured by themselves but could be adjusted for in any future trial.  
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To the best of my knowledge, this thesis was the first to propose the use of pairwise meta-
regression to set an adjusted NI margin for time in the case of NI trials. Using the pairwise 
meta-regression, this thesis was able to assess the constancy, set the NI margin and to calculate 
the sample size in the designing phase of the NI trial. In the analysis phase, this thesis was the 
first to compare the placebo and the test treatment indirectly in one network adjusted for the 
time. The proposed method worked effectively both when the constancy did not hold (the 
atorvastatin case study) and when the constancy did hold (the lidocaine case study). Finally, 
this thesis was among the first to use the network meta-regression approach to adjust for the 
changes in time while setting and analysing NI trials. The adjustment was performed both in 
the designing phase and in the analysis phase. 
One of the most important advantages of the method proposed in this thesis is that the use of 
the adjusted margin will give clinicians more flexibility to set the fraction of M1 to formulate 
the M2. By using the adjusted margin, any percentage from M1 will be protected from a false 
conclusion of NI and the clinician can use any percentage from the adjusted margin based on 
clinical judgement only and avoid the use of the constant 50% percentage recommended in the 
FDA regulations.     
9.4 Limitations 
Due to the scope of the thesis aims and objectives, I did not investigate other situations where 
there are no direct placebo-controlled trials or where there is more than one active control. 
Moreover, I did not investigate issues related to the setting of the M2 (clinical margin) as one 
of the challenges associated with NI trials. Although the historical information is important in 
setting the NI margin, M2 is the actual margin used in the comparison, and the results of any 
non-inferiority trial will depend on the chosen M2 that is based on the clinical expert’s opinion 
and usually can be changed by changing the clinical protocol used. However, I was able to 
demonstrate that M2 is not an alternative for the adjustment for time. Even with the adjusted 
margin, it is still necessary to set M2 to reflect the clinical opinion. 
Biocreep is one of the other important challenges in designing and analysis of NI trials. 
However, due to the scope of this thesis, biocreep was not discussed in detail. Moreover, I did 
not investigate whether the proposed adjusted methods could be effective in addressing the 
possibility of biocreep. 
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 Since only published data were used in this research, these results cannot be generalised to 
non-published data. On the other hand, according to the evidence synthesis, published data is 
more widely used than non-published data, which means that the data used related more closely 
to the real situation.  
In this research, the year of publication was used as a proxy for the year of trial conducting. 
This approach could affect the results since trials with negative results tend to be published 
later than trials with positive results (Rothstein et al., 2006). It was difficult to extract or 
determine the year of trial conducting, especially for the earlier trials, and for that reason the 
year reported in the meta-analysis was used as a proxy for the year of the trial conducting. 
I was not able to gain access to individual patient data (IPD) and, therefore, in Chapter 7 I could 
not apply adjusted methods that used IPD, or compare the results from methods that used 
aggregated data (AD) to those from methods that used IPD, for example, the one and two stage 
adjusted fixed margin and synthesis methods proposed by Xu et al. (2014).   
Furthermore, to test the proposed method I used hypothetical NI trials and not real trials. This 
could be considered as a limitation to the proposed method. However, the historical data was 
real data from Cochrane reviews and my aim concerned the design of an NI trial not the analysis 
and for that reason using the hypothetical NI trial was considered more appropriate. In addition, 
the method was tested for different years and with different percentages of M1, which could 
be considered as a strength of this thesis. Finally, usually in clinical trials, the time lag between 
designing a study and the analysis will vary. Using the year of design as the predicted year for 
setting the NI margin and sample size calculation could lead to biased results. Estimating the 
year of analysis and setting the NI margin based on that could be the answer to the problem. 
However, the changes in the analysis year could lead to changes in the NI margin and the 
conclusion of NI trial, especially when the constancy assumption does not hold.   
9.5 Future work 
Based on the results of this thesis, the future planned work will be to extend the work to include 
the use of network meta-regression in setting and analysis of non-inferiority trials where there 
is no direct placebo-controlled trial to compare the active control with placebo. The 
investigation could be extended to other situations where pairwise meta-regression and network 
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meta-regression cannot be used (if the number of trials is less than ten). Additionally, valid 
comparisons could be conducted between the IPD approaches for adjusted indirect comparison 
and the AD approaches and more investigations are needed in regard to the use of fixed or 
random effects model in setting the NI margin. And finally, future work could investigate 
whether the proposed approach can address the possibility of biocreep. 
9.6 Recommendations  
Based on the results of this thesis, it is recommended that, when possible, a placebo arm should 
be included in the trial design to ensure the sensitivity of the active control, adjust for the 
constancy, and reduce the risk of biases. The choice of a non-inferiority design should be fully 
justified.  
Additionally, there should be adjustment for time using the pairwise meta-regression regardless 
of the constancy assumption. In the case where the constancy does not hold, using the adjusted 
margin will protect from the conclusion of NI of an inferior test treatment. In the case of the 
constancy assumption, the use of the adjusted margin will reduce the sample size.   
It is further recommended to investigate the possible presence of any other effect modifiers 
(other than time) for any indirect comparison and adjusting for these possible effects, and 
modifiers should be the standard for any indirect comparison. Moreover, the available 
regulatory guidelines should include methods for adjusting for indirect comparison when 
setting the NI margin.  
Finally, to ensure that the clinical NI margin M2 is appropriate. M2 should be a fraction of the 
adjusted NI margin M1 regardless of whether the constancy assumption holds or not. This 
fraction should be based on the clinical opinion not used as a method to ensure the constancy.  
9.7  Overall conclusions  
Designing and conducting a non-inferiority trial is associated with methodological, statistical, 
and regulatory challenges. The main challenge is the need to borrow information from 
historical trials to conclude the relationship between the putative placebo and the test treatment. 
To avoid any violation of the methodological assumption regarding NI trials, firm regulatory 
guidelines to control the conducting and reporting of NI trials are needed. Despite the 
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methodological and regulatory challenges, NI trials present an excellent alternative to 
superiority trials when conducting the latter is not possible.  
This thesis aimed to investigate the constancy assumption and its effect on setting the NI 
margin. One of the main conclusions was that the changes that occur in the treatment effect 
over time are due not only to improvement in the placebo response, but mainly due to a decrease 
in the efficacy of the active control, both of which will lead to a decrease of the treatment 
difference between the active control and the placebo. This thesis was also able to confirm that 
there is a deficiency in reporting the setting and choosing of the NI margin in the published NI 
trials, which leads to misinterpretation of the results of NI trials.  
As a solution for the adjusting for a time in NI trials, this thesis recommends the use of pairwise 
meta-regression and network meta-regression approaches to assess the constancy assumption 
and to set and analyse NI trials when the constancy assumption does not hold. Including in the 
synthesis of this network not only the placebo-controlled trials but also all relevant trials that 
compare all possible active controls either to each other or to placebo, with all possible 
treatments, will provide a valid comparison between all active controls and the test treatment 
and the placebo both directly and indirectly. Moreover, this method will rank the treatments’ 
efficacy based on their relative effectiveness. The network meta-regression approach could also 
be used in the designing phase to choose the most appropriate active control for a determined 
sample size of the proposed NI trial and to set the NI margin for the fixed margin approach or 
synthesis approach. In the analysis phase, network meta-regression will provide a consistent 
comparison between all available treatments (assay sensitivity), will adjust the estimate for the 
time (constancy adjustment), and will compare both the direct and indirect evidence (bias 
minimise) and  investigate the presence of bio-creep in the NI trial. With the adjusted NI margin, 
the chosen M2 was more flexible since even the use of 100% of M1 was protected from the 
false conclusion of non-inferiority of an inferior treatment. Using the unadjusted margin when 
the constancy assumption does not hold will restrict the clinical choice to using either 50% or 
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Appendix A Chapter 2 
This appendix includes the alternative models used in the analysis of the OASIS trial and the 
R codes for Chapter 2 
A. 1 Random effects network meta-analysis 
 
Figure A. 1 Random effect network meta-analysis of OASIS trial  
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A. 2 Codes for network meta-analysis 
study<-c("Theroux 88", "RISC Group 90", "Cohen 90", "Cohen 94", "Holdright 94", "GurfinkelUFH 
1995", "GurfinkelLMWH 1995", "FRISCI11997", "OASIS52006") 
arm1<-c(rep("placebo",8),rep(" Fondaparinux",1)) 
arm2<-c(rep("active control",9)) 
#event1<- number of events in arm1(active control)  
#event2<- number of events in arm2 
event1<-c(4.5, 7.5, 1.5, 9.5, 40.5, 7.5,7.5, 36.5,619.5 ) 
event2<-c(2.5, 3.5, 0.5, 4.5, 42.5, 4.5, 0.5,13.5, 682.5) 
# n1<- total number of patients in arm 1 
#n2<- total number of patients in arm 2 
n2<-c(123, 211,38, 106, 155, 71, 69,757,10022 ) 
n1<-c(122, 190, 33, 110, 132, 74, 74,757, 10058) 
data <- data.frame(study, arm1, arm2, event1, event2, n1, n2) 
library(netmeta) 
data 
net1<- pairwise(list(arm1, arm2), list(event1, event2), n =list(n1, n2), studlab=study,data=data, 
sm="OR") 
net1 
nma1 <- netmeta(TE,seTE, treat1, treat2, studlab,sm="OR", data=net1) 
nmar <- netmeta(TE,seTE, treat1, treat2, studlab,sm="OR", comb.random = TRUE, data=net1) 
nmar 
summary (nmar) 
forest.netmeta(nmar, reference.group=" Fondaparinux") 
forest.netmeta(nmar, reference.group="active control") 
forest.netmeta(nmar, reference.group="placebo") 
summary(nmar) 




Appendix B Chapter 4  
This appendix includes the characteristics of the included trials in the systematic review, the 
extraction form discussed in Chapter 4 and a poster presented to the STC conference.  
B. 1 Characteristics of the included reviews 
Study Name Fund Blinding CI  NI margin Analysis Conclusio
n 
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Appendix C Chapter 5 
This appendix includes the results for Spearman correlations and SPSS codes for Chapter 5 
C. 1 Spearman Correlations  
 
Figure C. 1 Spearman Correlation between the Standardised Mean Difference and the 
Year of Publication 
 






Figure C. 3 Spearman Correlation between the Active Treatment and the Year of 
Publication 
 





C. 2 SPSS Codes for Correlations 
C. 2. 1 Pearson correlation 
Encoding: UTF-8. 
sort cases by CD. 
split file by CD. 
*2. Show only variable labels in output table. 
set tvars labels. 
CORRELATIONS 
  /VARIABLES=year d 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
* OMS. 
DATASET DECLARE  d1. 
OMS 
  /SELECT TABLES 
  /IF COMMANDS=['Correlations'] SUBTYPES=['Correlations'] 
  /DESTINATION FORMAT=SAV NUMBERED="CD" 
   OUTFILE='d1' VIEWER=YES 
  /TAG='CD'. 
CORRELATIONS 
  /VARIABLES=year d 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
omsend tag = ['CD']. 
* OMS. 
C. 2. 2 Partial Correlation 
*2. Show only variable labels in output table. 
set tvars labels. 
*3. Create correlation table. 
PARTIAL CORR 
  /VARIABLES=year P  BY N 
  /SIGNIFICANCE=TWOTAIL 
  /MISSING=LISTWISE. 
* OMS. 
DATASET DECLARE  ParP. 
OMS 
  /SELECT TABLES 
  /IF COMMANDS=['Partial Corr'] SUBTYPES=['Correlations'] 
  /DESTINATION FORMAT=SAV NUMBERED=TableNumber_ 
   OUTFILE='ParP' VIEWER=YES 
  /TAG='CD'. 
PARTIAL CORR 
  /VARIABLES=year P  BY N 
  /SIGNIFICANCE=TWOTAIL 
  /MISSING=LISTWISE. 
omsend tag = ['CD']. 
* Encoding: UTF-8. 




C. 2. 3 Spearman Correlation 
OMS 
  /SELECT TABLES 
  /IF COMMANDS=['Non Par Corr'] SUBTYPES=['Correlations'] 
  /DESTINATION FORMAT=SAV NUMBERED="CD" 
   OUTFILE='d1' VIEWER=YES 
  /TAG='CD'. 
NONPAR CORR 
  /VARIABLES=year d 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
omsend tag = ['CD']. 
*N 
* OMS. 





CD= read.spss(CD, to.data.frame = TRUE) 
View(CD) 
meta2<- metacont(N1, M1, SD1, N2, M2, SD2,data=CD, sm="MD", studlab=paste(ID)) 
M3<-forest(meta2,layout="RevMan5", comb.random=TRUE, 
           label.right="Favours experimental ", col.label.right="black", 
           label.left="Favours placebo", col.label.left="black", lab.e= "expiremental", lab.c= "Placebo", 
           prediction=FALSE, digits.sd = 2) 
a<-mean(CD$M1) 
b<-mean(CD$M2) 
mu1 <- update(meta2, byvar = year) 
m2<-metareg(mu1) 
names (meta2) 
bubble(m2, lwd = 2, col.line = "black", xlim = c(1980, 2015),ylim = c(0, 25), regline=TRUE, xlab= "Year", ylab= "Mean 
difference", pch=21, col="black" 





Appendix D Chapter 6 
This appendix includes graphs for the differences between the different datasets used  and the 
results of the different alternative regression models used in Chapter 6 in addition to the R 
Codes  
D. 1 Differences between the difference datasets extracted 
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D. 2 Main regression model:  
Checking the regression model adequacy (The main model using the training dataset): 
Outliers: An analysis of the residuals was carried out. The residuals were normally distributed 
(min= - 2.97, Max= 1.6) Mean (SD) = -0.027 (0.52); the histogram for the residuals indicate 
the data contained approximately normally distributed errors. In addition, the Q-Q plot of 
residuals confirms the conclusion of randomly normal distributed residuals. The maximum 
Cook’s distance was 0.34 which indicates no possible influential cases. 
 
Figure D. 2 Histogram of the Residuals 
 
Figure D. 3 The frequency distribution for the differences between SMD of previous trials 
and the last trial 
 
Collinearity: Tests to see if the data met the assumption of collinearity and both the variance 
inflation factor (VIF) and tolerance were below the concerned levels (Kutner et al., 2005). They 
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indicated that multicollinearity was not a concern (SMDdl; Tolerance = 0.748, VIF = 1.02; 
predicted year (Ylt) Tolerance = 0.97, VIF = 1.03, Year difference (Ymeta); Tolerance= 0.99, 
VIF = 1.009). The assumption of independent errors was met with the Durbin-Watson value = 
2.2 
Homoscedasticity, linearity and random normally distributed errors:  
Both the response variable (SMDlt) and the predictor variable (SMDdl) were normally 
distributed (Figure 6.10). The assumption of linearity between these two variables was met 
(Figure 6.11).  
Regarding the assumptions of homoscedasticity, the scatter plot of predicted values against the 
residuals showed that the data met the assumptions of homogeneity of variance and linearity. 
There was a random pattern in the plot for the predicted and the predicted values (Figure 6.9). 
It was observed that all the assumptions of multiple regression model were met. In addition, 
the model was adequately presented.  
Model validation 
Leave one out cross validation (LOOCV) 
Using this method, in each sample one case is the leave out and then the developed model is 
tested on the leave out case. There were 221 samples in total. The results of the resampling 
𝑅2for the test dataset were 0.55, RMSE= 0.49, MAE= 0.35. 
K-fold cross-validation 
In the K-fold cross validation the data are divided into k fold and each time one fold works as 
the test set and the K-1 fold works as the training set. 10 folds was considered an acceptable 
number of folds and the results from this method were: 
𝑅2for the test dataset was 0.57, RMSE= 0.47, MAE= 0.35 
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Repeated K-fold cross-validation 
In this method the k fold cross validation is repeated and the average results will be taken. For 
the model three repeats were used and k=10. The results were: 
𝑅2for the test dataset was 0.56 RMSE= 0.48, MAE= 0.35 
As noticed from the different methods used for validation, the original model I developed was 
valid and accurate.  
D. 3 Unweighted regression model using training dataset 
The results of the unweighted regression model are presented in the table below  
Table D. 1: Summary of the regression model to predict SMD of last trial using SMD from 
previous meta-analysis 
Model B Std. Error Beta t Significance 95.0% CI of  β 
(Constant) 26.97 13. 89  1.94 0.054 (-0.462; 54.41) 
SMDdl 0.98 0.072 0.729 13.68 < 0.001 (0.839; 1.121) 
Ymeta -0.003 0.003 -0.04 -0.75 0.45 (-0.009 ;-0.001) 
Ylt -0.013 0.007 -0.105 -1.94 0.054 (- 0.027; - 0.000) 
Weighted Least Squares Regression - Weighted by sample size of the historical meta-analyses. Dependent Variable: SMDlt; 
Standardised mean difference of predicted trial, Ymeta: year difference between first and last trials in the meta-analysis, 
SMDdl= Standardised mean difference of historical trials, Ylt= year of publication of the predicted trial  
The results of the final regression model include 168 reviews. The model indicated that SMD 
from the meta-analysis of all trials deleted last (SMDdl). Year difference and the year of 
predicted trial (Ylt) explain 52.8% of the variance in the model (𝑅2= 0.537, F (89.784), P 
<0.0001). SMDdl statistically significantly predicted the SMDlt (β = 0.98, P < 0.0001), for 
each unit increase in SMDdl the SMDlt increased by 0.917 units. The year difference in the 
meta-analysis was not statistically significantly associated with the predicted estimate or the 





D. 4 Regression model using the whole dataset: 
Table D. 2: Summary of the regression model to predict SMD of last trial using SMD from 
previous meta-analysis 
     B Std. Error Beta   Lower Bound Upper Bound 
 (Constant) 35.925 9.4  3.8 .0.00 17.309 54.54 
SMDdl 0.917 .057 0.732 16.055 .0000 0.804 1.03 
Ydiff   -0.007 .002 -0.162 -3.566 .000 -0.010 -0.003 
 Ylt -0.018 0.005 -0.173 -3.794 0.00 -0.027 - 0.009 
Weighted Least Squares Regression - Weighted by Ndl. Dependent Variable: Standardised mean difference last trial SMDlt, Ydiff= year 
difference between last trial and the oldest one, SMDdl= Standardised mean difference after deleting last trial, Ylt= year of publication of 
the predicted trial  
 
The results of final regression model include 221 reviews, two reviews were potential outliers 
and excluded from the final model to improve the 𝑅2 (Kutner et al., 2005). One case was 
considered as as influential case using Cook’s difference = 0.415 and was excluded from the 
model (Kutner et al., 2005).  
The model indicated the SMD from the meta-analysis of all trials deleted last (SMDdl). Year 
difference and the year of predicted trial (Ylt) explain 55.4% of the variance in the model 
(𝑅2= 0.554, F (89.784), P <0.0001). SMDdl statistically  significantly predicted the SMDlt (β 
= 0.917, P < 0.0001), for each unit increase in SMDdl the SMDlt increased by 0.917 units. 
For the year difference between the oldest trial and the predicted trial, for every one year 
increase in the difference the SMDlt decreased by -0.007 (β = - 0.007, P = 0.001). The year of 
the predicted trial (Ylt) statistically significantly predicted the SMDlt (β= - 0.018, P = 0.001).  
The final regression model was  





D. 4. 1 Checking the regression model adequacy 
Outliers: An analysis of the residuals was carried out and three possible outliers were detected. 
Removing these from the model improved the model’s predictability. With these outliers the 
residual were (Min = -3.06, Max = 2.21). Regarding the influence, the maximum Cook’s 
distance was 0.48. According to Kutner et al., if the removing of a potential influential case 
from the model changes the model inference, this case is considered an influential case and 
should be omitted from the model  (Kutner et al., 2005). After removing the three outliers the 
residuals were reduced to (Min= - 1.59, Max= 2.2). The 𝑅2value improved from 50% to 55.4%. 
Figure 7.9 describes the changes in the model after removing the potential influential and 
outlier cases. 
Collinearity: Tests to see if the data met the assumption of collinearity were conducted (Table 
7.1); both the variance inflation factor (VIF) and tolerance were below the concerned levels 
(Kutner et al., 2005). They indicated that multicollinearity was not a concern (SMDdl, 
Tolerance = 0.99, VIF = 1.01; last year (Ylt) Tolerance = 0.98, VIF = 1.014, Year difference 
Tolerance= 0.99, VIF = 1.009). The assumption of independent errors was met with the Durbin-
Watson value = 1.86. 
Homoscedasticity, linearity and random normally distributed errors:  
Both the response variable (SMDlt) and the predictor variable (SMDdl) were normally 
distributed. The assumption of linearity between these two variables was met. 
The histogram of residuals indicated that the data contained approximately normally distributed 
errors. In addition, both the normal P-P plot and Q plot of residuals confirmed the conclusion 
of randomly normal distributed residuals. 
Regarding the assumptions of homoscedasticity, the scatter plot of predicted values against the 
residuals showed that the data met the assumptions of homogeneity of variance and linearity. 




Figure D. 4. Bubble plots before and after removing the potential outliers and influential 
cases, the bubble size reflects Cook’s D 
 
Bubble plot for the predictive values against the residual with possible outliers 
 






D. 5 Regression analysis using the dataset seven (removing all 
studies with more than one last trial) 
Table D. 3. Summary of the regression analysis 
Model B Std. Error Beta t Significance 95.0% CI of  β 
(Constant) 39.43 12.068  3.268 0.001 (-15.678; 63.256) 
SMDdl 0.83 0.074 0.655 11.25 < 0.001 (0.69; 0.984) 
Ymeta -0.009 0.006 -1.86 -3.256 0.001 (-0.014 ;-0.004) 
Ylt -0.02 0.003 -0.197 -3.383 0.001 (- 0.031; - 0.008) 
A sensitivity analysis was done after removing all trials that contained more than one last trial. 
The remainder totalled 177 meta-analyses. The results were similar to the model from the 
whole dataset and there was no difference between the two datasets. 
Measuring the agreement between the predicted value and the 
observed SMDlt 
The Bland Altman plot (Bland & Altman, 1999) was used to measure the agreement between 
the predicted and the observed values in the training dataset and between the observed value in 
the test dataset and the prediction from the regression model built from the training dataset. 
The Bland Altman from the training dataset is presented in Figure 6.10. There is a good 
agreement between the two estimates, with the average mean difference (bias) = -0.03 and the 
limits of agreement LOA = (-1.04; 0.99). The critical difference was 1.2. As mentioned earlier 
in Section 6.5.2, the interpretation of Bland Altman depends on the visual inspection of the 
graph and pre-specified level of agreement. In this case, the most important factor is that the 
mean difference is close to 0 and the 95 % CI contains zero. On that basis, I can confirm that 




The Bland Altman plot for the agreement between the predicted and the observed values 
ispresented in Figure 6.11. The average mean difference (bias) = 0.06 and the limits of 
agreement LOA = (-1.14; 1.27). The critical difference was 1.2. which confirms that there is a 
good agreement between the observed and the predictive values in the model. However, it was 
noticed that the agreement was higher in the training dataset compared to the test dataset. That 
is because the model was built using the training dataset, and it would be expected to have a 
better agreement than the test dataset. 
 
 
Figure D5. Bland Altman plot for the agreement between the observed and the 


















Figure D6. Bland Altman plot for the agreement between the observed and the 




D. 6 R codes in Chapter 6  












all= read.spss(all, to.data.frame = TRUE) 
names (all) 
View (all) 


















Layout (matrix(c(1,2,3,4),2,2)) # optional 4 graphs/page 
Plot (lm(SMDlt~SMDdl+ y3+ 
          Lastyear, weights = Ndl, data = all)) 
Print (M1) 
P1<-predict(M1) 
all<- data.frame(all, P1) 
  R2 = rsquare(M1, data = all) 
  RMSE = rmse(M1, data = all) 
  MAE = mae(M1, data = all) 
predictions <- M1 %>% predict(all) 
data.frame( 
  R2 = R2(predictions, all$SMDlt), 
  RMSE = RMSE(predictions, all$SMDlt), 
  MAE = MAE(predictions, all$SMDlt)) 
Library (broom) 
Glance (M1) 
Layout (matrix(c(1,2,3,4),2,2)) # optional 4 graphs/page 
Plot (M1) 
# Split the data into training and test set 
Data (all) 
## 75% of the sample size 
smp_size <- floor(0.75 * nrow(all)) 
## set the seed to make your partition reproducible 
set.seed(123) 
train_ind <- sample(seq_len(nrow(all)), size = smp_size) 
train <- all[train_ind, ] 





# Build the model 
t1<- lm(SMDlt~SMDdl+ y3+ Lastyear, weights = Ndl, data = train) 
print (t1) 
P2<-predict(t1) 
train<- data.frame(train, P2) 
glance(t1) 
layout(matrix(c(1,2,3,4),2,2)) # optional 4 graphs/page 
plot(t1) 
qqPlot(t1, data=train, layout=c(1, 3)) 
# Make predictions and compute the R2, RMSE and MAE 




plot(test1$predictions, test1$SMDlt, type="p", 
     col="darkblue") 
cor(test1$predictions, test1$SMDlt, method = c("pearson", "kendall", "spearman")) 
RMSE (test1$predictions, test1$SMDlt)/mean(test.data$SMDlt) 
Plot (test1$predictions, test1$SMDlt) 
Cor (test1$predictions,test1$SMDlt ) 
R2 = R2(test1$predictions, test1$SMDlt) 
RMSE = RMSE(test1$predictions, test1$SMDlt) 





lmodel <- lm(SMDlt~SMDdl+ y3+ Lastyear, weights = Ndl) 






# Define training control 
train.control <- trainControl(method = "LOOCV") 
# Train the model 
model1 <- train(SMDlt~SMDdl+ y3+ Lastyear, weights = Ndl, data = all, method = "lm", 
  trControl = train.control) 
# Summarize the results 
print(model1) 
#K-fold cross-validation 
# Define training control 
set.seed(10)  
train.control <- trainControl(method = "cv", number = 10) 
# Train the model 
model12 <- train(SMDlt~SMDdl+ y3+ Lastyear, weights = Ndl, data = all, method = "lm", 
               trControl = train.control) 
# Summarize the results 
print(model12) 
#Repeated K-fold cross-validation 
set.seed(10) 
train.control <- trainControl(method = "repeatedcv",  
                          number = 10, repeats = 3) 
# Train the model 
model23 <- train(SMDlt~SMDdl+ y3+ Lastyear, weights = Ndl, data = all, method = "lm", 
    trControl = train.control) 
# Summarize the results 
Print (model23) 






lmodel <- lm(SMDlt~SMDdl+ y3+ Lastyear, weights = Ndl) 
lboot <- lm.boot(lmodel, R = 1000) 
summary(lboot) 
w <- all$Ndl 
lbootw <- lm.boot(lmodel, R = 1000, weights = w) 
summary(lbootw) 




Pa<-bland.altman.plot(group1= all$SMDlt, group2= all$P1,data= all,   xlab="Means", ylab="Differences", 
conf.int=.95) 
library(BlandAltmanLeh) 
Pa<-bland.altman.plot(group1= train$SMDlt, group2= train$P2,data= train,   xlab="Means", 
ylab="Differences", conf.int=.95) 












LT= read.spss(LT, to.data.frame = TRUE) 
View (LT) 
meta1<- metagen (d, SE, sm="SMD", data=LT, byvar = (CD)) 
names(meta1) 
View(meta1) 





meta1$lower.fixed.w #lower bound of 95% CI 
meta1$upper.fixed.w  #upper bound of 95% CI 





LTfixed<-rename(result, CD=meta1.bylevs, k=meta1.k.all.w, Pvalue= meta1.pval.fixed.w, SMD=meta1.TE.fixed.w, 
lower95=meta1.lower.fixed.w,upper95= meta1.upper.fixed.w) 
View(LTfixed) 
write.table(LTfixed, file="LTfixed.csv", sep=",") 




meta1$pval.random.w# p value 
meta1$TE.random.w #SMD 
meta1$lower.random.w #lower bound of 95% CI 
meta1$upper.random.w  #upper bound of 95% CI 





LTrandom<-rename(resultr, CD=meta1.bylevs, k=meta1.k.all.w, Pvalue= meta1.pval.random.w, 
SMD=meta1.TE.random.w, lower95=meta1.lower.random.w,upper95= meta1.upper.random.w) 
View(LTrandom) 





# conduct meta-analysis after deleting last trial both fixed and random 
 
Library (meta)  
Library (foreign) 
ttdl=file.choose() 
ttdl= read.spss(ttdl, to.data.frame = TRUE) 
View (ttdl) 
meta2<- metagen (d, SEd, sm="SMD", data=ttdl, byvar = (CD)) 
names(meta2) 
View(meta2) 





meta2$lower.fixed.w #lower bound of 95% CI 
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meta2$upper.fixed.w  #upper bound of 95% CI 





DLfixed<-rename(result2, CD=meta2.bylevs, k=meta2.k.all.w, Pvalue= meta2.pval.fixed.w, SMD=meta2.TE.fixed.w, 
lower95=meta2.lower.fixed.w,upper95= meta2.upper.fixed.w) 
View(DLfixed) 
write.table(DLfixed, file="DLfixed.csv", sep=",") 




meta2$pval.random.w# p value 
meta2$TE.random.w #SMD 
meta2$lower.random.w #lower bound of 95% CI 
meta2$upper.random.w  #upper bound of 95% CI 





DLrandom<-rename(result2r, CD=meta2.bylevs, k=meta2.k.all.w, Pvalue= meta2.pval.random.w, 
SMD=meta2.TE.random.w, lower95=meta2.lower.random.w,upper95= meta2.upper.random.w) 
View(DLrandom) 











metaTT <- metamean(N, d, V, data=TT, byvar = (CD)) 








metaTTDL <- metamean(N, d, V, data=TTDL, byvar = (CD)) 
 
 








ba.stats <- bland.altman.stats(fr2$lower95E3f,fr2$lower95E3r) 
print(ba.stats) 
ba.stats <- bland.altman.stats(fr2$upper95E3f,fr2$upper95E3r) 
print(ba.stats) 
ba.stats <- bland.altman.stats(fr2$SMDE3f,fr2$SMDE3r) 
print(ba.stats) 
ba.stats <- bland.altman.stats(fr2$distanceF,fr2$distanceR) 
print(ba.stats) 
P6<- ggplot(fr2, aes(x = mean, y = difference,size=N,  fill= I2)) + 
  geom_point(shape = 21)+ theme_bw()+ ylim(-2,2)+ xlab("mean for the main estimate")+   ylab("Difference of the main 
estimate") 
          p7<- p6+geom_hline(yintercept=-0.01024521, color = "darkblue") 
          p8<- p7+ geom_hline(yintercept=-0.2289256, linetype="dashed", color = "darkblue") 
          p9<- p8+ geom_hline(yintercept=0.2084352, linetype="dashed", color = "darkblue") 
        
          
 p16 <- ggplot(fr2, aes(x = meandistance, y = diffdistance,size=N,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+xlab("mean width 95% CI")+   ylab("Difference width 95% CI") 
          P17<- p16 +geom_hline(yintercept=-0.49649510, color = "darkblue") 
          p18<- P17+ geom_hline(yintercept=-0.09179477, linetype="dashed", color = "darkblue") 
          p19<- p18+ geom_hline(yintercept=0.3129056, linetype="dashed", color = "darkblue") 
 p26 <- ggplot(fr2, aes(x = meanup, y = diffup,size=N,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+ xlab("mean upper 95% CI")+   ylab("Difference upper 95% CI") 
          P27<- p26 +geom_hline(yintercept=-0.07669147, color = "darkblue") 
          p28<- P27+ geom_hline(yintercept=-0.41099310, linetype="dashed", color = "darkblue") 
          p29<- p28+ geom_hline(yintercept=0.25761016, linetype="dashed", color = "darkblue") 
 
p36 <- ggplot(fr2, aes(x = meanlower, y = difflower,size=N,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+ xlab("mean lower 95% CI")+   ylab("Difference lower 95% CI") 
          P37<- p36 +geom_hline(yintercept=0.0971819, color = "darkblue") 
          p38<- P37+ geom_hline(yintercept=-0.2434670, linetype="dashed", color = "darkblue") 
          p39<- p38+ geom_hline(yintercept=0.4378308, linetype="dashed", color = "darkblue") 
 
          grid.arrange(p9, p19,p29, p39, ncol = 2)       
     # number of trials      
 p6 <- ggplot(fr2, aes(x = mean, y = difference,size=Trials,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+xlab("mean of the main estimate")+   ylab("Difference of the main estimate") 
          P7<- p6 +geom_hline(yintercept=-0.01024521, color = "darkblue") 
          p8<- P7+ geom_hline(yintercept=-0.2289256, linetype="dashed", color = "darkblue") 
          p9<- p8+ geom_hline(yintercept=0.2084352, linetype="dashed", color = "darkblue") 
  p16 <- ggplot(fr2, aes(x = meandistance, y = diffdistance,size=Trials,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+xlab("mean width 95% CI")+   ylab("Difference width 95% CI") 
          P17<- p16 +geom_hline(yintercept=-0.49649510, color = "darkblue") 
          p18<- P17+ geom_hline(yintercept=-0.09179477, linetype="dashed", color = "darkblue") 
          p19<- p18+ geom_hline(yintercept=0.3129056, linetype="dashed", color = "darkblue") 
p26 <- ggplot(fr2, aes(x = meanup, y = diffup,size=Trials,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+ xlab("mean upper 95% CI")+   ylab("Difference upper 95% CI") 
          P27<- p26 +geom_hline(yintercept=-0.07669147, color = "darkblue") 
          p28<- P27+ geom_hline(yintercept=-0.41099310, linetype="dashed", color = "darkblue") 
          p29<- p28+ geom_hline(yintercept=0.25761016, linetype="dashed", color = "darkblue") 
           
 p36 <- ggplot(fr2, aes(x = meanlower, y = difflower,size=Trials,  fill= I2)) + 
            geom_point(shape = 21)+ 
            theme_bw()+ ylim(-2,2)+ xlab("mean lower 95% CI")+   ylab("Difference lower 95% CI") 
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          P37<- p36 +geom_hline(yintercept=0.0971819, color = "darkblue") 
          p38<- P37+ geom_hline(yintercept=-0.2434670, linetype="dashed", color = "darkblue") 
          p39<- p38+ geom_hline(yintercept=0.4378308, linetype="dashed", color = "darkblue") 
           






tte3= read.spss(tte3, to.data.frame = TRUE) 








metacd <- unique(tt$CD) 
res.rma<-rma.mv(d, Vd, mods= ~ year, data=tt, subset= (CD)) 
for (i in tt) { 
  res.rma <- rma.mv(d, Vd, mods =  ~ year  , data=tt, subset = (CD == "[i]")) 
} 
get.n.Name(data) 








tte3= read.spss(tte3, to.data.frame = TRUE) 
View (tte3) 
meta1<- metagen (d, SEd, sm="SMD", data=tte3, byvar = (CD)) 
names(meta1) 
View(meta1) 





meta1$lower.fixed.w #lower bound of 95% CI 
meta1$upper.fixed.w  #upper bound of 95% CI 





E3fixed<-rename(result, CD=meta1.bylevs, k=meta1.k.all.w, Pvalue= meta1.pval.fixed.w, SMD=meta1.TE.fixed.w, 
lower95=meta1.lower.fixed.w,upper95= meta1.upper.fixed.w) 
View(E3fixed) 
write.table(E3fixed, file="E3fixed.csv", sep=",") 








meta1$lower.random.w #lower bound of 95% CI 
meta1$upper.random.w  #upper bound of 95% CI 





E3random<-rename(resultr, CD=meta1.bylevs, k=meta1.k.all.w, Pvalue= meta1.pval.random.w, 
SMD=meta1.TE.random.w, lower95=meta1.lower.random.w,upper95= meta1.upper.random.w) 
View(E3random) 
write.table(E3random, file="E3random.csv", sep=",") 
 
Appendix E Chapter 8 
E. 1 Atorvastatin for lowering lipids 
This appendix includes the results for the random effects meta-regression, the detailed tables 
for the different percentage of M1 for the both examples and the R codes used in Chapter 8 and 
a special case of NI trial (the OASIS trial) 
E. 1. 1 Meta-regression using Random effects model 
Iterations = 5001:25000 
Thinning interval = 1  
Number of chains = 4  
Sample size per chain = 20000  
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
                           Mean     SD  Naive SE Time-series SE 
d.Atorvastatin.placebo -25.9078 0.5367 0.0018975       0.023378 
sd.d                     0.3073 0.2245 0.0007937       0.007489 
B                        4.8246 1.2582 0.0044483       0.011986 
2. Quantiles for each variable: 
                            2.5%      25%      50%      75%    97.5% 
d.Atorvastatin.placebo -26.94422 -26.2698 -25.8878 -25.5548 -24.8677 
sd.d                     0.01521   0.1262   0.2634   0.4468   0.8303 
B                        2.36472   3.9758   4.8267   5.6753   7.2756 
-- Model fit (residual deviance): 
    Dbar       pD      DIC  
59.57558 26.62229 86.19788  
48 data points, ratio 1.241, I^2 = 21% 
E. 1. 2 Use of different percentages of M1 to set M2 
 
Table E.1 Constancy assumed, 60% NI margin=14.7, n1=n2=14 
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 𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=4.9 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 4.5 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
4.95 
18.5 0.0 (-8.9; 8.9) 25.0 (17.0; 34.0) 18.0 (8.1; 28.0) 
16.5 -2.0 (-10.9; 6.9) 23.0 (15.0; 32.0) 16.0 (6.1; 26.0) 
14.5 -4.0 (-12.9; 4.9) 21.0 (13.0; 30.0) 14.0 (4.1; 24.0) 
13.5 -5.0 (-14.1; 3.8) 20.0 (12.0; 29.0) 13.0 (3; 22.0) 
13.0 -5.5 (-14.4; 3.4) 20.0 (11.0; 29.0) 12.0 (2.6; 22.0) 
12.5 -6.0(-14.8; 2.89) 19.0 (11.0; 28.0) 12.0 (2.2; 22.0) 
10.5 -8.0 (-16.7; 0.9) 17.0 (8.5; 26.0) 9.9 (0.26; 20.0) 
10.0 -8.5 (-17.0; 0.28) 17.0 (8.0; 26.0) 9.3 (-0.4; 19.0) 
9.5 -9.0 (-18.0; -.0.1) 16.0  (7.5; 25) 8.8 (-0.8; 19) 
1.5 -17.0 (-26.0; -8.1) 8.4 (-0.5; 17.0) 0.9 (-9.0; 11) 
Table E.2 Constancy assumed, 70% NI margin= 17.5, n1=n2= 11 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=5.13 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 
5.16 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
5.15 
18.5 0.0 (-10.1; 10.1) 25.0 (15.0; 36.0) 18.0 (7.0; 29.0) 
16.5 -2.0 (-12.0; 8.1) 23.0 (13.0; 34.0) 16.0 (5.1; 27.0) 
14.5 -4.0 (-14.1; 6.8) 21.0 (11.0; 32.0) 14.0 (3.1; 25.0) 
12.5 -6.0 (-16.0; 4.1) 19.0 (9.3; 30.0) 12.0 (1.0; 23.0) 
11.5 -7.0 (-17.1; 3.0) 18.0 (8.3; 28.0) 11.0 (0.0; 22.0) 
11.0 -7.5 (-17.5; 2.5) 18.0 (8.0; 28.0) 10.0 (-0.4; 21.0) 
9.5 -9.0 (-19.1; 1.1) 16.0 (6.3; 26.0) 8.8 (-2.0; 20.0) 
7.5 -10.9 (-21.0; -0.9) 14.0 (4.4; 25.0) 6.9 (-3.9; 18.0) 
3.5 -14.9 (-25.0; -5.0) 10.0  (0.4; 21.0) 2.9 (-7.9; 14.0) 
3.0 -15.6 (-25.6; -5.8) 9.9 (-0.2; 20.0) 2.3 (-8.6; 13.0) 
 
Table E.3  Constancy assumed, 80% NI margin= 19.6, n1=n2= 8 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=6.0 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 
6.01 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
6.03 
18.5 0.0 (-11.9; 11.6) 26.0 (14.0; 37.0) 18.0 (5.3; 30.0) 
16.5 -2.0 (-13.7; 9.6) 23.0 (12.0; 35.0) 16.0 (3.4; 28.0) 
14.5 -4.0 (-15.7; 7.7) 21.0 (9.7; 33.0) 14.0 (1.5; 26.0) 
12.5 -6.0 (-17.6; 5.7) 19.0 (7.6; 31.0) 12.0 (-0.5; 24.0) 
11.5 -7.0 (-18.7; 4.8) 18.0 (6.8; 30.0) 11.0 (-1.6; 23.0) 
10.5 -8.0 (-19.8; 3.6) 17.0 (5.5; 29.0) 9.8 (-2.6; 22.0) 
9.5 -9.0 (-20.7; 2.8) 16.0 (4.6; 28.0) 8.9 (-3.5; 21.0) 
7.5 -11.0 (-22.8; 0.8) 14.0 (2.7; 26.0) 6.8 (-5.6; 19.0) 
6.5 -12.0 (-23.7; -0.16) 13.0  (1.6; 25.0) 5.8 (-6.5; 18.0) 
4.5 -14.0 (-25.8; -2.2) 11.0 (-0.4; 23.0) 3.9 (-8.7; 16.0) 
 
Table E.4 Constancy assumed, 90% NI margin= 22.05, n1=n2= 7 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=6.36 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 6.3 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
6.6 
18.5 0.0 (-12.5; 12.4) 25.0 (13.0; 38.0) 18.0 (4.7; 31.0) 
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14.5 -4.0 (-16.6; 8.5) 21.0 (8.8; 34.0) 14.0 (0.7; 27.0) 
13.5 -5.0 (-17.7; 7.7) 20.0 (7.7; 33.0) 13.0 (-0.5; 26.0) 
12.5 -6.0 (-18.6; 6.6) 19.0 (6.7; 32.0) 12.0 (-1.4; 25.0) 
9.5 -9.0 (-21.6; 3.5) 16.0 (3.8; 29.0) 8.8 (-4.3; 22.0) 
9.0 -9.5 (-22.0; 3.1) 16.0 (3.3; 28.0) 8.3 (-4.8; 22.0) 
8.5 -10.0 (-22.5; 2.6) 15.0 (2.9; 28.0) 7.8 (-5.3; 21.0) 
7.5 -11 (-23.5; 1.68) 14.0 (1.9; 27.0) 6.8 (-6.3; 20.0) 
5.5 -13.0 (-25.6; -0.4) 13.0 (-0.3; 25.0) 4.8 (-8.4;18.0) 
 
Table E.5 Constancy assumed, M2= M1= 24.5, n1=n2= 6 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=6.9 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 6.9 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
7.1 
18.5 0.0 (-13.7; 13.5) 26.0 (12.0; 39.0) 18.0 (3.6; 32.0) 
14.5 -4.0 (-17.6; 9.5) 21.0 (7.8; 35.0) 14.0 (-0.3; 28.0) 
12.5 -6.0 (-19.5; 7.5) 19.0 (5.8; 33.0) 12.0 (-2.2; 26.0) 
9.5 -9.0 (-22.5; 4.6) 16.0 (2.8; 30.0) 8.9 (-5.2; 23.0) 
8.5 -10.0 (-23.6; 3.4) 15.0 (1.9; 29.0) 7.7 (-6.4; 22.0) 
7.5 -11 (-24.5; 2.5) 14.0 (0.6; 28.0) 6.8 (-7.3; 21.0) 
6.5 -11.9 (-25.7; 1.6) 14.0 (-0.2; 27.0) 5.9 (-8.4;20.0) 
4.5 14.0 (-27.6; -0.4) 11.0 (-2.1; 25.0) 3.8 (-10.0; 18.0) 
 
 Table E.6 Constancy not assumed, 60% NI margin=10.11, n1=n2= 30 
 𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=3.08 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 
3.14 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
3.68 
18.5 0.0 (-6.0; 6.1) 25.0 (19.0; 32.0) 18.0 (11; 25.0) 
16.5 -2.0 (-8.1; 4.1) 23.0 (17.0; 30.0) 16.0 (8.5; 23.0) 
15.5 -3.0 (-9.1; 3.1) 22.0 (16.0; 29.0) 15.0 (7.5; 22.0) 
14.5 -4.0 (-10.1; 2.1) 21.0 (15.0; 28.0) 14.0 (6.6; 21.0) 
12.5 -6.0 (-12.1; 0.1) 19.0 (13.0; 26.0) 12.0 (4.6; 19.0) 
11.5 -7.0(-13.1; -1.0) 18.0 (12.0; 25.0) 11.0 (3.6; 18.0) 
9.5 -9.0 (-15.0; -2.8) 16.0 (10.0; 23.0) 8.9 (1.6; 16.0) 
7.5 -11.0 (-17.1; -4.9) 14.0 (8.3; 21.0) 6.8 (-0.4; 14.0) 
3.5 -15.0 (-21.0; -.8.9) 10.0  (4.3; 17) 2.8 (-4.4; 10.0) 
0.5 -18.0 (-24.1; -11.9) 7.4 (1.2; 14.0) -0.2 (-7.5; 7.0) 
 
Table E.7 Constancy not assumed, 70% NI margin= 11.79, n1=n2= 22 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=3.6 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 3.6 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
4.13 
18.5 0.0 (-7.0; 7.1) 25.0 (18.0; 32.0) 18.0 (9.7; 26.0) 
16.5 -2.0 (-9.1; 5.1) 23.0 (16.0; 30.0) 16.0 (7.7; 24.0) 
14.5 -4.0 (-11.1; 3.1) 21.0 (14.0; 29.0) 14.0 (5.7; 22.0) 
14.0 -4.5 (-11.5; 2.5) 21.0 (14.0; 28.0) 13.0 (5.3; 21.0) 
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13.5 -5.0 (-12.2; 2.1) 20.0 (13.0; 28.0) 13.0 (4.7; 21.0) 
11.5 -7.0(-14.1; 0.0) 18.0 (11.0; 26.0) 11.0 (2.7; 19.0) 
9.5 -9.0 (-16.2; -1.9) 16.0 (9.3; 24.0) 8.8 (0.6; 17.0) 
8.5 -10.0 (-17.1; -2.9) 15.0 (8.3; 23.0) 7.8 (-0.2; 16.0) 
3.5 -15.0 (-22.0; -.7.8) 10.0  (3.3; 18) 2.8 (-5.3; 11.0) 
0.5 -18.0 (-25.1; -10.9) 7.5 (0.2; 15.0) -0.2 (-8.3; 8.0) 
 
 
Table E.8 Constancy not assumed, 80% NI margin= 13.48, n1=n2= 17 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=3.6 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 3.6 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
4.13 
18.5 0.0 (-8.1; 8.1) 25.0 (17.0; 34.0) 18.0 (8.8; 27.0) 
16.5 -2.0 (-10.1; 6.1) 23.0 (15.0; 32.0) 16.0 (6.8; 25.0) 
14.5 -4.0 (-12.1; 4.1) 21.0 (13.0; 30.0) 14.0 (4.9; 23.0) 
13.0 -5.5 (-13.5; 2.6) 20.0 (12.0; 28.0) 12.0 (3.4; 21.0) 
11.5 -7.0(-15.1; 1.0) 18.0 (10.0; 26.0) 11.0 (1.9; 20.0) 
9.5 -9.0 (-17.1; -0.9) 16.0 (8.3; 25.0) 8.8 (-0.2; 18.0) 
7.5 -11.0 (-19.2; -3.0) 14.0 (6.4; 23.0) 6.8 (-2.3; 16.0) 
3.5 -15.0 (-23.0; -.6.8) 10.0  (2.3; 19) 2.9 (-6.1; 12.0) 
0.5 -18.0 (-26.1; -10.0) 7.5 (-0.6; 16.0) -0.2 (-9.2; 8.7) 
 
Table E.9Constancy not assumed, 90% NI margin= 15.6, n1=n2= 14 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=3.6 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 3.6 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
4.13 
18.5 0.0 (-8.9; 8.9) 25.0 (16.0; 34.0) 18.0 (8.8; 28.0) 
16.5 -2.0 (-10.9; 6.7) 23.0 (14.0; 32.0) 16.0 (6.0; 25.0) 
14.5 -4.0 (-12.9; 4.9) 22.0 (13.0; 30.0) 14.0 (4.1; 24.0) 
12.5 -6.0 (-14.8; 2.9) 19.0 (11.0; 28.0) 12.0 (2.2; 22.0) 
11.5 -7.0 (-15.9; 1.9) 18.0 (9.5; 27.0) 11.0 (1.0; 21.0) 
10.5 -8.0 (-16.8; 1.1) 17.0 (8.4; 26.0) 9.9 (0.2; 20.0) 
9.5 -9.0 (-17.9; 0.0) 16.0 (7.5; 25.0) 8.8 (-0.8; 19.0) 
8.5 -10.0 (-18.9; -1.0) 15.0  (6.5; 24.0) 7.9 (-2.0; 18.0) 
1.5 -17.0 (-25.9; -8.2) 8.4 (-0.5; 17.0) 0.8 (-8.9; 11.0) 
 
Table E.10 Constancy not assumed, NI margin=M1=  16.85 , n1=n2= 11 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2020) (95% 
CrI), se=3.6 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), se= 3.6 
NMR (𝜇𝑇 − 𝜇𝑃) in 
(2020) (95% CrI), se= 
4.13 
18.5 0.0 (-10.1; 10.1) 25.0 (15.0; 36.0) 18.0 (7.0; 29.0) 
16.5 -2.0 (-12.0; 8.0) 23.0 (13.0; 33.0) 16.0 (5.0; 27.0) 
14.5 -4.0 (-14.0; 6.0) 21.0 (11.0; 31.0) 14.0 (3.1; 25.0) 
12.5 -6.0 (-16.0; 4.0) 20.0 (10.0; 30.0) 12.0 (1.1; 23.0) 
12.0 -6.5 (-16.6; 3.5) 19.0 (8.9; 29.0) 11.0 (0.5; 22.0) 
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11.5 -7.0(-17.3; 3.0) 18.0 (8.4; 28.0) 11.0 (0.0; 22.0) 
10.5 -8.0 (-18.0; 2.0) 17.0 (7.4; 27.0) 9.8 (-0.9; 21.0) 
7.5 -11.0 (-20.9; -0.9) 15.0 (4.3; 25.0) 6.8 (-3.9; 18.0) 
2.5 -16.0 (-26.0; -5.9) 9.4  (-0.7; 19) 1.8 (-8.9; 13.0) 
 
E. 1. 3 Use of 50% of M1 to set M2 in the years of 2025, 2030 
Table E.11 Comparison of the mean difference between the placebo and test treatment 
assuming the constancy(2025), NI=-12.25, N= 21 
 𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI trial 
(95% CrI), SE = (3.7) 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), SE = 
(3.74) 
NMR (𝜇𝑇 − 𝜇𝑃) in (95% 
CrI), SE = (4.53) 
18.5 0.0 (-7.2; 7.2) 25.0 (18.0; 33.0) 15.0 (6.4; 24.0) 
16.5 -2.0 (-9.2; 5.3) 23.0 (16.0; 31.0) 13.0 (4.5; 22.0) 
15.5 -3.0 (-10.0; 4.3) 22.0 (15.0; 30.0) 12.0 (3.4; 21.0) 
14.5 -4.0 (-11.0; 3.2) 21.0 (14.0; 29.0) 11.0 (2.5; 20.0) 
13.5 -5.0 (-12.3; 2.2) 20.0 (13.0; 28.0) 10.0 (1.6; 19.0) 
12.5 -6.0 (-13.2; 1.3) 19.0 (12.0; 27.0) 9.4 (0.5; 18.0) 
10.5 -8.0 (-15.3; -0.7) 17.0 (10.0; 25.0) 7.5 (-1.5; 16.0) 
8.5 -10.0 (-17.3; -2.7) 15.0 (8.2; 23.0) 5.3 (-3.6; 14.0) 
7.0 -11.4 (-18.5; -4.4) 14.0 (6.8; 21.0) 3.9 (-5.1; 13.0) 
1.5 -17.0 (-24.3; -9.7) 8.5 (1.1; 16.0) -1.7 (-11.0; 7.2) 
0.0 -18.5 (-25.7; -11.2) 6.9 (-0.4; 14.0) -3.2 (-12.0; 5.8) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜇𝑡 − 𝜇𝑐 refers to the mean difference between the active 
control and the test treatment, negative sign means the test treatment is less effective than the active control, SE: Standard 
error, 𝜇𝑡 is the treatment effect in the test group in the NI trial  
 
Table E.12 Comparison of the mean difference between the placebo and test treatment 
assuming the constancy(2030), NI=-12.25, N=21 
 𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI trial 
(2025) (95% CrI), SE 
= (3.7) 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), SE = 
(3.74) 
NMR (𝜇𝑇 − 𝜇𝑃) in (2025) 
(95% CrI), SE = (4.53) 
18.5 0.0 (-7.2; 7.2) 25.0 (18.0; 33.0) 12.9 (3.2; 22.5) 
16.5 -2.0 (-9.2; 5.3) 23.0 (16.0; 31.0) 10.9 (1.32; 20.5) 
15.5 -3.0 (-10.0; 4.3) 22.0 (15.0; 30.0) 9.9 (0.27; 19.7) 
14.5 -4.0 (-11.0; 3.2) 21.0 (14.0; 29.0) 8.9 (-0.7; 18.6) 
13.5 -5.0 (-12.3; 2.2) 20.0 (13.0; 28.0) 7.8 (-1.9; 17.5) 
12.5 -6.0 (-13.2; 1.3) 19.0 (12.0; 27.0) 6.9 (-2.8; 16.5) 
10.5 -8.0 (-15.3; -0.7) 17.0 (10.0; 25.0) 4.8 (-4.7; 14.5) 
8.5 -10.0 (-17.3; -2.7) 15.0 (8.2; 23.0) 2.8(-6.8; 12.5) 
7.0 -11.4 (-18.5; -4.4) 14.0 (6.8; 21.0) 1.3(-8.3; 11.0) 
1.5 -17.0 (-24.3; -9.7) 8.5 (1.1; 16.0) -4.1(-13.8; 5.5) 
0.0 -18.5 (-25.7; -11.2) 6.9 (-0.4; 14.0) -5.6(-15.2; 4.0) 
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NMA: network meta-analysis, NMR: network meta-regression, the 𝜇𝑡 − 𝜇𝑐 refers to the mean difference between the active 
control and the test treatment, negative sign means the test treatment is less effective than the active control, SE: Standard 
error, 𝜇𝑡 is the treatment effect in the test group in the NI trial  
 
Table E.13 Comparison of the mean difference between the placebo and test treatment, 
constancy not assumed (2025) NI=-7.17, N= 59 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2025) (95% 
CrI), SE= 2.20 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), SE= 
2.26 
NMR (𝜇𝑇 − 𝜇𝑃) in (2025) 
(95% CrI), SE= 3.46 
18.5 0.0 (-4.3; 4.3) 25.0 (21.0; 30.0) 15.4 (8.6; 22.2) 
16.5 -2.0 (-6.3; 2.3) 23.0 (19.0; 28.0) 13.3 (6.6; 20.0) 
16.0 -2.5 (-6.8; 1.8) 22.9 (18.5; 27.4) 12.9 (6.2; 19.5) 
15.5 -3.0 (-7.3; 1.3) 22.0 (18.0; 27.0) 12.4 (5.6; 19.0) 
13.5 -5.0 (-9.3; -0.7) 20.0 (16.0; 25.0) 10.3 (3.6; 17.1) 
12.5 -6.0 (-10.3; -1.7) 19.0 (15.0; 24.0) 9.3 (2.5; 16 .0) 
11.5 -7.0 (-11.3; -2.7) 18.0 (14.0; 23.0) 8.4 (1.6; 15.2) 
10.5 -8.0 (-12.3; -3.7) 17.0 (13.0; 22.0) 7.4 (0.6; 14.1) 
8.5 -10.0 (-14.3; -5.7) 15.0 (11.0; 20.0) 5.4 (-1.3; 12.2) 
7.0 -11.5 (-15.8; -7.1) 14.0 (9.5; 18.0) 3.8 (-2.8; 10.6) 
1.5 -17.0 (-21.3; -12.6) 8.5 (4.1; 13.0) -1.6 (-8.2; 4.9) 
0.0 -18.5 (-22.8; -14.1) 6.9 (2.5; 11.0) -3.2 (-9.8; 3.6) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜇𝑡 − 𝜇𝑐 refers to the mean difference between the active 
control and the test treatment, negative sign means the test treatment is less effective than the active control  
 
Table E.14 Comparison of the mean difference between the placebo and test treatment, 
constancy not assumed (2030) NI=-5.9, N= 87 
𝜇𝑡 𝜇𝑇 − 𝜇𝐶 from NI 
trial (2030) (95% 
CrI), SE= 1.8 
NMA (𝜇𝑇 − 𝜇𝑃) 
(95% CrI), SE= 
1.8 
NMR (𝜇𝑇 − 𝜇𝑃) in (2030) 
(95% CrI), SE= 3.7 
18.5 0.0 (-3.5; 3.5) 25.0 (22.0; 29.0) 13.0 (5.6; 20.2) 
16.5 -2.0 (-5.6; 1.5) 23.0 (20.0; 27.0) 10.8 (3.6; 18.1) 
16.0 -2.5 (-6.0; 1.1) 22.9 (19.2; 26.6) 10.3 (3.17; 1.7) 
15.5 -3.0 (-6.5; 0.6) 22.0 (19.0; 26.0) 9.8 (2.5; 17.2) 
13.5 -5.0 (-8.5; -1.4) 20.0 (17.0; 24.0) 7.6 (0.6; 15.1) 
12.5 -6.0 (-9.5; -2.4) 19.0 (16.0; 23.0) 6.8 (-0.6; 14.0) 
11.5 -7.0 (-10.6; -3.5) 18.0 (15.0; 22.0) 5.9 (-1.4; 13.2) 
10.5 -8.0 (-11.6; -4.5) 17.0 (14.0; 21.0) 4.9 (-2.41; 12.2) 
8.5 -10.0 (-13.6; -6.4) 15.0 (12.0; 19.0) 2.9 (-4.3; 10.3) 
7.0 -11.5 (-15.0; -7.9) 14.0 (10.0; 18.0) 1.4 (-5.8; 8.6) 
1.5 -17.0 (-20.6; -13.5) 8.5 (4.8; 12.0) -4.2 (-11.6; 3.1) 
0.0 -18.5 (-22.0; -15.0) 6.9 (3.2; 11.0) -5.7 (-13.1; 1.7) 
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NMA: network meta-analysis, NMR: network meta-regression, the 𝜇𝑡 − 𝜇𝑐 refers to the mean difference between the active 
control and the test treatment, negative sign means the test treatment is less effective than the active control  
 
 
E. 2 Lidocaine for pain reduction 
E. 2. 1  Random effects pairwise meta-regression 
Results on the Log Odds Ratio scale 
 
Iterations = 5001:25000 
Thinning interval = 1  
Number of chains = 4  
Sample size per chain = 20000  
1. Empirical mean and standard deviation for each variable, 
   plus standard error of the mean: 
                     Mean     SD  Naive SE Time-series SE 
d.Lidocaine.placebo 1.7053 0.1328 0.0004696       0.003390 
sd.d                0.1858 0.1389 0.0004912       0.005236 
B                   0.1187 0.2575 0.0009103       0.002957 
2. Quantiles for each variable: 
                         2.5%      25%    50%    75%  97.5% 
d.Lidocaine.placebo  1.455225  1.61537 1.7016 1.7906 1.9774 
sd.d                 0.004903  0.07111 0.1612 0.2728 0.5043 
B                   -0.383180 -0.05159 0.1175 0.2885 0.6317 
-- Model fit (residual deviance): 
 
    Dbar       pD      DIC  
46.92977 27.93494 74.86470  
E. 2. 2 Use of different percentages of M1 to set M2 
Table E.15  60% of M1, NI margin= 2.35 , n1=n2=227 (Assuming constancy) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.26 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.28 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.43 
15.00% 1.00 (0.60; 1.70) 5.30 (3.00; 9.30) 6.30 (2.70; 15.00) 
17.00% 1.10 (0.69; 1.90) 4.70 (2.70; 8.10) 5.50 (2.40; 13.00) 
19.00% 1.30 (0.80; 2.20) 4.00 (2.40; 6.90) 4.70 (2.00; 11.00) 
20.00% 1.40 (0.86; 2.29) 3.80 (2.20; 6.50) 4.40 (1.90; 10.00) 
21.00% 1.47 (0.90; 2.40) 3.61 (2.10; 6.13) 4.23 (1.85; 9.92) 
22.00% 1.56 (0.97; 2.54) 3.43 (2.02; 5.78) 4.00 (1.77; 9.29) 
23.00% 1.68 (1.05; 2.70) 3.18 (1.87; 5.36) 3.70 (1.63; 8.55) 
25.00% 1.85 (1.16; 2.98) 2.88 (1.69; 4.85) 3.37 (1.47; 7.75) 
30.00% 2.41 (1.53; 3.85) 2.21 (1.31; 3.67) 2.60 (1.15; 5.98) 
35.00% 3.01 (1.92; 4.79) 1.77 (1.06; 2.90) 2.08 (0.91; 4.70) 







Table E.16. 70% of M1, NI margin= 2.70 , n1=n2=167 (Assuming constancy) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.31 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.32 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.46 
15.00% 1.00 (0.54; 1.82) 5.33 (2.83; 10.00) 6.22 (2.55; 15.50) 
17.00% 1.14 (0.64; 2.05) 4.68 (2.52; 8.72) 5.45 (2.21; 13.5) 
19.00% 1.29 (0.73; 2.28) 4.12 (2.23; 7.57) 4.87 (2.01; 12.00) 
21.00% 1.50 (0.86; 2.62) 3.56 (1.94; 6.52) 4.18 (1.73; 10.10) 
22.00% 1.55 (0.89; 2.72) 3.45 (1.88; 6.23) 4.02 (1.66; 9.79) 
23.00% 1.66 (0.96; 2.93) 3.20 (1.74; 5.83) 3.76 (1.58; 9.20) 
25.00% 1.83 (1.06; 3.18) 2.91 (1.61; 5.23) 3.40 (1.45; 8.15) 
30.00% 2.39 (1.42; 4.14) 2.22 (1.23; 3.94) 2.63 (1.09; 6.30) 
33.00% 2.76 (1.64; 4.71) 1.92 (1.07; 3.38) 2.25 (0.96; 5.43) 
38.00% 2.98 (1.76; 5.10) 1.78 (0.99; 3.13) 2.11 (0.89; 4.99) 
Table E.18.  80% of M1, NI margin= 3.12 , n1=n2=128 (Assuming constancy) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.34 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.36 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.49 
15.00% 1.00 (0.51; 1.98) 5.32 (2.59; 10.9) 6.27 (2.38; 16.50) 
17.00% 1.12 (0.57; 2.20) 4.74 (2.33; 9.54) 5.53 (2.14; 14.60) 
19.00% 1.32 (0.69; 2.55) 4.04 (2.00; 8.05) 4.76 (1.86; 12.30) 
21.00% 1.45 (0.76; 2.79) 3.65 (1.82; 7.16) 4.29 (1.69; 11.00) 
22.00% 1.59 (0.85; 3.05) 3.35 (1.71; 6.47) 3.88 (1.55; 9.84) 
23.00% 1.66 (0.88; 3.18) 3.22 (1.63; 6.24) 3.75 (1.45; 9.60) 
25.00% 1.81 (0.98; 3.45) 2.93 (1.49; 5.67) 3.42 (1.37; 8.61) 
26.00% 1.97 (1.08; 3.71) 2.70 (1.36; 5.18) 3.17 (1.26; 7.88) 
30.00% 2.38 (1.31; 4.43) 2.24 (1.16; 4.27) 2.62 (1.06; 6.65) 
33.00% 2.76 (1.53; 5.16) 1.93 (1.00; 3.66) 2.23 (0.89; 5.57) 
Table E.19.  90% of M1, NI margin= 3.59 , n1=n2=101 (Assuming constancy) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.39 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.40 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.52 
15.00% 1.00 (0.46; 2.18) 5.29 (2.38; 11.8) 6.23 (2.22; 17.5) 
17.00% 1.16 (0.55; 2.46) 4.59 (2.10; 9.95) 5.40 (1.94; 14.9) 
19.00% 1.32 (0.64; 2.78) 4.03 (1.87; 8.60) 4.70 (1.72; 13.10) 
21.00% 1.48 (0.73; 3.08) 3.58 (1.66; 7.57) 4.22 (1.56; 11.30) 
23.00% 1.68 (0.82; 3.48) 3.20 (1.50; 6.70) 3.72 (1.38; 9.93) 
24.00% 1.77 (0.88; 3.64) 3.03 (1.41; 6.29) 3.51 (1.33; 9.16) 
25.00% 1.86 (0.93; 3.80) 2.87 (1.34; 5.90) 3.38 (1.25; 8.93) 
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27.00% 2.06 (1.04; 4.18) 2.58 (1.24; 5.27) 3.02 (1.15; 7.98) 
30.00% 2.40 (1.22; 4.87) 2.23 (1.07; 4.50) 2.58 (0.98; 6.83) 
31.00% 2.49 (1.27; 5.05) 2.13 (1.01; 4.32) 2.50 (0.94; 6.62) 
32.00% 2.60 (1.33; 5.23) 2.03 (0.97; 4.09) 2.41 (0.92; 6.30) 
 
 
Table E.20.  100% of M1, NI margin= 4.14 , n1=n2=82 (Assuming constancy) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.43 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.45 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.55 
15.00% 1.00 (0.43; 2.33) 5.35 (2.21; 12.9) 6.22 (2.14; 18.70) 
17.00% 1.09 (0.47; 2.57) 4.88 (2.02; 11.5) 5.69 (1.87; 16.9) 
19.00% 1.30 (0.57; 2.99) 4.12 (1.74; 9.55) 4.79 (1.63; 13.8) 
21.00% 1.51 (0.69; 3.40) 3.54 (1.52; 8.08) 4.11 (1.47; 11.8) 
23.00% 1.61 (0.74; 3.58) 3.29 (1.42; 7.47) 3.84 (1.36; 11.0) 
25.00% 1.85 (0.85; 4.13) 2.88 (1.25; 6.40) 3.35 (1.19; 9.44) 
26.00% 1.97 (0.92; 4.34) 2.69 (1.17; 5.94) 3.17 (1.13; 8.84) 
27.00% 2.08 (0.98; 4.59) 2.55 (1.11; 5.68) 3.00 (1.09; 8.39) 
29.00% 2.23 (1.05; 4.89) 2.41 (1.07; 5.24) 2.80 (1.01; 7.65) 
30.00% 2.36 (1.12; 5.17) 2.26 (0.99; 4.89) 2.60 (0.94; 7.30) 
 
Table E.21. 60% of M1, NI margin= 2.38 , n1=n2=220 (adjusted for time) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.27  
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se=  0.29 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.43 
15.00% 1.00 (0.58; 1.69) 5.32 (2.99; 9.46) 6.28 (2.66; 14.80) 
17.00% 1.19 (0.72; 2.01) 4.51 (2.57; 7.85) 5.21 (2.26; 12.20) 
19.00% 1.34 (0.82; 2.23) 3.98 (2.27; 6.88) 4.60 (1.99; 10.80) 
20.00% 1.42 (0.86; 2.35) 3.73 (2.15; 6.47) 4.38 (1.91; 10.50) 
21.00% 1.55 (0.94; 2.54) 3.47 (2.01; 5.90) 4.05 (1.77; 9.43) 
23.00% 1.72 (1.06; 2.83) 3.11 (1.80; 5.31) 3.60 (1.56; 8.43) 
25.00% 1.90 (1.18; 3.07) 2.80 (1.64; 4.74) 3.29 (1.43; 7.57) 
30.00% 2.44 (1.54; 3.94) 2.18 (1.28; 3.65) 2.55 (1.12; 5.92) 
35.00% 3.07 (1.95; 4.91) 1.73 (1.03; 2.89) 2.02 (0.88; 4.62) 
36.00% 3.26 (2.07; 5.20) 1.63 (0.97; 2.70) 1.92 (0.85; 4.33) 
 
Table E.22 70% of M1, NI margin= 2.75 , n1=n2=162 (adjusted for time) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.31 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.32 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.46 
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15.00% 1.00 (0.54; 1.84) 5.33 (2.82; 10.20) 6.24 (2.50; 15.30) 
17.00% 1.15 (0.63; 2.08) 4.63 (2.47; 8.72) 5.40 (2.23; 13.50) 
19.00% 1.30 (0.72; 2.34) 4.11 (2.18; 7.68) 4.77 (1.96; 11.8) 
21.00% 1.52 (0.86; 2.71) 3.50 (1.88; 6.40) 4.09 (1.70; 10.1) 
23.00% 1.69 (0.97; 2.99) 3.15 (1.70; 5.76) 3.70 (1.52; 8.77) 
25.00% 1.88 (1.08; 3.30) 2.86 (1.55; 5.19) 3.30 (1.38; 8.02) 
30.00% 2.40 (1.40; 4.18) 2.21 (1.22; 3.95) 2.62 (1.10; 6.26) 
33.00% 2.76 (1.62; 4.76) 1.93 (1.07; 3.41) 2.26 (0.95; 5.39) 
35.00% 3.01 (1.78; 5.24) 1.77 (0.98; 3.13) 2.040.85; 4.82) 
 
Table E.23. 80 % of M1, NI margin= 3.18 , n1=n2=124 (adjusted for time) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.35 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.37 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.51 
15.00% 1.00 (0.49; 2.01) 5.33 (2.57; 11.10) 6.21 (2.34; 16.7) 
17.00% 1.19 (0.61; 2.37) 4.43 (2.16; 9.12) 5.22 (2.00; 13.80) 
19.00% 1.33 (0.68; 2.62) 4.00 (1.97; 8.08) 4.68 (1.79; 12.20) 
21.00% 1.55 (0.82; 3.00) 3.45 (1.72; 6.82) 4.00 (1.57; 10.30) 
22.00% 1.63 (0.85; 3.13) 3.30 (1.64; 6.58) 3.85 (1.49; 9.97) 
23.00% 1.69 (0.9; 3.27) 3.11 (1.56; 6.09) 3.68 (1.42; 9.43) 
25.00% 1.86 (0.98; 3.57) 2.88 (1.45; 5.60) 3.35 (1.32 (8.61) 
30.00% 2.47 (1.33; 4.66) 2.16 (1.10; 4.13) 2.49 (0.98; 6.30) 
33.00% 2.77 (1.50; 5.25) 1.94 (0.98; 3.68) 2.26 (0.88; 5.69) 
Table E.24. 90% of M1, NI margin= 3.67 , n1=n2=98 (adjusted for time) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.40 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.41 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.53 
15.00% 1.00 (0.45; 2.20) 5.32 (2.35; 12.10) 6.32 (2.23; 18.0) 
17.00% 1.16 (0.53; 2.55) 4.60 (2.05; 10.10) 5.35 (1.92; 15.40) 
19.00% 1.34 (0.63; 2.85) 3.97 (1.76; 8.59) 4.70 (1.71; 13.00) 
21.00% 1.52 (0.73; 3.22) 3.52 (1.61; 7.57) 4.14 (1.50; 11.30) 
23.00% 1.72 (0.83; 3.61) 3.10 (1.43; 6.59) 3.61 (1.33; 9.73) 
24.00% 1.81 (0.88; 3.81) 2.94 (1.37; 6.19) 3.45 (1.25; 9.25) 
25.00% 1.92 (0.94; 4.06) 2.80 (1.29; 5.85) 3.20 (1.18; 8.64) 
26.00% 2.03 (1.01; 4.28) 2.64 (1.22; 5.56) 3.08 (1.12; 8.30) 
30.00% 2.48 (1.25; 5.10) 2.15 (1.00; 4.41) 2.49 (0.92; 6.60) 
Table E.25. 100% of M1, NI margin= 4.24 , n1=n2= 80 (adjusted for time) 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2020) se= 0.44 
NMA,  OR (𝜋𝑃/𝜋𝑇) 
se= 0.46 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2020) se= 0.57 
15.00% 1.00 (0.42; 2.43) 5.31 (2.13; 13.30) 6.22 (2.03; 19.30) 
17.00% 1.21 (0.51; 2.88) 4.38 (1.78; 10.60) 5.13 (1.71; 15.60) 
19.00% 1.42 (0.62; 3.30) 3.74 (1.55; 8.86) 4.41 (1.50; 13.00) 
21.00% 1.54 (0.68; 3.59) 3.47 (1.45; 8.04) 4.04 (1.38; 11.70) 
23.00% 1.79 (0.80; 4.11) 2.98 (1.27; 6.84) 3.49 (1.21; 10.10) 
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25.00% 1.91 (0.87; 4.35) 2.79 (1.19; 6.38) 3.27 (1.13; 9.27) 
26.00% 2.05 (0.93; 4.66) 2.61 (1.12; 5.92) 3.03 (1.04; 8.62) 
27.00% 2.17 (0.99; 4.91) 2.45 (1.06; 5.47) 2.87 (1.01; 8.20) 
28.00% 2.31 (1.06; 5.23) 2.27 (0.97; 5.11) 2.69 (0.93; 7.52) 
E. 2. 3 Use of 50% of M1 in the years 2025, 2030 
Table E.26. Comparison of the odds ratio between the placebo and test treatment 
assuming the constancy (2025), NI =2.03 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2025) (95% CrI),SE=0.22  
NMA,  OR (𝜋𝑃/𝜋𝑇) 
(95% CrI),SE= 0.22 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2025) (95% CrI), SE= 0.41 
15.00% 1.0 (0.65; 1.53) 5.31 (3.29; 8.62) 6.47 (2.60; 16.70) 
17.00% 1.10 (0.72; 1.67) 4.87 (3.02; 7.87) 5.60 (2.23; 14.70) 
19.00% 1.32 (0.88; 2.00) 4.01 (2.53; 6.39) 4.88 (1.96; 12.10) 
20.00% 1.40 (0.94; 2.11) 3.80 (2.41; 6.00) 4.60 (1.86; 11.70) 
21.00% 1.51 (1.01; 2.27) 3.54 (2.23; 5.54) 4.30 (1.75; 11.10) 
23.00% 1.68 (1.13; 2.50) 3.18 (2.01; 4.99) 3.81 (1.55; 9.97) 
25.00% 1.89 (1.28; 2.81) 2.83 (1.80; 4.41) 3.42 (1.36; 8.68) 
30.00% 2.41 (1.65; 3.55) 2.20 (1.42; 3.41) 2.69 (1.10; 6.74) 
35.00% 3.05 (2.11; 4.47) 1.75 (1.12; 2.69) 2.10 (0.86; 5.40) 
40.00% 3.75 (2.59; 5.49) 1.42 (0.91; 2.19) 1.75 (0.72; 4.34) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜋𝑡/𝜋𝑐 refers to the odds ratio between the test treatment 
and the active control, the 𝜋𝑝/𝜋𝑡 refers to the odds ratio between the placebo and the test treatment odds ratio >1 indicates 
worse outcome (high pain intensity 
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Table E.27. Comparison of the odds ratio between the placebo and test treatment 
assuming the constancy (2030), NI =2.03 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2030) (95% CrI),SE=0.22  
NMA,  OR (𝜋𝑃/𝜋𝑇) 
(95% CrI),SE= 0.22 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2030) (95% CrI), SE= 0.41 
15.00% 1.0 (0.65; 1.53) 5.31 (3.29; 8.62) 6.63 (2.35; 19.10) 
17.00% 1.10 (0.72; 1.67) 4.87 (3.02; 7.87) 5.92 (2.07; 17.70) 
19.00% 1.32 (0.88; 2.00) 4.01 (2.53; 6.39) 5.08 (1.78; 14.50) 
20.00% 1.40 (0.94; 2.11) 3.80 (2.41; 6.00) 4.82 (1.75; 14.20) 
21.00% 1.51 (1.01; 2.27) 3.54 (2.23; 5.54) 4.36 (1.60; 12.70) 
23.00% 1.68 (1.13; 2.50) 3.18 (2.01; 4.99) 4.03 (1.41; 11.70) 
25.00% 1.89 (1.28; 2.81) 2.83 (1.80; 4.41) 3.53 (1.22; 9.97) 
30.00% 2.41 (1.65; 3.55) 2.20 (1.42; 3.41) 2.77 (0.97; 7.94) 
35.00% 3.05 (2.11; 4.47) 1.75 (1.12; 2.69) 2.20 (0.75; 6.49) 
40.00% 3.62 (2.44; 5.44) 1.42 (0.91; 2.19) 1.79 (0.62; 5.22) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜋𝑡/𝜋𝑐 refers to the odds ratio between the test treatment 
and the active control, the 𝜋𝑝/𝜋𝑡 refers to the odds ratio between the placebo and the test treatment odds ratio >1 indicates 
worse outcome (high pain intensity)  
Table E.28. Comparison of the odds ratio between the placebo and test treatment 
assuming the constancy (2025), NI =2.07, N= 310 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2025) (95% CrI),SE=0.23  
NMA,  OR (𝜋𝑃/𝜋𝑇) 
(95% CrI),SE= 0.25 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2025) (95% CrI), SE= 0.47 
15.00% 1.00 (0.64; 1.55) 5.33 (3.27; 8.72) 6.52 (2.63; 16.30) 
17.00% 1.15 (0.75; 1.77) 4.62 (2.84; 7.44) 5.55 (2.18; 14.20) 
19.00% 1.32 (0.87; 2.03) 4.04 (2.50; 6.54) 4.84 (1.92; 12.40) 
20.00% 1.40 (0.93; 2.14) 3.81 (2.37; 6.09) 4.66 (1.88; 12.00) 
21.00% 1.51 (1.0; 2.30) 3.52 (2.18; 5.59) 4.35 (1.69; 11.00) 
23.00% 1.69 (1.13; 2.55) 3.13 (1.96; 4.95) 3.82 (1.52; 9.67) 
25.00% 1.89 (1.27; 2.85) 2.82 (1.77; 4.46) 3.37 (1.35; 8.48) 
30.00% 2.41 (1.63; 3.60) 2.22 (1.40; 3.47) 2.66 (1.07; 6.83) 
35.00% 3.04 (2.09; 4.54) 1.75 (1.11; 2.72) 2.14 (0.84; 5.32) 
40.00% 3.74 (2.56; 5.56) 1.42 (0.90; 2.21) 1.71 (0.69; 4.36) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜋𝑡/𝜋𝑐 refers to the odds ratio between the test treatment 
and the active control, the 𝜋𝑝/𝜋𝑡 refers to the odds ratio between the placebo and the test treatment odds ratio >1 indicates 
worse outcome (high pain intensity)  
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Table E.29. Comparison of the Odds ratio between the placebo and test treatment 
assuming the constancy (2030), NI =2.09, N= 305 
Risk of failure 
(𝜋𝑇) 
𝑂𝑅(𝜋𝑇/𝜋𝐶) from NI trial 
(2025) (95% CrI),SE=0.23  
NMA,  OR (𝜋𝑃/𝜋𝑇) 
(95% CrI),SE= 0.25 
NMR, OR (𝜋𝑃/𝜋𝑇)  
in (2025) (95% CrI), SE= 0.54 
15.00% 1.00 (0.64; 1.56) 5.34 (3.25; 8.80) 6.56 (2.31; 19.30) 
17.00% 1.16 (0.75; 1.80) 4.60 (2.81; 7.48) 5.65 (2.31; 16.80) 
19.00% 1.32 (0.87; 2.02) 4.03 (2.50; 6.50) 5.15 (1.75; 15.20) 
20.00% 1.41 (0.93; 2.14) 3.78 (2.35; 6.08) 4.71 (1.66; 13.40) 
21.00% 1.53 (1.00; 2.33) 3.48 (2.18; 5.56) 4.44 (1.53; 12.80) 
23.00% 1.72 (1.14; 2.60) 3.11 (1.93; 4.36) 3.88 (1.38; 11.80) 
25.00% 1.94 (1.30; 2.95) 2.75 (1.71; 4.36) 3.46 (1.19; 8.12) 
30.00% 2.44 (1.65; 3.65) 2.19 (1.37; 3.44) 2.75 (0.96; 8.12) 
35.00% 3.06 (2.08; 4.57) 1.75 (1.11; 2.74) 2.12 (0.75; 5.95) 
40.00% 3.77 (2.58; 5.59) 1.42 (0.91 2.21) 1.77 (0.65; 5.23) 
NMA: network meta-analysis, NMR: network meta-regression, the 𝜋𝑡/𝜋𝑐 refers to the odds ratio between the test treatment 
and the active control, the 𝜋𝑝/𝜋𝑡 refers to the odds ratio between the placebo and the test treatment odds ratio >1 indicates 
worse outcome (high pain intensity)   
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E. 3 R Codes for the network meta-regression and network 
meta-analysis 







# Create a new network by specifying all information. 
treatments <- read.table(textConnection(  ' 
  id  description 
  Atorvastatin   "active-control" 
  placebo   "placebo"    ' 
), header=TRUE) 
data <- read.table(textConnection( 
  '  study       treatment           mean      std.dev  sampleSize     
  McInnes     Atorvastatin         23.3     12         50              
  McInnes     placebo             -2.2     12         47           
  Loughrey    Atorvastatin         23.2     12         24           
  Loughrey    placebo              4.9      12         26            
  Hernandez   Atorvastatin         26.2     12         21             
  Hernandez   placebo              0        12         19            
  Koh         Atorvastatin         27.7     12         42           
  Koh         placebo              5        12         44           
  Monteiro    Atorvastatin         25.65    12         30            
  Monteiro    placebo              -2.6     12         30           
  Singh       Atorvastatin         22.2     12         23               
  Singh       placebo              2.5      12         24            
  AVALON      Atorvastatin         24.4     8.3        193           
  AVALON      placebo              0.9      9.1        229   
  Cubeddu     Atorvastatin         24.1     12         25 
  Cubeddu     placebo              4.95     12         24 
  COMETS      Atorvastatin         28.1     10         155 
  COMETS      placebo              0.7      9.7        78 
  Lins        Atorvastatin         25       10         23 
  Lins        placebo              5        8          19 
  Sposito     Atorvastatin         27.9     12         17 
  Sposito     placebo              -2       12         15 
  Davidson    Atorvastatin         25       11.3       127 
  Davidson      placebo            0        10.3       132 
  Raison      Atorvastatin         27.7     9.8        12 
  Raison      placebo              -1.6     10.4       11 
  Sardo       Atorvastatin         27       12         20 
  Sardo         placebo            -2.8     12         20 
  Tan         Atorvastatin         32.9     12         39 
  Tan         placebo              1.3      12         41 
  Hunninghake Atorvastatin         27       12         18 
  Hunninghake placebo              -4       12         19 
  Muscari     Atorvastatin         26.25    12         27 
  Muscari     placebo              2.7      12         30 
  Olsson      Atorvastatin         32       7.6        12 
  Olsson      placebo              2.2      12         29 
  Oranje      Atorvastatin         32.2     12         9 
  Oranje      placebo              2.25     12         10 
  Tanaka      Atorvastatin         29.4     12         18  
  Tanaka      placebo              2.9      12         18 
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  Wang        Atorvastatin         31.1     12         26 
  Wang          placebo            0        12         28    
  Schrott      Atorvastatin        29        11.6       11 
  Schrott     placebo             -2        8.4        9 
  J-CLAS       Atorvastatin       27.4       12.2       27 
  J-CLAS      placebo             0.7        10.7       27 
  Nawrocki    Atorvastatin        30.3       8          11 
  Nawrocki    placebo            -4.8       8          12 
  ' ), header=TRUE) 
year <- read.table(textConnection(  ' 
  study           year     
  McInnes         2014 
  Loughrey          2013 
  Hernandez       2011 
  Koh             2010 
  Monteiro        2008 
  Singh           2008 
  AVALON          2006 
  Cubeddu         2006 
  COMETS          2005 
  Lins            2004 
  Sposito         2003 
  Davidson        2002 
  Raison          2002 
  Sardo           2002 
  Tan             2002 
  Hunninghake     2001 
  Muscari         2001 
  Olsson          2001 
  Oranje          2001 
  Tanaka          2001 
  Wang            2001 
  Schrott         1998 
  J-CLAS          1997 
  Nawrocki        1995    '), header=TRUE) 
network <- mtc.network(data, description="network", treatments=treatments, studies = year) 
# sd ~ half-Normal(mean=0, sd=0.25) 
# network meta-regression 
model <- mtc.model(network) 
regressor <- list(coefficient= 'shared', 
                  variable='year', 
                  control= 'Atorvastatin') 
model <- mtc.model(network, 
                   type="regression", 
                   regressor=regressor, 
                   hy.prior=hy.prior,linearModel="fixed") 
result <- mtc.run(model) 
summary (result) 
plot (result) 
forest(relative.effect(result, 'placebo', covariate = 2020)) 
forest(relative.effect(result, 'Atorvastatin', covariate = 2020), digit=3) 
summary(relative.effect(result, 'placebo', covariate = 2020)) 
 









# Create a new network by specifying all information. 
treatments <- read.table(textConnection(  ' 
  id  description 
  Atorvastatin   "active-control"  placebo   "placebo" 
  test   "test treatment"  ' 
), header=TRUE) 
data <- read.table(textConnection(  ' 
  study       treatment           mean      std.dev  sampleSize     
  McInnes     Atorvastatin         23.3     12         50              
  McInnes     placebo             -2.2     12         47           
  Loughrey    Atorvastatin         23.2     12         24           
  Loughrey    placebo              4.9      12         26            
  Hernandez   Atorvastatin         26.2     12         21             
  Hernandez   placebo              0        12         19            
  Koh         Atorvastatin         27.7     12         42           
  Koh         placebo              5        12         44           
  Monteiro    Atorvastatin         25.65    12         30            
  Monteiro    placebo              -2.6     12         30           
  Singh       Atorvastatin         22.2     12         23               
  Singh       placebo              2.5      12         24            
  AVALON      Atorvastatin         24.4     8.3        193           
  AVALON      placebo              0.9      9.1        229   
  Cubeddu     Atorvastatin         24.1     12         25 
  Cubeddu     placebo              4.95     12         24 
  COMETS      Atorvastatin         28.1     10         155 
  COMETS      placebo              0.7      9.7        78 
  Lins        Atorvastatin         25       10         23 
  Lins        placebo              5        8          19 
  Sposito     Atorvastatin         27.9     12         17 
  Sposito     placebo              -2       12         15 
  Davidson    Atorvastatin         25       11.3       127 
  Davidson      placebo            0        10.3       132 
  Raison      Atorvastatin         27.7     9.8        12 
  Raison      placebo              -1.6     10.4       11 
  Sardo       Atorvastatin         27       12         20 
  Sardo         placebo            -2.8     12         20 
  Tan         Atorvastatin         32.9     12         39 
  Tan         placebo              1.3      12         41 
  Hunninghake Atorvastatin         27       12         18 
  Hunninghake placebo              -4       12         19 
  Muscari     Atorvastatin         26.25    12         27 
  Muscari     placebo              2.7      12         30 
  Olsson      Atorvastatin         32       7.6        12 
  Olsson      placebo              2.2      12         29 
  Oranje      Atorvastatin         32.2     12         9 
  Oranje      placebo              2.25     12         10 
  Tanaka      Atorvastatin         29.4     12         18  
  Tanaka      placebo              2.9      12         18 
  Wang        Atorvastatin         31.1     12         26 
  Wang          placebo            0        12         28    
  Schrott      Atorvastatin        29        11.6       11 
  Schrott     placebo             -2        8.4        9 
  J-CLAS       Atorvastatin       27.4       12.2       27 
  J-CLAS      placebo             0.7        10.7       27 
  Nawrocki    Atorvastatin        30.3       8          11 
  Nawrocki    placebo            -4.8       8          12 
  NI2020      Atorvastatin        18.5      12        22 
  NI2020        test             7     12        22'  
), header=TRUE) 
year <- read.table(textConnection(  ' 
  study           year     
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  McInnes         2014 
Loughrey          2013 
  Hernandez       2011 
  Koh             2010 
  Monteiro        2008 
  Singh           2008 
  AVALON          2006 
  Cubeddu         2006 
  COMETS          2005 
  Lins            2004 
  Sposito         2003 
  Davidson        2002 
  Raison          2002 
  Sardo           2002 
  Tan             2002 
  Hunninghake     2001 
  Muscari         2001 
  Olsson          2001 
  Oranje          2001 
  Tanaka          2001 
  Wang            2001 
  Schrott         1998 
  J-CLAS          1997 
  Nawrocki        1995   
  NI2020          2020' 
), header=TRUE) 
network <- mtc.network(data, description="network", treatments=treatments, studies = year) 
# sd ~ half-Normal(mean=0, sd=0.25) 
# network meta-regression 
model <- mtc.model(network) 
regressor <- list(coefficient= 'shared', 
                  variable='year', 
                  control= 'Atorvastatin') 
model <- mtc.model(network, 
                   type="regression", 
                   regressor=regressor, 
                   hy.prior=hy.prior,linearModel="fixed") 
result <- mtc.run(model) 
forest(relative.effect(result, 'placebo', covariate = 2020)) 
forest(relative.effect(result, 'Atorvastatin', covariate = 2020), digit=3) 




summary(relative.effect(result, 'test', covariate = 2020)) 
summary(relative.effect(result1, 'placebo')) 
 
#pairwise meta-regression for the lidocaine example 







# Create a new network by specifying all information. 
treatments <- read.table(textConnection(' 
id  description 
Lidocaine   "active-control" 




data <- read.table(textConnection(  ' 
study                 treatment       responders  sampleSize  
Kim                   Lidocaine         17          40 
Kim                   placebo           17          20 
Tariq                 Lidocaine         0           100 
Tariq                 placebo           6           100 
Sethi                 Lidocaine         7           100 
Sethi                 placebo           40          100 
Krobbuaban            Lidocaine         1           133 
Krobbuaban            placebo           1           135 
Bachmann-Mennenga     Lidocaine         10          112 
Bachmann-Mennenga     placebo           33          112 
Bachmann-Mennenga1     Lidocaine         15          111 
Bachmann-Mennenga1     placebo           38          110 
Kwak                  Lidocaine         0           46 
Kwak                  placebo           5           45 
Tariq1                 Lidocaine         1           50   
Tariq1                 placebo           2           50 
Tariq2                 Lidocaine         3           50 
Tariq2                 placebo           9           50 
Minogue               Lidocaine         7           42 
Minogue               placebo           26          39 
Yew                   Lidocaine         0           25 
Yew                   placebo           1           25 
Harmon                Lidocaine         2           45 
Harmon                placebo           15          45 
Ho                    Lidocaine         36          120 
Ho                    placebo           22          30 
Parmar                Lidocaine         16          77 
Parmar                placebo           19          38 
OHara                Lidocaine         8           31 
OHara                placebo           19          31 
OHara1                Lidocaine         10          31 
OHara1                placebo           14          31 
Gajraj                Lidocaine         6           54 
Gajraj                placebo           7           13 
McDonald              Lidocaine         1           33 
McDonald              placebo           11          31 
King                  Lidocaine         46          267 
King                  placebo           51          98 
Barker                Lidocaine         5           27 
Barker                placebo           16          28 
Gehan                 Lidocaine         12          157 
Gehan                 placebo           6           38 
Newcombe              Lidocaine         6           47 
Newcombe              placebo           23          46 
Helbo-Hansen          Lidocaine         2           40 
Helbo-Hansen          placebo           13          40' 
), header=TRUE) 
year <- read.table(textConnection(  ' 
  study               year     
  Kim                 2010 
Tariq                 2010 
Sethi                 2009 
Krobbuaban            2008 
Bachmann-Mennenga     2007 
Bachmann-Mennenga1    2007 
Kwak                  2007 
Tariq1                2006 
Tariq2                2006 
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Minogue               2005 
Yew                   2005 
Harmon                2003 
Ho                    1999 
Parmar                1998 
OHara                 1997 
OHara1                1997 
Gajraj                1996 
McDonald              1996 
King                  1992 
Barker                1991 
Gehan                 1991 
Newcombe              1990 
Helbo-Hansen          1988    ' 
), header=TRUE) 
network <- mtc.network(data, description="network", treatments=treatments, studies = year) 
model <- mtc.model(network) 
# network meta-regression 
regressor <- list(coefficient= 'shared', 
                  variable='year', 
                  control= 'Lidocaine') 
# sd ~ half-Normal(mean=0, sd=0.32) 
hy.prior <- mtc.hy.prior(type="std.dev", distr="dhnorm", 0, 9.77) 
model <- mtc.model(network, 
                   type="regression", 
                   regressor=regressor, 
                   hy.prior=hy.prior, 
                   linearModel="fixed") 
result <- mtc.run(model) 
summary (result) 
forest(relative.effect(result, 'test', covariate=2020),digits=3) 
forest(relative.effect(result, 'Lidocaine', covariate=2020), digits=3) 
summary (relative.effect(result, 'test', covariate=2020),digits=3) 




forest(relative.effect(result1, 'test'), digits=3) 
 







# Create a new network by specifying all information. 
treatments <- read.table(textConnection(' 
id  descriptionLidocaine   "active-control" 
test      "test tratment" 
placebo   "placebo"' 
), header=TRUE) 
data <- read.table(textConnection(  ' 
study                 treatment       responders  sampleSize  
Kim                   Lidocaine         17          40 
Kim                   placebo           17          20 
Tariq                 Lidocaine         0           100 
Tariq                 placebo           6           100 
Sethi                 Lidocaine         7           100 
Sethi                 placebo           40          100 
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Krobbuaban            Lidocaine         1           133 
Krobbuaban            placebo           1           135 
Bachmann-Mennenga     Lidocaine         10          112 
Bachmann-Mennenga     placebo           33          112 
Bachmann-Mennenga1     Lidocaine         15          111 
Bachmann-Mennenga1     placebo           38          110 
Kwak                  Lidocaine         0           46 
Kwak                  placebo           5           45 
Tariq1                 Lidocaine         1           50   
Tariq1                 placebo           2           50 
Tariq2                 Lidocaine         3           50 
Tariq2                 placebo           9           50 
Minogue               Lidocaine         7           42 
Minogue               placebo           26          39 
Yew                   Lidocaine         0           25 
Yew                   placebo           1           25 
Harmon                Lidocaine         2           45 
Harmon                placebo           15          45 
Ho                    Lidocaine         36          120 
Ho                    placebo           22          30 
Parmar                Lidocaine         16          77 
Parmar                placebo           19          38 
OHara                Lidocaine         8           31 
OHara                placebo           19          31 
OHara1                Lidocaine         10          31 
OHara1                placebo           14          31 
Gajraj                Lidocaine         6           54 
Gajraj                placebo           7           13 
McDonald              Lidocaine         1           33 
McDonald              placebo           11          31 
King                  Lidocaine         46          267 
King                  placebo           51          98 
Barker                Lidocaine         5           27 
Barker                placebo           16          28 
Gehan                 Lidocaine         12          157 
Gehan                 placebo           6           38 
Newcombe              Lidocaine         6           47 
Newcombe              placebo           23          46 
Helbo-Hansen          Lidocaine         2           40 
Helbo-Hansen          placebo           13          40 
NI2020               Lidocaine           53          316 
NI2020                test               53           316  ' 
), header=TRUE) 
year <- read.table(textConnection(  ' 
  study               year     
  Kim                 2010 
Tariq                 2010 
Sethi                 2009 
Krobbuaban            2008 
Bachmann-Mennenga     2007 
Bachmann-Mennenga1    2007 
Kwak                  2007 
Tariq1                2006 
Tariq2                2006 
Minogue               2005 
Yew                   2005 
Harmon                2003 
Ho                    1999 
Parmar                1998 
OHara                 1997 
OHara1                1997 
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Gajraj                1996 
McDonald              1996 
King                  1992 
Barker                1991 
Gehan                 1991 
Newcombe              1990 
Helbo-Hansen          1988   
  NI2020                2020' 
), header=TRUE) 
network <- mtc.network(data, description="network", treatments=treatments, studies = year) 
model <- mtc.model(network) 
# network meta-regression 
regressor <- list(coefficient= 'shared', 
                  variable='year', 
                  control= 'Lidocaine') 
# sd ~ half-Normal(mean=0, sd=0.32) 
hy.prior <- mtc.hy.prior(type="std.dev", distr="dhnorm", 0, 9.77) 
model <- mtc.model(network, 
                   type="regression", 
                   regressor=regressor, 
                   hy.prior=hy.prior, 
                   linearModel="fixed") 
result <- mtc.run(model) 
summary (result) 
forest(relative.effect(result, 'test', covariate=2020),digits=3) 
forest(relative.effect(result, 'Lidocaine', covariate=2020), digits=3) 
summary (relative.effect(result, 'test', covariate=2020),digits=3) 
# network meta-analysis 
model1<-mtc.model(network, hy.prior=hy.prior,linearModel="fixed") 
result1<- mtc.run(model1) 
forest(relative.effect(result1, 'test'), digits=3) 
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